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Manuscript Delineation
This thesis focuses on the qualitative modelling of TLR4-JAK/STAT sig-
nalling pathways and protein-protein interactions of MAL with BTK and PKCδ ,
where MAL is a key protein in the TLR4 signalling pathway. It contains five chapters
outlined as below.
Chapter 1 includes a brief introduction to the core problem of sepsis and
emphasizes the need for systems-level approaches and protein-protein interaction
studies to understand the biological regulatory mechanism both in septic and non-
septic (infections which do not lead to sepsis) physiological conditions.
Chapter 2 describes the relevant literature about the role of TLR4-JAK/STAT
signalling pathways in sepsis along with the computational approaches for the iden-
tification and re-construction of biological regulatory networks and protein-protein
interactions of MAL with PKCδ and BTK.
Chapter 3 describes in detail the methods and approaches for the modelling
of TLR4-JAK/STAT signalling pathways, computation of logical parameters, pertur-
bations in the signalling events along with the comparative protein modelling, quality
assessment and protein-protein interactions (PPIs) of MAL with BTK and PKCδ .
Chapter 4 provides key findings obtained by the simulation of qualitative
models of the TLR4-JAK/STAT signalling pathways and protein-protein interactions
of MAL with PKCδ and BTK. Particularly, the analysis of qualitative modelling gives
insights into: (a) the recurrent induction of pro- and anti-inflammatory responses; (b)
intervention in SOCS-1 mediated down-regulation of inflammatory cytokines; (c)
interventions in TLR4, NFκB and STAT mediated signalling for the down-regulation
of immune responses; (d) association between the activation patterns of inflammatory
cytokines and subsequent down-regulation by IFN-β and SOCS-1 at different levels of
signalling; and (e) perturbations in IFN-β signalling, etc. while the analysis of protein-
protein interactions of MAL with BTK and PKCδ demonstrated that: (f) BTK binds
vii
within Tyr86 and Tyr106 regions of MAL; (g) PKCδ binds only within the region of
Tyr106 of MAL; (h) charge distribution on the surfaces of BTK and PKCδ are distinct
but compatible with the specific interaction sites of MAL; (i) competitive action of
both BTK and PKCδ is present at the site of Tyr106; and (j) residues of MAL, which
interact with other TIR domains are also involved with kinases and, finally,
Chapter 5 briefly summarises all the previous chapters (findings) and dis-
cusses different aspects of findings in relation to the previous experimental data and
literature.
Appendices (A-D) furnish the supplementary material and the published re-
search articles from this thesis.
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ABSTRACT
In this thesis, the medical condition of sepsis is considered at molecular level
(signalling pathways) using computational systems-level approaches in order to get in-
sights into the mechanism of disease progression. Sepsis is the pathological condition
provoked due to the presence of bacterial endotoxin in the bloodstream. Subsequently
Toll like receptors (TLR)4 and JAK/STAT signalling pathways attempt to reduce the
pathogen burden by inducing pro- and anti-inflammatory innate immune responses.
However, in some instances, an overwhelmed immune system could not properly
regulate the balance between infection and inflammation that may ultimately lead to
organ damage and consequently to death. In recent years, there has been an increasing
amount of literature on the pattern of pro- and anti-inflammatory response elicited
during sepsis, though; there has been a little agreement on the roles of pro- and anti-
inflammatory cytokines (AiCyts) in sepsis. This study mainly aims to address the
controversy behind roles of pro- and anti-inflammatory cytokines in sepsis by mod-
elling the signalling pathway of TLR4 and one of the connected signalling cascades of
JAK/STAT using qualitative modelling approach introduced by René Thomas’. The
possible system dynamics of TLR4-JAK/STAT signalling pathways are produced for
two medical conditions i.e. non-sepsis (type of infections that generally do not cause
sepsis) and sepsis along with perturbations in these two cases. As a result, recurrent
induction and inactivation of pro-inflammatory cytokines is found as the basic fea-
ture associated with sepsis. Besides AiCyts, IFN-β and SOCS-1 are found to mediate
down-regulation of pro-inflammatory cytokines at different stages of signalling which
cause variation of pro-inflammatory cytokines levels. It is observed that intervention
in IFN-β mediated down-regulation of pro-inflammatory cytokines at earlier stages
of system dynamics, while intervening the SOCS-1 mediated down-regulation of pro-
inflammatory cytokines at later stages ensures hyper-inflammatory condition. On the
other hand, interventions in TLR4, NFκB (transcription factor involved in the TLR4
1
Abstract
signalling pathway) and JAK/STAT signalling are good choices for supporting the
anti-inflammatory immune responses. Thus only possible protein-protein interactions
involved in the initial downstream interactions of TLR4 signalling are studied in order
to predict a more appropriate target in these interactions. Previous studies indicated
that MyD88 adaptor-like protein (MAL) is an endogenous adaptor protein recognized
as an important protein involved in the induction of TLR4 mediated downstream
signalling pathway. Moreover, it has also been demonstrated that BTK and PKCδ
phosphorylate MAL (positions Tyr86 and Tyr106) which ultimately activates MAL.
Thus the modelling of PKCδ and protein-protein interactions of both BTK and PKCδ
with MAL is performed in order to explore their competitive interaction. Molecular
docking and physicochemical analysis reveals that PKCδ may phosphorylate only
Tyr106 of MAL, while BTK may phosphorylate MAL at both positions. Interestingly,
the charge and hydrophobicity at interfaces of PKCδ and BTK are found different
in nature yet well-compatible with the individual positions of Tyr86 and Tyr106 of
MAL. The most prominent findings emerged from this analysis is that position Tyr86
of MAL may explicitly be phosphorylated by BTK, while position Tyr106 of MAL
may be phosphorylated by the competing interest of both PKCδ and BTK.
In conclusion, this thesis will enhance our understanding about the signalling
and protein-protein interactions involved in sepsis which will contribute to the devel-
opment of drugs and vaccines against the medical condition of sepsis.
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Chapter 1
INTRODUCTION
1.1 Biological Systems
Biological systems are complex and dynamic which are composed of vari-
ous sets of genes and proteins performing their functions at multiple levels such as
organelles, cells, tissues, organs and organisms. Genes encode proteins which form
complexes to create functional organelles of the cells such as nucleus, cell membrane,
mitochondria, etc.. The organelles join together to form an individual cell. Cells with
the extracellular matrix form tissues. Several tissues combine to form organs that are
inter-linked together to form the complete organism. The properties of each molecular
level characterize the subsequent level. Each of these levels represents a specific be-
haviour of the entire system with its own dynamics which usually differs from others
since the nature of the molecular level and its interactions are different.
Advances in high-throughput technologies have assisted in conducting large-
scale studies of biological molecules in biological systems (Abraham et al., 2004;
Giuliano et al., 2003). To study a biological system on a larger scale, it is always
deemed necessary to describe how different units of a system interact with one an-
other and produce a combined effect, which is otherwise difficult to understand if
the units are studied individually (Joyce and Palsson, 2006). For instance, immune
response to infection is a complex biological phenomenon and is believed to be
elicited by the Toll like Receptors (TLRs), along with other mechanisms, producing
signal transduction involving several protein-activation and inactivation mechanisms
(Brandl et al., 2005; Fitzgerald et al., 2003; Lu et al., 2008; Miller et al., 2005). Sub-
sequent to TLR signalling cascade, selected transcriptional factors, such as Nuclear
Factor κB (NFκB), Activator Protein 1 (AP-1) and Interferon Regulatory Factors
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(IRFs), are transported to the nucleus where they transcribe several cytokines, for ex-
ample Interferon (IFN)-α/β/γ , Tumour Necrosis Factor (TNF)-α , Tumour Growth
Factor (TGF)-β , Interleukin (IL)-4, IL-10, IL-13, etc., in order to act appropriately
against the received signal. Some of the inactivating mechanisms perform their func-
tions before the transcription of cytokines where others are activated by themselves
(Miggin, 2006). These sets of information are explaining the mechanistic insights
into the molecular events that are necessary to explain the mechanism of immune
response but are essentially descriptive and thus require a network of activation and
inactivation mechanisms, which can elucidate their functions in an integrated and
parallel manner.
The reductionist approach of breaking down biological systems into respec-
tive components has been efficient in making platforms for several biological events
(Van Regenmortel, 2004). There are situation when the complex interplay between the
components provides a behaviour that cannot be predicted by studying the parts alone.
So is there any formal approach, which can be used to explain the whole system?
How should the biological complexity be dealt? A relatively new branch of science
called systems biology (Alm and Arkin, 2003; Kitano, 2002; Zhao et al., 2013) can
provide the answers to these questions.
1.2 Systems Biology
System-wide analysis of biological systems has been accepted as a powerful
approach for the analysis of biological properties of different molecular entities in a
system. Thus, adopting this approach contributes to the generation of useful informa-
tion and effective solutions in the areas of medicine and biotechnology (Kitano, 2002;
Zhao et al., 2013). Systems biology offers solutions in the form of both qualitative
and quantitative analyses of the system. Generally, the mechanisms involved in the
signalling pathways are not fully explored, which signify the use of qualitative anal-
ysis as compared to quantitative one. This leads to the fact that building a complete
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quantitative model is somehow difficult or even impossible, however, the importance
of quantitative models cannot be neglected.
Among the several qualitative modelling techniques the simplest way to model
a biological regulatory networks (BRNs) is the Boolean approximation, introduced
first by Kauffman (1969), where entities of the models (BRN) can either be in active
or inactive (on/off) state (transcriptional level). This can also be explained as either
the particular protein is present (1) or absent (0) (translational levels) (Figure 1.1).
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Figure 1.1. A simple Boolean network. (A) Regulatory network has been shown
consisting of three entities “x”, “y” and “z” joined with black arrows, representing
the activating interactions, and red lines with stop, representing the inactivating inter-
action. Transitions of states are governed by the logical functions (B), which describe
the update rules of the network. For example, if “x” is in state “1” than after the tran-
sition, the state of “z” will be “0”. The global state of the network is the combination
of all of the states of three entities (C). A sequence of consecutive global states is
known as trajectory (D) for the model.
Boolean rules (e.g. AND, OR) are defined to determine the states of all entities
at the next time point. Later on, René Thomas presented multivalued (0,1,2,...) kinetic
logic, a modified form of the Boolean logic, for the qualitative modelling of BRNs
(Demongeot et al., 2000; Snoussi and Thomas, 1993; Thomas, 1978, 1979, 1991,
1998; Thomas and Kaufman, 2001). Comparatively, the Boolean modelling approach
utilizes synchronous transitioning (more than one entity can change its level in a single
transition) between states.Unlike this, the kinetic logic approach allows asynchronous
transitions (evolution of one entity at a time) (Thomas and d’Ari, 1990).
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The applicability of this approach can be estimated by other studies in which
this logic has already assisted in analysing a number of biological processes and sys-
tems, for example the prediction of differentiation control in helper T-cells (Mendoza,
2006), segmentation in embryogenesis in Drosophila melanogaster (Sanchez and
Thieffry, 2003), regulation of organ differentiation in Arabidopsis thaliana flowers
(Mendoza et al., 1999). and most recently the TLRs signalling (Ahmad et al., 2012;
Aslam et al., 2014).
1.3 Modelling Biological Regulation in Diseases
Over the last three decades, modelling of the pathophysiological conditions
has experienced a vast development. Among the analysed models, the immune re-
sponse generated against certain stimuli have also been modelled for the explanation
of underlying defence mechanisms of human body (Ahmad et al., 2012; Aslam et al.,
2014; Louzoun, 2007) Likewise, in this study, qualitative modelling and simulation
of TLR4 and JAK/STAT signalling network are conducted to understand the immune
regulatory mechanisms involved in a life-threatening medical condition i.e. sepsis.
1.4 Sepsis
Sepsis is potentially a life-threatening medical condition provoked by the
bacterial endotoxins in blood borne infections (Bone et al., 1992; Lever and Macken-
zie, 2007; Wheeler and Bernard, 1999). Among the pathogenic bacterial species,
Escherichia coli (Ziegler et al., 1982), Klebsiella (Bone, 1993) , Pseudomonas aerug-
inosa (Smorodchenko and Specht, 2002), Serratia (Roth et al., 2000), Enterobacter
(Hervas et al., 2001) and Proteus species (Sugerman et al., 1981) have been mostly
associated with a cause of sepsis. The American College of Chest Physicians and the
Society of Critical Care Medicine established four different levels of septic conditions,
including: (1) SIRS; (2) Sepsis, when SIRS is confirmed along with any infectious
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agent; (3) Severe sepsis, a condition of organ dysfunction due to sepsis along with
hypoperfusion (insufficient blood flow) and hypotension (low blood pressure); and
(4) Septic shock, a condition of sepsis with persisting arterial hypotension or hypop-
erfusion despite therapeutic and supporting strategies (Bone et al., 1992).
The number of septic patients is rising irrespective of the improvements in
the therapeutic and supportive strategies (Hotchkiss and Karl, 2003; Stone, 1994). In
1992, about 500,000 septic patients were observed in the United States, among them
35% were led to death (Wenzel, 1992). In 2001, approximately 750,000 instances
of sepsis with 28.6% deaths annually were registered (Angus et al., 2001). Trend
analysis from 1993-2003 described a substantial growth in the events of severe sepsis
and hospitalization (Dombrovskiy et al., 2007) and, according to a recent report, it is
still growing (Lagu et al., 2012). Former studies focused the pathogenic agents and
type of infections to describe the sepsis, however, later clinical findings implicate that
host immunity in sepsis play a critical part and thus characterized SIRS. Earlier studies
proposed that pro-inflammatory behaviour is the major cause of the SIRS and deaths,
while the anti-inflammatory behaviour was linked to relatively fewer serious health
issues (Walley et al., 1996; Wang et al., 1997). However, simple anti-inflammatory
treatment does not diminish mortality rate due to sepsis. On the other hand, recent
studies dis- prove earlier hypothesis about the roles of PiCyts in sepsis and suggested
that AiCyts behaviour and immunomodulation could establish compensatory anti-
inflammatory response syndrome (CARS), impairment of the organs with eventual
death (Ashare et al., 2005; Gogos et al., 2000; Harris et al., 2005; Loisa et al., 2003;
Ward et al., 2008). In this way, scientists started to interrogate, whether deaths in sepsis
are just related with uncontrolled pro-inflammatory immune response? Furthermore,
other findings illustrated that both types of immune behaviours are possible and offer
chances to septic patients for controlling the micro-organism and hyper-inflammation
at distinct stages of sepsis (Hotchkiss et al., 2013a; Iskander et al., 2013). In addition,
a few septic patients die at the earlier phase of immune reaction, yet most patients
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die in the later stages of sepsis with extended period of immune depression. The
competing theories of the host immune response in sepsis are presented in Figure 1.2.
Figure 1.2. Theories of the host immune response in sepsis. (A) Theory 1 delin-
eates the concurrent activation of both pro- and anti-inflammatory immune responses
subsequent to the sepsis. The activation of PiCyts (blue line; days 1–3) can result in
the deaths in sepsis (red line; day 3). Most patients survive the infection by restoring
the innate and adaptive immune responses (recovery phase; green and blue lines; day
6). In case, sepsis persists for longer than 6 days, the immune suppressive state occurs
due to overwhelmed innate and adaptive immune response (red and blue lines; after
day 6). Deaths probably occur due to an inability of the patients to resolve primary in-
fections along with the development of secondary infections. (B) Theory 2 represents
that there is an earlier activation phase of innate immune responses and inhibition
of adaptive immunity, and deaths in sepsis are due to the persistent activated innate
immunity which results into uncontrollable inflammation and leads to organ injury.
Figure reproduced from Hotchkiss et al. (2013b).
8
Chapter 1 1.4 Sepsis
1.4.1 TLR4 and JAK/STAT pathway
The earlier stage of sepsis is associated with the unrestrained induction of
antigen recognition system and pro-inflammatory immune responses contributing to
the severe dysfunction of multi-systems in the body. Immune cells transcribe various
antigen receptors on the surface of cell membrane known as pattern recognition re-
ceptors (PRRs). These receptors can quickly activate the body’s defence mechanism
following to bacterial infection or tissue injury. Presence of bacterial invasion is gener-
ally detected systemically by the presence of pathogen-associated molecular patterns
(PAMPs). Toll-like receptors (TLRs) or subtypes of PRRs can recognize PAMPS and
stimulate the inflammatory immune response (Takeda et al., 2003). TLR4 induction is
crucial for the activation of inflammatory immune response because TLR4 is capable
to make a receptor complex with MD2 and CD14 to mediate lipopolysaccharide (LPS)
recognition and hence activating an inflammatory immune response. The earlier stud-
ies have established that induction of TLR4 was high in LPS challenged monocytes
of healthier human (Wittebole et al., 2005) as well as in septic patients (Brandl et al.,
2005; Härter et al., 2004). Induction of TLR4 contributes to the expression of PiCyts
and AiCyts through two unlike signalling cascades (Hoebe et al., 2004) (Figure 1.3).
TLR4 is unique within the family of TLRs for the reason that it can stimulate toll-
interleukin 1 receptor (TIR) domain containing adapter inducing interferon-β (TRIF)
as well as myeloid differentiation primary response gene (MyD)88 dependent sig-
nalling cascades (Kawai and Akira, 2010). These two cascades result in the genesis of
Interferon-β (IFN-β ) and PiCyts, respectively. Alongside, TRIF dependent signalling
possesses the attribute of stimulating Nuclear factor κ B (NFκB) by TNF receptor
associated factor (TRAF)6 (Kendrick and Jones, 2008).
Complex formation between TLR4, MYD88 and MyD88 Adaptor Like pro-
tein (MAL) activates MyD88 dependent pathway. This signalling cascade results in
the induction of NFκB with consequent expression of PiCyts (Kawai et al., 1999).
Whereas, MyD88 independent or TRIF dependent pathway is activated due to the es-
9
Chapter 1 1.4 Sepsis
Figure 1.3. TLRs Signalling Pathway. Illustration reproduced courtesy of Cell
Signalling Technology, Inc. (www.cellsignal.com).
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tablishment of TLR4, TRIF and TIR-domain-containing adapter molecule 2 (TICAM2
also known as TRIF related adaptor molecule (TRAM)) complex (Yamamoto et al.,
2003). This multiplex consequently triggers Interferon regulatory factor 3 (IRF3)
with subsequent transcription of IFN-β (Yamamoto et al., 2003) Furthermore, the
TRIF mediated signalling has also been involved in the slow induction of NFκB
by TRIF dependent TRAF6 induction, nevertheless, MyD88 dependent pathway is
explicitly involved in the expression of PiCyts (Yamamoto et al., 2003). PiCyts and
IFN-β expedited JAK/STAT activation is substantive for the recruitment of pro- and
anti-inflammatory immune system, respectively (Kisseleva et al., 2002; Scott et al.,
2002). IFN-β and PiCyts induce JAKs, and result in the activation of STAT and its
dimerization, which translocate into the nucleus and express requisite genes to re-
spond suitably in the presence of micro-organisms or inflammation (Schindler et al.,
2007; Scott et al., 2002). JAK/STAT signalling cascade is shown in Figure 1.4.
TLR4 facilitated immune reactions are down-regulated due to numerous neg-
ative feedback signalling (Liew et al., 2005). TLR4 dependent signalling preserved
homoeostasis between infection and hyper-inflammatory reactions (Yang et al., 2011).
A20 zinc finger protein, sterile alpha-and armadillo-motif-containing protein (SARM)
and suppressor of cytokine signalling-1 (SOCS-1) are considerably described for
their repressive functions in TLR4 signalling (Boone et al., 2004; Carty et al., 2006;
Yoshimura et al., 2007). Recently, IFN-β has been reported for shifting TH1 to TH2
responses to down regulate PiCyts (Belardelli, 1995; Mahieu and Libert, 2007; Šega
et al., 2004; Weighardt et al., 2006). SOCS-1 is essential for protection against endo-
toxemia and hyper-inflammation by suppressing PiCyts and IFN-β facilitated JAK/S-
TAT signalling, respectively (Baetz et al., 2004; Johnston, 2004; Prêle et al., 2008).
1.5 Role of Proteins in Signalling
Proteins play substantial roles in the biological events; hence, it is crucial to
interpret how they execute signalling. To understand and explore the protein-protein
11
Chapter 1 1.5 Role of Proteins in Signalling
Figure 1.4. JAK/STAT Signalling Pathway. Illustration reproduced courtesy of
Cell Signalling Technology, Inc. (www.cellsignal.com).
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interactions (PPI) mechanism in the case of sepsis condition, as demonstrated in the
thesis, the PPI of phosphorylated BTK (termed as pBTK) and phosphorylated PKCδ
(termed as pPKCδ ) with MAL is performed, as these proteins are the crucial part of
the TLR4 signalling pathway.
1.6 MyD88 Adaptor Like protein (MAL)
MAL has a crucial function in TLR2 and TLR4 facilitated MyD88 depen-
dent signalling. It has been associated with various other cellular events after bind-
ing with different other proteins such as IL-1 receptor-associated kinase (IRAK)-
1, IRAK-2, IRAK-4, plasma membrane, SOCS-1, TRAF6, BTK and PKCδ . IRAK
protein phosphorylate and ubiquitinate MAL with subsequent degradation (Dunne
et al., 2010; Muzio et al., 1997). MAL interacts with cellular membrane through
the phosphatidylinositol-4,5-biphosphate (PIP2) binding motif at N-terminal (Kagan
and Medzhitov, 2006). MAL interacts with TRAF6 for activation of NFκB (Verstak
et al., 2009). SOCS-1 has been affiliated with the inactivation of MAL and provides
a negative feedback to the expression of PiCyts (Mansell et al., 2006).
1.6.1 Kinase mediated activation of MAL
At molecular level, MAL interacts solely with the cytosolic regions of TLR2
and TLR4. PKCδ and BTK have been involved in the phosphorylation of MAL that
is subsequently activated to perform its functions. BTK modifies the residues Tyr86
and Tyr106 with phosphorylation (Figure 1.5) , which is essential for MAL, however,
the phosphorylation positions are unclear in case of PKCδ mediated post-translation
modification of MAL and still need further elucidations. To better understand the func-
tional regions of MAL and kinase proteins, in silico structural analysis is performed
in this study to describe in detail the protein-protein interactions (PPI) of phospho-
rylated BTK (termed as pBTK) and phosphorylated PKCδ (termed as pPKCδ ) with
MAL.
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Figure 1.5. Crystal structure of MAL/TIRAP. Cartoon of crystallized structure of
TIR domain of MAL (PDB Id: 3UB2). Two phosphorylatable positions of MAL i.e.
Tyr86 and Tyr106 are shown in red sticks.
1.6.2 Role of MAL in TLRs signalling
Various proteins such as TLRs and other adaptor proteins contain TIR-domains.
These TIR-domains generally consist of five parallel β -sheets, termed as βA-βE sur-
rounded by 5 α-helices, termed as αA–αE (Xu et al., 2000). These sheets and helices
are connected by loops of variable lengths that also cater specificity of interactions
between TIR-TIR-domain interactions of various adaptor proteins with TLRs. It has
been observed that various TLRs recruit different adaptor proteins (O’Neill and Bowie,
2007). In this context, TLR3 and TLR4 can recruit TRAM, whereas TLR2 and TLR4
recruit MAL (Sheedy and O’Neill, 2007). Thus, TLR4 can induce MyD88 and TRIF
dependent (MyD88 independent) signalling by recruiting MAL and TRAM, respec-
tively. In this aspect, two sets of adaptor protein may compete with each other for
binding with the TIR-domain of TLR4 (Sheedy and O’Neill, 2007). This event need
to be further explored on molecular level.
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The complexes of MAL with MyD88 and TRAM with TRIF have been asso-
ciated with different sets of immune responses. Complex formation of MAL-MyD88
with TLR2 and TLR4 is observed as the necessary event in the activation of NFκB
and mitogen-activated protein kinase (MAPK) mediated expression of PiCyts such as
TNFα , IFN-γ , IL-la, IL1β and IL6 (Dinarello, 2000). Whereas, TRAM-TRIF com-
plex is necessary to induce IFN regulatory factor 3 (IRF3) mediated induction of
cytokines such as IFN-β (Arancibia et al., 2007).
1.7 Aims and Objectives of the Study
• Aim of the study
The aims of the study include the formal modelling of TLR4 and JAK/STAT
signalling pathway in both non-septic and septic pathological conditions to iden-
tify and investigate specific signalling events and characteristics of signalling
networks and, structural evaluation and protein-protein interactions studies of
targeted proteins which could be utilized to design specific therapeutic inter-
ventions.
• Objectives of the study
– A comprehensive computational analysis of TLR4 and JAK/STAT signal-
ing pathway to isolate signaling events and proteins that could be success-
fully targeted for therapeutic interventions;
– To identify and model the potential biological regulatory network of TLR4
and JAK/STAT signalling pathway with the help of documented literature
support and observe in detail the behaviours of the system;
– Modelling of different types of immune responses in both non-septic and
septic pathological conditions elicited by TLR4 and JAK/STAT pathways;
– To sought the support from literature about the perturbations/interventions
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and system dynamics in the constructed models of non-septic as well as
of septic case;
– To elaborate the system dynamics leading to pro-inflammatory or anti-
inflammatory responses in both physiological conditions and;
– The structural evaluation and modelling of targeted proteins (if required)
in TLR4 and JAK/STAT pathway and its protein-protein interactions anal-
yses to explore the interaction interfaces in relation to their physicochem-
ical properties;
– In general, the use of integrated approaches of computational and systems
biology along with proteomics to design an efficient pipeline, to com-
prehend the complete system dynamics of selected signalling framework
at particular instance of time, that would allows investigating different
characteristics of signalling networks such as multi-point simultaneous
targeting/knock-down, which otherwise is difficult to address experimen-
tally.
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LITERATURE REVIEW
Cell is a functional and structural unit of all living beings. The functions of a
cell and its nature are primarily characterized by deoxyribonucleic acid (DNA) that
is a polymer of nucleic acids and contains genetic information of the organisms. In
advanced genetics and molecular biology, it is generally believed that the complete
hereditary information is encoded in the genome of an organism either in the form of
DNA or in ribonucleic acid (RNA: for some viruses). The specific segment of DNA
that is carrying the genetic information is called genes. These genes are transcribed
into messenger RNA that is translated into proteins. Proteins are composed of one
or more chains of amino acids and are structural and functional components of cells.
In the early 1960s, it has been identified that the transcription process of genes are
regulated by some proteins. These regulatory proteins can either inhibit or activate the
expression of genes in a living being. This regulation of gene expression through the
networks of DNA, RNA and proteins along with their interactions is called biological
regulatory networks (BRN). There are numerous genes, proteins and possible inter-
actions in a single network that make them very complex and intricate, for instance
see Figures 1.3 and 1.4. In this scenario, it is very difficult to extract the biological
information such as the consequences of over or under expression of certain genes
on the complete network. It is quite obvious that computational models can be used
to predict and understand the system dynamics of complex biological networks and
allow data compilation and analysis in pre- and post-experimental stages, in addition
to laying down the grounds for modelling and simulation (Hogeweg, 2011; Roberts,
2006).
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2.1 Computational Biology
The field of Computational biology addresses the development and applica-
tion of theoretical and analytical approaches that are used for the study of biological
systems (De Jong, 2002; Kim and Eils, 2008; Kitano, 2002). This field encompass
the use of mathematical equations, laws of physics, chemical nature of molecules and
computer science to figure out the behaviour of complex biological systems. Mod-
elling and simulation are performed to predict the behaviour of the system using
different settings that may represent the induced changes in the normal biological sys-
tems. The results of simulations are further used to predict the possible outcomes in
response to different conditions applied to the system (Aluru, 2005; Hogeweg, 2011).
2.1.1 Systems biology
Systems biology uses a blend of methods to study the biological systems,
especially, the responses of a specified system in the presence of perturbations like
suppression, mutation and possible effects of a drug (Kitano, 2002). This field has
been conceived as the “search for the syntax of biological information”- the study
of the dynamic networks of interacting biological elements (Kim and Eils, 2008).
Systems biology has also been identified as a comprehensive quantitative study of the
signalling pathway in which every component of a biological framework interact func-
tionally with one another over time (Zak and Aderem, 2009). Fundamentally, systems
biology gives a way out from the formal reductionist aspect of biology, underlining
the importance of a holistic aspect of biological systems. Modelling and simulation of
complex signalling networks make the basis of systems biology; the union of in silico
models with in vitro and in vivo studies, with a recursive approach between model
based experimental studies and in return experimentation based model refinement,
which can furnish apprehension of the biological systems.
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2.1.2 Modelling in computational biology
Models in the computational biology are usually constructed to imitate a single
or a group of events originally observed in the biological systems to gain understand-
ings about the processes and to predict the observations for a specific set of given
inputs to the model. The presence of several biological systems at different molecular
hierarchic levels defined diverse molecular modelling strategies as shown in Figure
2.1. The benefits of a computational model are numerous, including: (a) it provides
the role of the components in a given system and their relation with each other (b) it
allows for executing simulations and monitoring the outcome and in this way (c) it
assists in analysing the function of every component by the study of perturbations,
(d) it aids both in scheming marginal systems that could culminate in a specific phe-
notype, besides examining the outcome of newer factors into the system and (e) it is
highly tractable for high-throughput computer simulations, valuable particularly in
drug designing and discovery. Therefore, models not only furnish substantial perspec-
tives into the underlying biological systems, but also allow for the economical study
of impracticable or inconceivable experimentations of complex biological processes.
2.1.3 Computational biology in practice
Computational biology is primarily associated with the modelling of systems,
detailing signalling networks, metabolism processes, structures of proteins, genes and
protein-protein or gene interactions. As shown in Figure 2.2, various methods of
modelling are in practice, which require a wide spectrum of input data and level of
details to produce plausible outputs. The levels of biological hierarchy levels at which
such methods can be used are already shown in Figure 2.1.
At the lowest level of resolution are the qualitative models of the biological
systems along with the statistical learning models and Bayesian networks (Di Ventura
et al., 2006). At some higher levels of resolution, topological analysis of networks,
which are based on the data of association, can also furnish intriguing perspectives
19
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into the constitution and attributes of biological systems (Junker and Schreiber, 2008).
Discrete modelling techniques can furnish significant contributions in several areas.
Boolean modelling is based on a little more data than previously discussed modelling
strategies, where biological interactions between the entities are presented by the
usage of Boolean functions such as “AND”, “OR”, “AND NOT”, etc (Wang et al.,
2012).
Flux balance analysis (FBA) and stoichiometric studies rely predominantly
on the global characteristics of the biological networks such as mass conservation
and stoichiometry, rather than the intricate kinetic properties (Orth et al., 2010). At
higher level of resolution, the modelling of molecular networks that usually require
differential equations detailing the stochastic modelling and kinetic parameters. At
the highest level of resolution, the molecular recognition models followed by atom-
istic models such as quantum mechanics (Lo et al., 2002) and molecular dynamics
(Rapaport, 2004) require the atomistic details.
The selection of modelling approach is particularly decided by the nature and
amount of data, which are accessible through experimental studies. For instance, if
well-characterised kinetic parameters are procurable for a set of reactions in a specific
signalling cascade, a kinetic modelling approach comprising of differential equations
depicting the rate of reactions of all of the entities can be built. Such a framework
of equations can subsequently be solved to get insight into the importance of each
element.
2.1.4 René Thomas’ formalism
In 1970, René Thomas introduced kinetic logic which support the qualita-
tive modelling of BRNs (Thomas, 1978, 1979; Thomas and d’Ari, 1990; Thomas
et al., 1995). Kinetic modelling of BRNs facilitated in predicting system dynamics
of various complex signalling pathways such as control of differentiation in helper
T-cells (Mendoza, 2006), segmentation in embryogenesis in Drosophila melanogaster
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(Sanchez and Thieffry, 2003), regulation of organ differentiation in Arabidopsis thaliana
flowers (Mendoza et al., 1999) and TLRs signalling (Ahmad et al., 2012; Aslam et al.,
2014; Paracha et al., 2014a).
Briefly, a BRN is modelled as a labelled directed graph composed of “nodes”
representing the biological entities interconnected with each other by “edges” repre-
senting the possible interactions among entities. Influence of entities either in positive
or negative manner can activate or inactivate other entities, respectively, so edges are
labelled with signs “+ & −”, which represent the stimulatory and inhibitory influ-
ences among entities connected with edges. The transition (evolution) of an entity
between two states (i.e. active or inactive) is of sigmoid nature and depends upon
certain levels (threshold levels) of its activator or inhibitor – defining the logical rules
governing the behaviour of the BRN. Positive integers represent these threshold levels
necessary for activating or inhibiting an entity. In presence of activator and absence
of inhibitor, the entity is always liable to be activated so evolution of the expression
of an entity depends on the set of resources at any instant of time. Logical parame-
ters, symbolically represented as (Kevolving protein(regulator/s)), are used to describe
the evolution of an entity. A resource is either an activator when it is present (above
threshold) or an inhibitor when it is absent (below threshold). The values of the pa-
rameters (positive integers) are unknown a priori. Computation of logical parameters
are validated by the proved conjectures of René Thomas (Thomas and d’Ari, 1990)
as well as from the biologically observed steady states (wet lab observations). SM-
BioNet can also be used to compute the logical parameters that is programmed at the
René Thomas’ kinetic logic and accepts a BRN with unspecified logical parameters
along with a specific observed biological behaviour coded in terms of Computational
Tree Logic (CTL) (Huth and Ryan, 2004).
One of the limitations of qualitative study is the production of large size of
state transition graph, which increases exponentially with number of entities in a
system (Gunawardena, 2010). Therefore, reduction of the biological regulatory net-
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work (BRN) prior to dynamical studies is usually performed following the strategies
described by .
GENOTECH developed by Ahmad et al. (2012) and GINSIM Chaouiya et al.
(2012) facilitate to construct a qualitative model of BRNs according to Thomas’ for-
malism, and gives the results in the form of state graph that represents dynamical
behaviour of the BRN.
2.1.5 Protein-protein interactions
PPIs have significant roles in the activities of a cell at the molecular level.
It is significant to understand the molecular mechanisms of PPIs by getting more
information about residue interactions, binding area and structural flexibility. The
structure determination of single proteins has been advancing and can be evidenced
by the expanding database of PDB. However, among other challenges, the structural
characterization of proteins complex is still challenging. It can be presented by the fact
that in NMR spectroscopy, if the molecular complex has large molecular weight than
it is either difficult or impossible to obtain and analyse the required data. Furthermore,
intermolecular nuclear Overhauser effects (NOEs) suppress the useful information
about the resonance of amino acids. Currently, the exclusive method for the systematic
study of large protein complexes is the strategy of in silico protein-protein docking.
This strategy employs the unbound (free-form) protein structures, determined either
experimentally or modelled comparatively, and predict the most probable orientations
of proteins against each other in a complex.
Several software packages have been developed for PPIs and majority of them
predict the protein-protein complexes based upon their energetic and/or geometrical
properties. In PPI, familiar sampling techniques include fast Fourier transform algo-
rithms (e.g., as used in PIPER (Kozakov et al., 2006), ZDOCK (Chen et al., 2003),
GRAMM-X (Tovchigrechko and Vakser, 2006), DOT (Mandell et al., 2001), CLUS-
PRO (Comeau et al., 2004) and MolFit (Katchalski-Katzir et al., 1992)) and Monte
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Carlo minimization (e.g., as used in ICM-DISCO (Fernández-Recio et al., 2003) and
RosettaDock (Lyskov and Gray, 2008)). A recently developed tool i.e. HADDOCK
(High Ambiguity-Driven DOCKing) adopts a unique approach for docking the given
proteins based on nuclear magnetic resonance (NMR) (and non-NMR) empirical
knowledge. Along with the data driven dockings, HADDOCK can employ ab initio
approach, if the experimental data is not available (De Vries et al., 2010; Dominguez
et al., 2003).
2.2 Sepsis
2.2.1 History & terminology
The term sepsis has been associated with intensive care nowadays, however,
the concept relatively belong to the ages. Hippocrates (460-370 B.C) presented the
term “sepsis” derived from the Greek word sipsi (“make rotten”). Countless deaths
have been caused due to the infections in the history of human life: from the Black
Death, “bubonic plague” in medieval Europe (Shrewsbury, 2005) to the current Se-
vere Acute Respiratory Syndrome (SARS) in Asia (Sorensen et al., 2006). Sepsis, a
Greek word meaning “putrid”, was supposed to be the cause for mortality when a
wound comes in contact with air and the process of putrefaction reached to the blood
(septicaemia). In 2735 B.C, Chinese Emperor Shen Nong treated the fever, recog-
nized as a sign of infection, with herbal medicines. In the 19th century, the English
surgeon, Lister, and Austrian obstetrician, Semmelweis, presented the idea that infec-
tion is the most likely reason for sepsis (Funk et al., 2009). Afterwards, the sepsis
was usually described in association with bacterial infection. In 1991, the Ameri-
can College of Chest Physicians (ACCP) and the Society of Critical Care Medicine
(SCCM) organized a "Consensus Conference" and outlined the sepsis, severe sep-
sis, systemic inflammatory response syndrome (SIRS) and septic shock (Bone et al.,
1992). After 10 years, ACCP, SCCM, European Society of Intensive Care Medicine
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(ESICM), American Thoracic Society (ATS) and the Surgical Infection Society (SIS)
revised these definitions and rationalised them, along with proposing a new scheme
for describing and staging the host response to infection i.e Predisposition + Insult +
Response + Organ dysfunction (PIRO) (Granja et al., 2013; Murakami et al., 1996).
2.2.2 Etiology
Sepsis is a severe condition related to aggravated human immune response
against endotoxins and severe infections (Bone et al., 1992; Lever and Mackenzie,
2007; Wheeler and Bernard, 1999). Medically significant gram-negative cocci can
cause meningitis (Neisseria meningitidis), sexually transmitted diseases (Neisseria
gonorrhoeae) and respiratory symptoms (Moraxella catarrhalis). Gram-negative
bacilli can cause primarily urinary problems (Escherichia coli, Proteus mirabilis,
Serratia marcescens and Enterobacter cloacae), respiratory problems (Hemophilus
influenzae, Legionella pneumophila, Klebsiella pneumoniae and Pseudomonas aerug-
inosa) and gastrointestinal problems (Salmonella enteritidis, Helicobacter pylori and
Salmonella typhi). Gram-negative bacteria Acinetobacter baumannii can cause noso-
comial infections such as secondary meningitis, bacteremia and ventilator-associated
pneumonia in the hospitals intensive-care units (Abe et al., 2010). Gram negative
bacilli have been implicated for severe infection, severe sepsis, organ damage and
septic shock due to an unknown mechanism (Hotchkiss and Karl, 2003; Remick,
2007). The bacteria, which can cause severe pathogenic symptoms are given in an
order Escherichia coli, followed by Klebsiella, P. aeruginosa, Serratia, Enterobacter
and Proteus species (Sugerman et al., 1981).
2.2.3 Risk factors
Risk factors have been considered vital for the development of gram-negative
sepsis. These risk factors include immunosuppressive treatments (radiation therapy
and chemotherapy in treatment of cancers and immunosuppressive agents to compro-
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mise transplant rejection rate and steroids), broad spectrum antibiotic therapy, medical
procedures such vascular and bladder catheters, drainage tubes, surgery, prosthetic
devices, inhalation therapy equipment, anatomic obstruction, burns or other trauma,
intestinal ulceration, progressive clinical conditions such as acquired immune defi-
ciency syndrome (AIDS), diabetes and serious chronic diseases (Bone et al., 1989;
Brun-Buisson et al., 1995; Mizock, 1984). Contaminated intravenous fluids have also
been associated with bacteremia (Matsaniotis et al., 1984).
2.2.4 Epidemiology
The economic and clinical impact of bacterial infections is huge in the de-
veloping world and if the patient develops certain diseases, for example, sepsis the
condition becomes more threatening. Data from health care economic surveys and
epidemiological studies have estimated that about 3% patients discharged from hos-
pital were observed positive, for severe sepsis and among them about 20% admitted
into the intensive care units ICU (Angus et al., 2001). Effective methods to prevent
sepsis and to identify these patients are a matter of choice, which may help to reduce
the hospital costs and moralities.The estimated ratio of deaths due to severe sepsis
was nearly 215,000 (28.6%) among 750,000 severe septic patients per annum in the
USA. The mortality related to severe sepsis has been testified as high as 30-50%. The
per annum budget of treating severe septic patients in the USA is estimated to be
around $17 billion. In 1992, about 500,000 instances of sepsis were observed in the
United States, amongst them 35% led to death (Wenzel, 1992). In 2001, approximately
750,000 instances of sepsis with 28.6% deaths annually were registered (Angus et al.,
2001). Trend analysis from 1993-2003 described a substantial growth in events of
severe sepsis and hospitalization (Dombrovskiy et al., 2007), which, according to a
recent report is still growing (Lagu et al., 2012). The estimated number of fatal cases
in the European Union, is 150,000 per annum bearing a cost of treatment nearly equal
to $ 6.7 billion (Levy et al., 2003).
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2.2.5 Treatment and management of sepsis
The cases of sepsis is increasing regardless of the advances in efficient ther-
apeutic and supportive strategies (Hotchkiss and Karl, 2003; Stone, 1994). Probable
deaths from 20% to 50% from sepsis are due to the gram-negative bacteria (Ibrahim
et al., 2000) and the fraction increases when septic patients lead towards septic shock.
The mortality rate could be elevated up to 90% in those septic patients, who proceed
towards complications of shock and organ failure (Carrigan et al., 2004).
The administration of suitable antimicrobial agents at earlier stages of sep-
sis is an important aspect of the successful control of sepsis (Hotchkiss and Karl,
2003). Management with suitable antibiotics have been implicated with 50% curtail
in shock and mortality rates (Kreger et al., 1980). As the microbiological results of
blood culture and susceptibility testing cannot usually be delivered in less than 2-4
days so 50% of the deaths caused by the gram-negative sepsis happen within first 2
days of the sepsis. So broad-spectrum antibacterial therapy via the parenteral route
is a therapeutic choice for management of sepsis (Baumgartner and Calandra, 1999).
Therapy for sepsis typically comprise of a blend of therapeutic agents e.g. aminogly-
coside (gentamicin and tobramycin) along with either anti-pseudomonal penicillin or
expanded-spectrum cephalosporin may be administered. Amikacin or netilmicin may
be delivered, if the patient is resistant to previous choices. In nosocomial infections,
broad spectrum cephalosporin is used rather than aminoglycosides because the infec-
tion could be likely due to the Klebsiella species as compared to the Pseudomonas. In
case of resistance against aminoglycosides and cephalosporins, imipenem can be used.
The appropriate management of electrolytes and fluid is also necessary. The other
supportive therapeutic regimen includes dobutamine, dopamine, norepinephrine, hep-
arin, naloxone, transfusions of granulocytes and immunotherapies etc. (Baumgartner
and Calandra, 1999).
The implications for contribution of pro- and anti-inflammatory immune re-
sponses in sepsis results in the discrepancies between scientific conclusions. Earlier
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studies recommended that pro-inflammatory responses along with the bacteremia are
the foremost reason of deaths, whereas anti-inflammatory reactions were related to
moderately rarer severe problems (Walley et al., 1996). In contrary, recent studies
contradict preceding studies and specified that anti-inflammatory immune responses
and immunodepression along with bacteremia is actually liable for CARS, severe sep-
sis, tissue damage and mortality (Gogos et al., 2000; Harris et al., 2005; Loisa et al.,
2003). Other studies have associated the mixed role of pro- and anti-inflammatory im-
mune responses during sepsis, which can deliver prospects to septic patients with the
control of pathogens and hyper-inflammation at various stages of sepsis (Hotchkiss
et al., 2013a,b).
2.2.6 Pathophysiology
(A) Microbial factors
A number of factors associated with the microbes can bring about the typical
septic inflammatory cascade. Pathogen-associated molecular patterns (PAMP) are
molecules of invading pathogens. PAMPs are usually LPS or flagellin in case of Gram-
negative bacteria, whereas muramyl dipeptide within the peptidoglycan cell wall of
Gram-positive micro-organisms as well as CpG bacterial DNA. In some instances,
capsules of bacteria (like in case of Streptococcus pneumonia), can easily escape
the phagocytosis, whilst pili of E.Coli enables that micro-organism to stick to the
epithelium of the kidneys. Sepsis due to gram-negative microbes is connected mostly
with the host’s response to LPS, generally known as endotoxins, which are present
in the cell wall of pathogens. However, gram-positive bacteria may lead to sepsis by
discharging exotoxins. A few exotoxins act like super-antigens and can easily cause
an instant burst of cytokines, that may consecutively bind to Major histocompatibility
complex (MHC) as well as with T-cell receptor (Hall et al., 1998).
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(B) Host factors
Most of these PAMPs are usually recognized by the innate immune system’s
pattern recognition receptors (PRR). Various receptors might be membrane-bound as
well as cytosolic (Takeuchi and Akira, 2010). So far 4 groups of PRRs are studied: the
toll-like receptors, the nucleotide oligemerization domain-like receptors, the C-type
lectin receptors, along with the Rig I-helicases (Meylan et al., 2006). Series of intra-
cellular signalling cascades are induced by the association of PAMP and PRR. Con-
sequentially, transcribing elements, including NFκB and activating protein-1 (AP1)
induce the transcription of PiCyts and AiCyts (Kawai and Akira, 2010). PiCyts and
AiCyts have the ability to mediate endogenous inflammation and immunomodulation,
respectively. PiCyts including TNFα , IL1β , IL-la, IL6 and IFNγ induce a series of im-
mune responses to overcome the pathogen load (Dinarello, 2000). In contrary, AiCyts
such as IL-lra, IL-4, IL-10, IL-13, TGF-β , tumour necrosis factor receptor (sTNFR)-I
and sTNFR-II control the immune responses and tempt immunodepression in sep-
tic patients (Opal and Depalo, 2000). These molecules produce profound effects by
acting on the kidneys, lungs, liver, cardiovascular system, coagulation cascade and cen-
tral nervous system. Multi-organ failure, including myocardial dysfunction, hepatic
failure, renal failure, acute respiratory distress syndrome (ARDS), and disseminated
intra-vascular coagulation may be followed by mortality.
2.3 Innate and Adaptive Immunity of the Host
The potent immunologic pressure induced by micro-organisms enforce the
induction of host’s strong immune response. The immune system of human beings
is specifically designed for reacting against infection through the collaboration of
two well associated systems, including innate and adaptive immunity, each of which
employs distinctive cellular processes to cope up with microbial infections (Medzhi-
tov and Janeway Jr, 1997). Particularly, the innate immune system detects infectious
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organism using pathogen-recognition receptors (PRRs) that recognize certain molec-
ular structures distinct for each class of the infectious organisms, while the adaptive
immune system utilizes clonally expressed and arbitrarily produced receptors of di-
verse specificity (Cooper and Alder, 2006; Medzhitov and Janeway Jr, 1997). PRRs
are deliberately expressed on cells, which are in the front rows against pathogens,
for example, surface epithelia, antigen presenting cells (APCs), including dendritic
cells (DCs). Specific PAMPs are recognized by PRRs and trigger various biological
processes including the induction of AiCyts and PiCyts. This first line defence agitate
adaptive immune reactions which lead to the activation of pathogen-specific B and T
cells to limit the pathogen load and its further spread in the host.
2.4 Toll-like Receptors
TLRs are the best characterized among PRRs . These PRRs were initially
identified in Drosophila as an essential component of its immune system against
fungal infections (Lemaitre et al., 1996). Soon after, the human homologue of the
Drosophila toll receptors, called as TLR were identified as significant receptors be-
tween the induction of innate and adaptive immunity (Medzhitov and Janeway Jr,
1998). To date, an aggregate of 10 TLRs has been characterized in human beings (Lee
et al., 2012). The first evidence of PRR attachment with PAMP was presented by the
identification of an endotoxin, i.e. LPS derived from the cell wall of gram-negative
bacteria, in complex with TLR4 (Medzhitov and Janeway Jr, 1998; Poltorak et al.,
1998). Subsequently, identification of other PAMPs with an origin of viral genetic
material, bacterial lipoproteins, glycolipids, unmethylated bacterial DNA, mycobac-
teria, fungi and parasites were identified in making complex with other TLRs (Kumar
et al., 2009; Takeda et al., 2003). The TLRs are groups of type-I transmembrane
proteins bearing a horseshoe-like solenoid shaped ectodomain holding 16-28 pairs
of leucine-rich repeats, which are important for distinguishing the PAMPs (Jin et al.,
2007; Kim et al., 2007; Matsushima et al., 2007; Ohto et al., 2007). The sequences
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of ectodomain are very much homologous in all the TLRs, regardless of that, TLRs
can recognize a number of different types of ligands. This selectivity for the complex
formation between TLRs and ligand is due to the variable amino acid composition
within the leucine-rich repeats (LxxLxLxxN) (Lee et al., 2012). All the TLRs share a
common cytoplasmic domain known as TIR (Toll-IL-1 receptor) domain (Akira and
Takeda, 2004), which consists of nearly 150 residues.
Three subgroups of TIR-domains have been identified, so far. Receptors with
first type of TIR-domains are those receptors, which respond to interleukins produced
by immune cells including dendritic cells, monocytes and macrophages. Receptors
with this type of TIR-domains have extracellular immunoglobulin domains. Receptors
with second types of TIR-domains are classical TLRs and respond to the pathogen
components. A third type of TIR-domain is present in the adaptor proteins that inter-
acts with the subgroup 1 and 2 TIR-domain receptors and induce signal transduction
(Xu et al., 2000).
TLRs are mostly engaged in forming dimers (Ozinsky et al., 2000). Some of
them such as TLR1-TLR2, TLR8-TLR7, TLR2-TLR6 form heterodimers, whereas
TRL3, TLR4 and TLR9 form homodimers (O’Neill and Bowie, 2007; Wang et al.,
2006). Before binding with ligands, TLR monomers have low affinity for another
member of dimer. Though subsequent to that stage, conformational changes within
the TLRs are believed to position the two TIR-domains in a closer position, which
ultimately result in a suitable platform for the formation of an active TLR-adaptor
complex. This complex result in the activation of downstream signalling. Activation
of TLRs signalling induce specific biological processes, which not only interfere with
the bacterial invasion but also are involved in the immune pathogenesis.
TLRs induce the innate immune system by the induction of two major path-
ways, including MyD88 dependent and/or independent pathways. These two path-
ways are associated with the expression of PiCyts and AiCyts, including IL6, TNFα ,
IL-12, IL-10 and type 1 interferons etc.
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2.4.1 TLR4 signalling
In previous studies, it has been manifested that healthy volunteers challenged
with LPS (Wittebole et al., 2005) as well as septic patients (Brandl et al., 2005; Härter
et al., 2004) bear elevated cellular levels of TLR4. Induction of TLR4 contributes
to the expression of PiCyts and AiCyts by inducting various signalling cascades
(Hoebe et al., 2004). TLR4 is specific amongst other members of its family because it
possesses the property of stimulating MyD88 and TRIF dependent pathways (Kawai
and Akira, 2010), briefly described below.
(A) MyD88 dependent pathway
Different adaptor proteins are involved in TLR signalling that are specific to
each type of ligand and determine the outcome of innate immunity as a response.
MyD88 dependent pathway recruits adaptor and signalling proteins such as MAL,
IRAK1, IRAK4, TRAF6, TAB1 and 2, TAK1, ERK, JNK, p38, IKKs that lead to
the activation and translocation of NFκB into the nucleus where it transcripts the
cytokine genes (Medzhitov, 2001). Adaptor proteins are involved in contributing va-
riety to TLR signalling (Akira et al., 2001). MyD88 is typically considered as the
universal adaptor for the TLRs (except TLR3) because studies with MyD88 deficient
mice manifested a significantly weakened response to ligands of TLR2, TLR4, TLR5,
TLR7, TLR9 and IL-1 Receptor subfamily (Medzhitov et al., 1998). MyD88 is re-
cruited to the TLRs upon ligand attachment and consequently leads the activation
of IRAK family members, specifically IRAK1 and IRAK4 that start a complicated
signalling including the poly-ubiquitination of important signalling proteins. TRAF6
and E3-ligase are vital downstream protein targets of the IRAK, which activates and
receives K63 auto-ubiquitination. Poly-ubiquitinated TRAF6 assists the induction
of transforming-growth-factor-b-activated kinase (TAK1) via the ubiquitin-binding
adaptors TAK1-binding protein 1 and 2 (TAB) as well as IKK kinases through bind-
ing of the IKKγ subunit (Singhirunnusorn et al., 2005). Active TAK1 consequently
33
Chapter 2 2.4 Toll-like Receptors
contributes to the induction of the Nuclear Factor-kB kinase (IKK) complex and
thence NFκB besides the activation of p38, JNK and particular IRFs with subsequent
expression of cytokines and type I interferons (Ninomiya-Tsuji et al., 1999).
(B) MyD88 independent or TRIF dependent pathway
MyD88 independent or TRIF dependent pathway is induced when TLRs,
specifically TLR3 and TLR4 recruits, TRIF adaptor molecule. This pathway is shared
by TLR3 and TLR4 and contributes to the production of Type I interferons, includ-
ing IFN-α\β (Akira and Takeda, 2004). TRIF recruits TRAF3, TBK (TRAF fam-
ily member-associated NFκB activator binding kinase) and IKK ε that result in the
IRF3 mediated transcription of IFN-β gene and other genes including IP-10. How-
ever, TRIF signalling cascade can utilize many of the same adaptor proteins as the
MyD88 dependent pathway to carry out parallel signalling towards NFκB. The impor-
tant adaptor proteins in TRIF dependent signalling are TRAF3 and RIP1 manifested
critical for the induction of TRIF-mediated NFκB activation, nevertheless, MyD88
dependant signalling cascade has been described as unequivocal signalling pathway
for the induction of PiCyts. The signalling cascades are portrayed in Figure 1.3.
2.4.2 Negative regulation of TLR4 pathway
TLR4 induced innate immunity is influenced by various down-regulatory pro-
teins (Liew et al., 2005). Down-regulation of TLR4 signalling preserve homoeostasis
between infection and inflammatory behaviour of the host (Yang et al., 2011). In-
hibitory proteins like A20 zinc finger protein, SOCS-1 and SARM are previously
accounted for their inhibitory roles (Boone et al., 2004; Carty et al., 2006; Yoshimura
et al., 2007). IFN-β recruits TH1 to TH2 reposition, which repress the expression
levels of propagating PiCyts (Mahieu and Libert, 2007; Šega et al., 2004; Weighardt
et al., 2006). A number of studies highlighted the importance of SOCS-1 in down-
regulation of endotoxemia and hyper-inflammation by inhibiting PiCyts and IFN-β
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dependent signalling, respectively (Baetz et al., 2004; Prêle et al., 2008).
2.4.3 TIRAP/MAL
MAL is a 221 amino acid long protein (Uniprot ID: P58753) with a Pro, Glu,
Ser, Thr-containing (PEST) region at N-terminal and TIR-domain on the C-terminal
(Lin et al., 2012). MAL has an essential role in the TLR2 and TLR4 mediated MyD88
dependent downstream signalling. It has also been associated with multiple regula-
tory events after interacting with various other proteins such as the plasma membrane,
IRAK-1, IRAK-2, IRAK-4, TRAF6, SOCS-1, BTK and PKCδ . MAL interacts with
plasma membrane through phosphatidylinositol -4,5-biphosphate (PIP2) binding mo-
tif at N-terminal (Kagan and Medzhitov, 2006). TRAF6 has been observed for acti-
vation of NFκB after interaction with MAL (Verstak et al., 2009). IRAKs have been
associated with the phosphorylation and ubiquitination of MAL followed by its degra-
dation (Dunne et al., 2010; Muzio et al., 1997). SOCS-1 has been associated with the
degradation of MAL and provide a negative feedback loop to the induction of PiCyts
(Mansell et al., 2006).
Mutagenic studies of MAL at positions 96, 100, 108,115, 117, 121, 132, 143,
165, 180, 184, 190 and 197 as loss of function mutations (Fitzgerald et al., 2001;
Khor et al., 2007; Nagpal et al., 2009). The mutation of Ser180Leu in the gene of
MAL/TIRAP either presents the homozygous (Ser/Ser or Leu/Leu) or heterozygous
(Ser/Leu) individuals. Ser/Ser homozygosity has been associated with the condi-
tion of hyperinflammation when the subjects are in contact with pathogenic species,
whereas Leu/Leu homozygosity do not allow the signalling to be over-active. This
phenomenon suggests that modulating the structure of MAL, immune disorders re-
lated to TLR2 and TLR4 can be controlled.
In a recent study, high-throughput recombinant cloning and expression analy-
sis were performed to discover stabilised constructs of human MAL TIR-domain and
its crystal structure. They examined different constructs, including a construct without
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29 N-terminal residues and a construct with 79-221 residues, which yield the crystal
structure deposited in Protein Data Bank (PDB) with ID:3UB2 (Lin et al., 2012). The
structure of TIR-domain of MAL (Figure 2.3) displays an individual molecule in
the asymmetric unit made up of a TIR-domain having five-stranded parallel β -sheets
(βA–βE) bordered by four α-helices (αA and αC–αE). The TIR-domain of MAL
has been illustrated as a different structure from remaining TIR-domain structures as
it does not have a helical segment (αB) between the βB- and βC-sheets and rather
bears a longer loop known as AB-loop between the helix (αA) and the βB-sheet.
Nearly all of the residues making up this loop were not solved in the electron density,
presumably due to underlying flexibility.
Figure 2.3. TIR-domain of MAL. (A) Overview of the 3D structure (PDB ID:3UB2)
of TIR-domain of MAL. Phosphorylatable residues and variants are marked and given
in legend. (B) Topology diagram of TIR-domain of MAL. Figure reproduced from
Paracha et al. (2014b).
2.5 Protein Kinase in TLR Signalling
Protein Kinase are enzymes, which activate or inactivate different proteins by
adding phosphate groups at specific serines, thryonines and tyrosines. Phosphoryla-
tion generally leads to structural alteration by changing its activity, or affiliation with
other biological molecules and is a crucial requirement for cellular signalling (Burnett
and Kennedy, 1954). Two important subgroups of kinase proteins in TLR signalling
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are tyrosine kinase (TK) and serine/threonine kinase (STK), briefly discussed below.
2.5.1 Tyrosine kinase
Tyrosine kinase are those proteins, which can shift a γ-phosphate of Adeno-
sine TriPhosphate (ATP) to a tyrosine residue in a substrate protein. It serves as an
“activation” or “inactivation” change over of substrates in numerous biological func-
tions. TKs can be divided into receptor and cytoplasmic/non-receptor TKs. There are
58 known receptor TKs and 32 cytoplasmic TKs. TLRs and its known adaptors do
not possess intrinsic tyrosine kinase activity. There are three main families of tyrosine
kinases, including the sarcoma (Src), spleen tyrosine kinase (Syk) and tyrosine kinase
expressed in hematocellular carcinoma (TEC) recognised for their engagement in
TLR signalling (Page et al., 2009).
(A) Bruton’s tyrosine kinase
BTK is a member of TEC family of cytoplasmic TKs. Except plasma and
T-cells, BTK is induced in all the hematopoetic cells (Brunner et al., 2005), especially
in B lymphocytes (Khan et al., 1995). The BTK comprises of 659 residues with
a molecular weight (M.W). 77 kilo daltons (kDa). Due to the homology of the C-
terminal region, it has been associated with the Src family of tyrosine kinases (SFK),
whereas its N-terminal has been related to Src homology 2 (SH2) domain and SH3
domain (Tsukada et al., 1993; Vetrie et al., 1993). Together with Itk (Heyeck and
Berg, 1993), TXK (Haire et al., 1994), Bmx (Tamagnone et al., 1994) and Tec (Mano
et al., 1990), BTK form the Tec family of kinases (TFK). The TFK members are
differentiated from the SFK due to the existence of a Pleckstrin homology (PH)
region accompanied by a Tec homology (TH) domain present at the N-terminal of
the SH domains, reviewed in (Smith et al., 2001) (Figure 2.4). In contrast to the
globular configuration of Src involving numerous intra-molecular interactions, a low-
resolution structure of the full-length BTK protein indicated a linear arrangement
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of the domains with no, or few, intra-molecular interactions (Márquez et al., 2003).
The domains in BTK are important for protein-protein or lipid-protein interactions,
regulating the localization and activity of the protein. Several proteins have been
shown to interact with the different domains in BTK (Takesono et al., 2002).
Catalytic domain is the largest region in BTK. This region is also known
as the kinase domain or seldom as the SH1 domain. Among tyrosine kinases, the
kinase domain is largely conserved. Around 250 residues are arranged into 2 lobes
among which the ATP binding site and catalytic site are present. This formation is
characteristic of most of the kinases. Typically, kinase domains possess conserved
tyrosines placed in an activation loop near the catalytic site. Upon activation, these
tyrosines are phosphorylated (Al-Obeidi et al., 1998). Phosphorylation of Tyr551 at
BTK has been implicated in its activation mediated by SFK (Rawlings et al., 1993).
In a study Gray et.al. (2006) observed that MAL experiences tyrosine phos-
phorylation by BTK during TLR signalling and that this phosphorylation is needed
for MAL so that it can result in the induction of NFκB dependent gene expression
(Gray et al., 2006). Moreover, the study also implicated about the phosphorylation of
Tyr86, Tyr106, and Tyr187 of MAL by BTK upon activation of TLR2 and TLR4 in
response to LPS.
Figure 2.4. Domains of BTK and relative availability of crystal structures.
(A) Protein feature view of PDB entries mapped to a UniProt sequence of BTK
(ID:Q06187). (B) The cartoon representation of crystallized BTK structure available
in PDB with ID:4OT5. Balls represent the co-crystallized ligand in 4OT5.
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2.5.2 Serine/Threonine kinases
Serine/threonine kinases transfer the γ-phosphate of ATP to hydroxyl (OH)
group of serine or threonine of a substrate protein (Burnett and Kennedy, 1954).
Mostly, serine/threonine kinases including TBK1, IRAKs, the IKKs and TAK1 are
involved in TLR signalling. Previous studies indicated the engagement of PKCδ in
TLR4 signalling by phosphorylating the MAL TIR-domain (Kubo-Murai et al., 2007;
Loegering and Lennartz, 2011). Nevertheless, location of phosphorylation is still to
be elucidated.
(A) Protein kinase C
Protein kinase C (PKC) (EC 2.7.11.13) is a class of protein kinases, which are
engaged in modifying the functionality of other substrate proteins through phosphory-
lation. PKC enzymes are triggered by increases in the levels of calcium ions (Ca2+) or
diacylglycerol (DAG). The PKC family comprises of 15 isozymes in humans (Mellor
and Parker, 1998). They are separated into 3 subfamilies including conventional (or
classical), novel, and atypical (Nishizuka, 1995). Conventional (c) PKCs comprise of
α , β I, β II, and γ isoforms. These require DAG, Ca2+ and phosphatidylserine for ac-
tivation. Atypical (a) PKCs (involving protein kinase Mζ and ι / λ isoforms) require
neither Ca2+ nor DAG for activation. On the other hand, novel (n) PKCs include the
δ , ε , η , and θ isoforms, do not require Ca2+ though only require DAG for activation.
All PKCs comprise of almost similar secondary structures and domains, in-
cluding a regulatory and a catalytic domain bound together due to a hinge region.
The catalytic domain is conserved between different isoforms of PKCs. Within the
classes, the regulatory domain is similar though due to different requirements for
second messengers, variations are present among each class (Figure 2.5-B).
Numerous studies have attempted to explain the role of PKC in TLR signalling.
The relationship between LPS and PKC has been investigated by Aksoy et al. (2002)
and Shinji et al. (1994). Moreover, it has been suggested that TLR4 is an important
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component in the LPS induced translocation of PKC isoforms in the macrophages
of LPS-responsive mouse (Shinji et al., 1994). PKCζ , an atypical PKC isoform, is
suggested to activate IRAK in the presence of LPS (Hu et al., 2002), whereas, PKCε ,
a novel PKC isoform, is essential for LPS induced IL-12 expression (Aksoy et al.,
2002). Additionally, PKCε deficient murine macrophages demonstrated their inability
to resolve bacterial infections (Castrillo et al., 2001).
(B) Protein kinase C δ
PKCδ is the member of novel PKC family. PKCδ has been implicated in
growth inhibition and apoptosis, although has also been illustrated to contribute in
mitogenesis, differentiation, tumour progression and tissue remodelling during inflam-
mation.
PKCδ is 78 kDa and protein and comprises of two major domains including a
regulatory and a catalytic domain. The N-terminal regulatory domain consists an auto-
inhibitory part known as “pseudosubstrate” and four conserved regions, including the
C1 and C2 motifs at N-terminal and the C3 and C4 at C-terminal. Besides, PKCδ
comprises of five variable domains (V). The variable domain 3 (V3), known as hinge
region, splits the regulatory and catalytic domains (Figure 2.5-B).
The C1 motif carries Phorbol 12-myristate 13-acetate (DAG/PMA) interacting
sequences that enable the interaction to a hydrophilic cleft situated on a non-polar
interface of this region. Interaction to the cleft casts a adjacent hydrophobic interface
that encourages the interaction of PKC to membranes. PKCδ has a C2-like domain
situated at the N-terminal. It has the comparable core amino acids of the C2 region,
although it is deficient in the essential Ca2+ coordinating acidic amino acids that
enable classical PKCs to bind Ca2+. The C3 and C4 domains are mandatory for
ATP and substrate binding and catalytic activity. The pseudosubstrate region, situated
between the C1 and C2 motifs, preserves PKCδ in an passive state by hindering the
access to the substrate binding pocket. The proteolytic activation of PKCδ yields a 40
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kDa segment that can translocate to the mitochondria and/or nucleus. The complete
information about different domains of PKCδ is given in Table 2.1.
In a study, Kubo-Murai et al. (2007) investigated the effects of pharmaco-
logical and phospholipid inhibitors and suggested the involvement of nPKC family
members, particularly PKCδ , in association with MAL. Additionally, the authors
have also proposed that TIR-domain of MAL makes its interactions with PKCδ . Fur-
thermore, it illustrates the fact that PKCδ -deficient RAW264.7 cells have lost the
activation of IKK. However, the study lacks the provision of structural inferences
such as sites of MAL that are particularly phosphorylated by MAL and role of PKCδ
in the presence of BTK.
C1A C1B C2 C3 C4PS
C1A C1BC2 C3 C4PS
C1PB1 C3 C4PS
Kinase DomainRegulatory Domain
cPKC: α, βI, βII, γ
nPKC: δ, θ, ε, η 
aPKC: ξ, ι/λ
A
C1A C1BC2 C3 C4PS
Pseudosubstrate 
domain
Caspase-3
Cleavage site
Activation 
loop
Translocation 
Inhibitor Site
Translocation
Activator Site
ATP Binding
Sequence
Nuclear 
Localisation
signal
NH 2 COOH
Turn 
Motif
Hydrophobic
Motif
B
Tyr52 Tyr64 Tyr155
Tyr
187
Tyr
505
Tyr
512
Tyr
565
Figure 2.5. Domains of PKC isoforms. (A) Top: PKCs bear a conserved kinase
domain and inconsistent regulatory regions. Regulatory domains of all PKCs have a
pseudosubstrate motif (PS) (in green). Tandem C1 domains are the sensors of phorbol
12-myristate 13-acetate (PMA) / DAG in cPKC and nPKC isoforms, whereas they
are absent in aPKC and C1 could not bind with DAG/PMA. The C2 regions (in
yellow) work as calcium-dependent phospholipid binding modules in cPKCs. nPKC
C2 domains do not bind calcium; the PKC C2-like domain is a phosphotyrosine
interaction module. Variable regions in PKC isoform are rendered in white. Source
(Newton, 1995). (B) Domains of PKCδ with important phosphorylation sites. The
phosphorylation sites of PKCδ were acquired from Uniprot:ID Q05655.
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2.6 Diseases Linked with TLR4
Various types of ligands (both endogenous and pathogen-oriented) distin-
guished as TLR4 agonists indicate that it is prone to be linked with various diseases.
Numerous studies proposed that TLR4 is connected with asthma, cardiac disease,
renal disease, inflammatory bowel disease, obesity, liver disease, multiple sclerosis,
atherosclerosis, diabetes (types I and II), Parkinson’s disease, rheumatoid arthritis,
Alzheimer’s disease and infectious diseases. Hereditary information is in develop-
ment to confirm the affiliation of TLR4 with respective diseases (Kanzler et al., 2007;
O’Neill, 2003; O’Neill et al., 2009).
Protection against endotoxemia has been observed in TLR4 knock-out mice
(Hoshino et al., 1999), though an enhanced susceptibility was observed due to the sys-
temic Gram-negative infections as caused by Salmonella typhimurium (O’brien et al.,
1980). Since induction of TLR4 is a necessary event for induction of innate immunity
against pathogens, although can also mediate the consequences of endotoxins present
in the systemic circulation. Investigations of various Gram-negative microbes, includ-
ing Klebsiella pneumoniae, Haemophilus influenzae, E. coli, Neisseria meningitides
and Brucella abortus (Schnare et al., 2005) have illustrated the role of TLR4 in stimu-
lating innate immunity. Moreover, the pathogenic role of TLR4 in infection caused by
Mycobacteria tuberculosis and S. pneumoniae has also been observed (Schnare et al.,
2005). There are now a great number of published studies relating polymorphisms
in TLR4 with infectious diseases, including sepsis, Gram-negative infections, other
bacterial diseases (including tuberculosis, malaria, and infections with respiratory syn-
cytial virus and Candida spp.) (Ferwerda et al., 2008).The connection of TLR4 with
numerous maladies stresses the importance of TLR4 as a therapeutic choice. A num-
ber of diverse processes is in consideration to modify TLR4 mediated pharmacology,
including receptor antagonists, agonist and inhibition of signal transduction.
The selective modulation of two signalling pathways i.e. TRAM/TRIF and
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MAL/MyD88 can provide the opportunity for selective modulation of TLR4 sig-
nalling. The exact clinical objective for altering TLR4 signalling is a captivating
research. In patients with sepsis, for instance, it has been proposed to be more advan-
tageous to utilize a partial agonist as opposed to an antagonist which can decrease
the TLR4 activity to half of the normal, so that some activity of TLR4 stays to em-
power defensive immunity. Likewise, the auxiliary action of a partial agonist that
specifically empowers TRAM/TRIF signalling would be more therapeutically useful
than a full TLR4 agonist, which may induce exacerbated hyper-inflammatory immune
responses.
At present, TLR4 antagonists are going through different phases of clinical
tests for the management of sepsis, however same options may well be valuable for
the treatment of an extent of various other conditions. Against Gram-negative induced
sepsis, antagonists of lipid A have been under research prior to the discovery of TLRs.
Former work discovered various analogues of lipid A (Rhodobacter sphaeroides lipid
A and lipid IVa) (Golenbock et al., 1991). In 1995, synthetic Rhodobacter capsulatus
lipid A was created that work against E. coli lipid A. This synthetic lipid A constituted
the basis for E5531 (Christ et al., 1995). E5564 (eritoran) is an altered form of E5531,
which is in clinical trials for treatments of Gram-negative sepsis and endotoxemia
(Mullarkey et al., 2003). E5564 has been observed in antagonizing the interaction of
protein ligand EDA with TLR4 (Okamura et al., 2001), recommending its other uses
rather than only for the treatments of sepsis and endotoxemia. Different antagonists of
TLR4 such as auranofin (an anti-rheumatic gold compound), curcumin, acrolein and
cinnamaldehyde inhibit homo-dimerization of TLR4 (Lee et al., 2008; Youn et al.,
2008, 2006), although particular mechanism is doubtful. However, management of
septic patients with anti-inflammatory agents has not been found as beneficial in
improving the outcomes (Rittirsch et al., 2008); hence, it will be very stimulating to
assure the clinical efficacy of inhibiting TLR4/MD-2 pathway in sepsis.
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MATERIALS AND METHODS
3.1 Qualitative Modelling
Biological regulatory networks (BRNs) can be modelled with a number of
approaches. Currently both quantitative and logic modelling are used to model BRNs
(Le Novere, 2015). Quantitative models are based on reaction kinetics and have been
used to describe BRNs (metabolic networks, signalling pathways and gene regulation)
(Le Novere, 2015). Experimental findings and data of a qualitative nature such as gene
targeting and phenotype screening have led to the development of methods to model
BRNs on the basis of logical rules (Boolean logic and Kinetic logic) (Thomas, 1979;
Wang et al., 2012). Brief introduction of different approaches have been given in
Chapter 2 (Sections 2.1.2 and 2.1.3).
3.1.1 Asynchronous Kinetic logic
Kinetic logic is introduced by René Thomas’ which is a qualitative approach
for the modelling of a BRN composed of entities, their threshold levels and type of
interactions (Thomas, 1979). A BRN can be modelled as a labelled directed graph
composed of “nodes” representing the entities interconnected with each other by
“edges” that represent the possible interactions among entities. A threshold level rep-
resents the qualitative level of an entity to activate or inhibit a particular target entity in
a BRN. Entities can either be genes, mRNA, proteins or small molecules etc. which in-
teract with one another. Types of interactions in a BRN can be illustrated in a positive
or negative manner representing activation or inhibition, respectively. Activation and
inhibition of entities can be depicted as sigmoid curves (Figure 3.1), i.e. non-linear
bounded curves are briefly described below.
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Figure 3.1. Dummy tendency graphs of biological regulation. (A) Upper left sig-
moid graph represents the positive regulation of a target entity Y by its activator X ,
whereas lower left graph depicts the step function of activation. (B) Upper right sig-
moid graph represents the negative regulation of a target entity Y by its inhibitor X ,
whereas lower right one represents the step function of inhibition. When the qualita-
tive level of X is < threshold levels (represented by σ on X-axis) then there is no or
little effect on the levels of Y . On the other hand, if qualitative level of X is ≥ to σ
then activation (A) or inactivation (B) of Y is happened.
Activation If an entity (X) increases the rate of formation (synthesis) of a target
entity (Y ), then it is said to be a positive regulator or an activator. This phenomenon is
represented by increasing sigmoid curve (Figure 3.1-A). It can be seen that X slightly
regulate the rate of activation of target entity Y below a specific threshold level σ .
However, as soon as the qualitative level of X reaches to its threshold then the rate
of formation of target entity Y rapidly elevated at a level, where it becomes saturated.
In other words, whenever X < σ then X is unable to activate its target entity Y and if
X ≥ σ , then it has the ability to activate Y .
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Inactivation If an entity (X) reduces the rate of activation of its target entity (Y ),
then it is said to be a negative regulator or inhibitor and phenomenon is considered
as down-regulation, inactivation or inhibition. Process of inhibition is also dependent
on the threshold level of X , which means that whenever it achieves its threshold level
σ then X will be effective to reduce the activation levels of its target entity Y up
to a level where Y will completely abolish or become inactive. The phenomenon of
inactivation is shown as decreasing sigmoid curve in Figure 3.1-B.
3.1.2 Semantics of Kinetic logic
This section presents the semantics of René Thomas’ formalism using the
definitions and hypothetical toy example of a BRN made up of three proteins and
interactions among them (Figure 3.2). Definitions 1-6 and hypothetical toy example
have been adapted from (Ahmad et al., 2012).
a
bc
+1
+1
+1
Figure 3.2. Example of a toy BRN. Example of a toy BRN consisting of three
proteins or entities i.e. a,b and c are shown as nodes and interaction among them
as edges. All edges are labelled with “+" sign to show that each entity activates its
successor entity, whereas threshold levels are labelled by integer “1". Figure adapted
from Ahmad et al. (2012).
Definition 1 (Directed Graph) “A labelled directed graph (D) is a tuple (V,E),
where V is the set of all vertices, nodes or entities and E ⊆V ×V is the set of edges.
In the directed graph D(V,E) (Figure 3.2), V = {a,b,c} where edges between
them are E = {(a,b),(b,c),(c,a)}. An edge (a→ b) is considered to be directed from
a to b; a is the tail where head of the edge is b. In a directed graph D(V,E), D−(e)
47
Chapter 3 3.1 Qualitative Modelling
and D+(e) denote the set of predecessors and successors of a node e. In Figure 3.2,
D−(a) = c and D+(a) = b.”
Definition 2 (Biological Regulatory Network) “A biological regulatory network (BRN)
is a labelled directed graph D(V,E), where V is a set of vertices which represents
biological entities and E ⊆V ×V , is a set of all possible edges which represent the
interaction between entities.
• Each edge in E = {(a,b),(b,c),(c,a)} is labelled by a pair (σi j,ωi j), where i
and j represents the vertices at tail and head of an edge, σi j is a positive integer
(qualitative threshold level) and ωi j is either (+) or (-), where (+) represents
activation and (-) represents inactivation imposed by vertice i at j. For example
in Figure 3.2, σab = 1, σbc = 1 and σca = 1 where ωab = +, ωbc = + and
ωca =+.
• Each vertex i has a limit li, which is equal to the outdegree of i (the total number
of targets of a vertex i, such that ∀ j ∈D+(i) each σi j ∈ {1,2, ...,ri} where ri≤ li.
• Each vertex i has its abstract expression in the set Zi = {0,1, ....,ri}.”
Definition 3 (Qualitative States) “ The state of a BRN is a tuple s ∈ M, which de-
notes a configuration of the qualitative expression levels of all entities, where:
M =Πi∈V Zi
A qualitative state is represented by a vector (xi)∀i∈V , where xi denotes the level of
expression of i ∈V . A qualitative state represents a configuration of all the elements
of a BRN at any instant of time. The number of activators of a particular variable at
a given level of expression are represented by its set of resources (see Definition 4
of Resources). In the following definition, the set of resources is formally defined,
which represents all the activators of an entity at any instance of time."
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Definition 4 (Resources) At level xi, the set of resources Rxi of an entity i ∈ V is
defined as Vxi = { j ∈ D−(i)|(x j ≥ σi j and ω ji =+) or (x j < σ ji and ω ji =−)}.
Definition 5 (Logical Parameters) “Dynamic behaviour of a BRN is under the in-
fluence of logical parameters. The set of logical parameters are defined as:
K(D) = {Ki(Rxi) ∈ Zi ∀i ∈ V} The information about the evolution of xi is inferred
by the parameter Ki(Rxi) (at a level x of i). There are three cases: (1) xi cannot evolve
from its current level if xi = K(Rxi) (2) xi increases by one unit if xi < Ki(Rxi) (3) xi
decreases by one unit if xi > Ki(Rxi).”
Logical parameters and set of resources are illustrated in Table 3.1 for the running
example of three entities (Figure 3.2). With the help of an evolution operator “”
(Bernot et al., 2007), it is convenient to describe the transition between two qualitative
states.
xi  Ki(Rxi) =

xi +1 if xi < Ki(Rxi);
xi−1 if xi > Ki(Rxi);
xi if xi = Ki(Rxi).
where xi and Ki(Rxi) ∈ Z≥0
Definition 6 (State Graph) “Let D(V,E) be a BRN and sxi represents the activation
level of entity i in a state s ∈M. Then the state graph of the BRN will be the directed
graph G = (S,T ), where S is a set of states and T ⊆ S× S represents a relation
between states, called the transition relation, such that s→ s′ ∈ T if and only if:"
1. ∃ a unique i ∈V such that sxi ̸= s′xi and s′xi = sxi  Ki(Rxi), and
2. ∀ j ∈V \{i} s′x j = sx j .
State graph of example BRN (Figure 3.2) is illustrated in Figure 3.3. Qualitative
(discrete) states are represented by nodes. Values given inside a node stand for the
qualitative levels of protein or entities a,b and c, respectively. Values of "0" and "1"
represent the active and inactive status of entities, respectively.
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Table 3.1. States, resources and logical parameters for the toy BRN The states,
resources and logical parameters of toy BRN illustrated in Figure 3.2. Table adapted
from Ahmad et al. (2012).
xa xb xc Rxa Rxb Rxc Ka(Rxa) Kb(Rxb) Kc(Rxc)
0 0 0 {} {} {} 0 0 0
0 0 1 {c} {} {} 1 0 0
0 1 0 {} {} {b} 0 0 1
0 1 1 {c} {} {b} 1 0 1
1 0 0 {} {a} {} 0 1 0
1 0 1 {c} {a} {} 1 1 0
1 1 0 {} {a} {b} 0 1 1
1 1 1 {c} {a} {b} 1 1 1
All the states (xi), set of resources (Rxi ) and logical parameters Ki(Rxi ) of the toy BRN (Figure 3.2) are listed.
100
000
110
010
011
111
101
001
abc
Figure 3.3. State space/graph of the toy BRN. A state space or graph of the toy
BRN, illustrated in Figure 3.2 adapted from Ahmad et al. (2012)
Definition 7 (Trajectories) An alternating sequence of states and transitions in the
state graph G constitute a trajectory (path).
For example, in Figure 3.3, “100 → 110 → 010 → 011 → 001 → 101 → 111” is a
trajectory. A trajectory is the representation of a part of system evolution and could
lead the system either towards stable state or system homoeostasis (oscillations or
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cyclic trajectories).
Definition 8 (Cycle) A cycle is a closed trajectory that starts and ends at the same
state.
For example, in Figure 3.3, “100 → 110 → 010 → 011 → 001 → 101 → 100” is a
cycle. A system remains in cycles during homoeostasis, on the other hand the system
stabilizes itself in stable state (e.g. state “111”). Other trajectories are transient in
nature and visited once during system dynamics.
Definition 9 (Strongly connected components (SCCs)) In a state graphG =(S,T ),
a strongly connected component (SCC) is a sub-graph with maximal set of states S’⊆S
such that for every pair of states si and s j in S′, there is a trajectory from si to s j and
vice versa.
Strongly connected components define the regulatory cycles of signalling networks.
SCCs are those parts of the trajectory in which the system loops through specific
trajectories (Allesina et al., 2005).
(A) Model Checking
Graph traversing algorithms can be employed to find simple behaviours in-
cluding the presence of deadlock (stable states) or cycles but comparatively structured
and formal querying mechanism is needed for the systematic search of significant be-
haviours in the state graph. Model checking is an exhaustive computational technique
that confirms that whether a state graph holds a property in states or not (Clarke et al.,
1999).
Model Checking is one of the formal approaches that can account for the
limitations of Rene Thomas’ formalism related with the determination of logical
parameters. To compute the values of logical parameters in Rene Thomas’ formal-
ism, Bernot et al. (2004) have used Computational Tree Logic (CTL) based model
checking to infer their values from experimental observations (represented as CTL
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formulae). In this approach, first state graphs are generated by all possible linear
combination of logical parameters, and then only those sets of parameter are selected
which satisfy the CTL formulae (Bernot et al., 2004; Khalis et al., 2009; Richard et al.,
2006).
(B) Computational Tree Logic (CTL)
is a branching time logic which is applicable to state graph of a BRN (Clarke
et al., 1999) to explore the properties of a system such as stable states and cycles.
The complete specification of the CTL formula, as well as its abstract grammar
have been discussed in detail by Clarke et al. (1999); Khalis et al. (2009).
For the semantics of CTL propositional connectives ¬,
Definition 10 (Syntax of CTL) A CTL formula for a BRN is inductively defined by:
• φ and ψ represent propositional logic formulae (can also be atomic formulae).
• Then (¬φ ), (φ ∧ψ), (φ ∨ψ), (φ⇒ψ), (φ⇔ψ), AXφ , EXφ , A[φUψ], E[φUψ],
AGφ , EGφ , AFφ , EFφ are formulae.
The formulae ⊤ and ⊥ represent the always true and false formulae, respec-
tively; a state s satisfies all the atomic formulae; ¬, ∧,∨, ⇒, ⇔ are the usual con-
nectives (respectively not, and, or, implication, equivalence) (see Appendix D). All
the temporal connectives are pairs of symbols: the first element of the pair is A or E
followed by X, F, G or U whose meanings are given below and illustrated in Figure
3.4. The path trees (execution trees) in this figure show the paths of the state graph
depicted in Figure 3.3.
• A (also written as ‘∀’), for “All paths choices”. This quantifier selects all paths
originating from a current state to hold the boolean property.
• E (also written as ‘∃’), for “at least one path choice (Exist)”. This quantifier
selects at least one path originating from a current state to hold the expression.
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• X, for “neXt state”. This quantifier selects the immediate successor along the
selected path(s) to hold the boolean expression.
• F (also written as ‘’), for “some Future state”. This quantifier selects at least
one state, which may be the current state itself, along the selected path(s) to
hold the expression.
• G (also written as ‘’), for “all future states (Globally)”. This quantifier se-
lects all states, inclusive of the current, along the selected path(s) to hold the
expression.
• U, for “Until”.
The semantics of CTL is defined on the path trees of the state graph which are com-
pletely defined by their initial state and the transition relation (see Definition 6). The
semantics given by the definition of the satisfaction relation s |= φ meaning that the
formula φ is satisfied on the execution tree starting at state s.
(C) Inference of logical parameters
The tool, Selection of Models of Biological Networks (SMBioNet) is used to
compute the values of logical parameters (Bernot et al., 2004; Khalis et al., 2009).
In brief, SMBioNet is based on the Kinetic logic of René Thomas that accepts a
BRN with unspecified logical parameters along with a specific observed biological
behaviour coded in terms of Computational Tree Logic (CTL) (Huth and Ryan, 2004)
formulae. SMBioNet requires an input under three sections including ‘VAR’, ‘REG’
and ‘PARA’. The entities in the BRN along with the minimum and maximum discrete
levels are declared under the ‘VAR’ section, followed by the definition of the BRN
under the ‘REG’ section. The final section ‘CTL’ lists the CTL formulae which are
used by SMBioNet to check the sets of parameters. In result, it generates all possible
models of the BRN, satisfying the CTL formula, as output. SMBioNet selects among
the produced models by calling a model checker NuSMV (Cimatti et al., 1999).
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ϕ=(c=0)
AX(ϕ)
100
110000
111010
000 011
111001
000 101
100 111
ϕ=(b=1)
EX(ϕ)
100
110000
111010
000 011
111001
000 101
100 111
ϕ=(c=1)
EF(ϕ)
100
110000
111010
000 011
111001
000 101
100 111
ϕ=(a=0 ∨ a=1)
AG(ϕ)
100
110000
111010
000 011
111001
000 101
100 111
ϕ=(c=0)
EG(ϕ)
100
110000
111010
000 011
111001
000 101
100 111
ϕ=(a=0 ∨ (b=1 ∧ c=1))
AF(ϕ)
100
110000
111010
000 011
111001
000 101
100 111
ϕ=(a=1)
ψ=(b=1∧ c=0)
E(ϕUψ)
100
110000
111010
000 011
111001
000 101
100 111
ϕ=(a=1)
ψ=(a=0 ∨ b=1)
A(ϕUψ)
100
110000
111010
000 011
111001
000 101
100 111
Figure 3.4. Semantics of temporal connectives of CTL. The states in grey colour
represent those sates of paths (trajectories) from the initial state (100), where formulae
φ or ψ are true in their respective path trees.
3.2 Qualitative Modelling of TLR4 and JAK/STAT Pathway
In this section, the qualitative modelling of TLR4 and JAK/STAT pathway is
described. The complete work-flow of qualitative modelling of TLR4 and JAK/STAT
signalling pathway is given in Figure 3.5.
3.2.1 Reduction of the signalling pathways
Basic limitation of the Kinetic logic is the production of large state space as
an output, which increases exponentially with the number of entities and interactions
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Reduction of the TLR4 
and JAK/STAT 
Signalling Pathway
Computation of logical 
parameters using 
SMBioNet
Construction and 
simulation of BRN for 
the case of non-sepsis.
Changing the value of logical parameter 
KTLR4 ({SOCS-1,NFκB}) from “0” to “1” for the 
simulation of case of sepsis.
Interventions 
in the BRN
TLR4 and JAK/STAT 
signalling pathways
Analysis of non-intervened 
signalling in both cases of non-
sepsis and sepsis.
Analysis of intervened signalling 
in both cases of non-sepsis and 
sepsis.
Figure 3.5. Complete work-flow of qualitative modelling of TLR4 and JAK/S-
TAT signalling pathways.
within a system (Thomas and d’Ari, 1990). For instance, the TLR4 and JAK/STAT
signalling cascades provided in Figure 3.6 have numerous entities, and on simulation
the state space could be consisted of huge number of states, which is difficult to
analyse. Therefore, reduction of the pathways prior to the modelling was performed
to make the state space tractable. Initiating from the complete signalling cascades of
TLR4 and JAK/STAT, the BRN was reduced iteratively by following the strategies of
Naldi et al. (2009, 2011) and Saadatpour et al. (2013) for the reduction of pathways
to an abstracted form as shown in Figure 3.8.
The strategy of pathway reduction can be explained with the help of an exam-
ple that is if any entity “A” induce other entity “B” that successively activates “C” and
in turn “C” inhibits “A”, then the entity “B” can be omitted. This relation can be pre-
sented as a simple feedback loop where “A” induces “C” and “C” inhibits “A”. In the
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Figure 3.6. TLR4 and JAK/STAT signalling pathway. Overview of TLR4 and
JAK/STAT signalling cascades acquired from previous literature and signalling path-
ways databases (Jones et al., 2001; Kanehisa et al., 2008; Kawai and Akira, 2011;
Kumar et al., 2009; Mi et al., 2013; Schindler et al., 2007; Scott et al., 2002). Figure
reproduced from Paracha et al. (2014a).
reduction approach, the responses of the abstracted entity “B” is kept implicitly in the
activation of “C” by “A”. Another example has been provided in Figure 3.7 adopted
from Saadatpour et al. (2013), where a network of 13 molecules (Figure 3.7-A) has
been reduced to 3 proteins (Figure 3.7-B) using the rules of reduction. Likewise in
the study of Naldi et al. (2009), Figure 3.7-D illustrates a related example of pathway
reduction.
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Figure 3.7. Examples of BRN reduction. (A-B) represents an example of abcisic
acid (ABA) signalling pathway adapted from (Saadatpour et al., 2013). (A) Complete
BRN of ABA signalling. (B) The reduced BRN of ABA signalling pathway obtained
after reduction. (C) represents another example of reduction of pathways adapted
from (Naldi et al., 2009). (D) The BRN given was reduced by removing entity “g4”
from the BRN given in (C).
3.2.2 Inference of logical parameters for the BRN
The complete source code for the computation of parameters values using
SMBioNet is provided in Appendix A. In ‘VAR’ section, the minimum and maximum
discrete values for the entities TLR4, IFN-β , NFκB and SOCS-1 were selected “0”
and “1”, respectively. Whereas, the minimum and maximum values for the PICyts
were selected “0” and “2”, respectively. Value “1” was utilized as threshold levels for
all of the interactions among entities except for PiCyts mediated activation of NFκB-
JAK/STAT that is equivalent to “2”. This adjustment is made, so that PiCyts could
stimulate SOCS-1 on achieving the expression level of “1” and further stimulates
NFκB-JAK/STAT at another expression level of “2”.
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Figure 3.8. Biological Regulatory Network of TLR4 and JAK/STAT signalling
cascade. The BRN of TLR4-JAK/STAT signalling cascade has been inferred from
Figure 3.6. Nodes symbolize entities, while edges depict the interactions within en-
tities. Mathematical symbols on the edges represent the type of relation between
entities i.e. negative symbol for inhibition (depicted as dotted arrows) and positive
symbol for the activation (represented by solid arrows). Integers such as "0-2" labelled
on the edges stand for the threshold levels (see Appendix B for complete description
about the BRN). Figure reproduced from Paracha et al. (2014a).
In “REG” section, the BRN was defined using interaction. Each expression
of interaction is comprised of 3 parts: (1) first represents the entity that is making the
interaction; (2) second within the “[()]” indicates the threshold level of that entity;
and (3) the third after “⇒” shows the entity/ies being affected. Following interactions
were defined for all entities in the BRN.
• TLR4 [(TLR4≥ 1)] ⇒ IFN-β NFκB.
• SOCS-1 [(SOCS-1<1)] ⇒ IFN-β TLR4 NFκB PICyts.
• NFκB [(NFκB<1)] ⇒ IFN-β TLR4.
• IFN-β [(IFN-β ≥1)] ⇒ SOCS-1 NFκB.
• PICyts [(PICyts≥1)] ⇒ SOCS-1.
• PICyts [(PICyts≥2)] ⇒ NFκB.
• IFN-β [(IFN-β<1)] ⇒ PICyts.
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• NFκB [(NFκB≥1)] ⇒ PICyts.
In ‘PARA’ section, the range of lowest and maximum qualitative levels were
given to SMBioNet for sets of logical parameters for each entity as described in Table
3.2. In the last section of ‘CTL’, following formula was given to SMBioNet:
φa = (T LR4 = 1 ∧ IFN−β = 0 ∧ NFκB = 1 ∧ PICyts = 0 ∧ SOCS1 = 0) (3.1)
φb = (T LR4 = 1 ∧ IFN−β = 1 ∧ NFκB = 1) (3.2)
φc = (T LR4 = 1 ∧ IFN−β = 0 ∧ NFκB = 0 ∧ PICyts = 0 ∧ SOCS1 = 0) (3.3)
φd = (T LR4 = 0 ∧ IFN−β = 0 ∧ NFκB = 0 ∧ PICyts = 0 ∧ SOCS1 = 0) (3.4)
Φ1 = φa ⇒ EF(φb) (3.5)
Φ2 = φc ⇒ EF(AG(φd)) (3.6)
Φ=Φ1∧Φ2 (3.7)
In these equations, ∧ is the Boolean conjunction operator. The formula φ1 states
that after the activation of TLR4, it will then activate the downstream signalling
in response to LPS, which eventually leads to the activation of IFN-β and NFκB
(Fitzgerald et al., 2003; Lu et al., 2008; Nagpal et al., 2009; Takeuchi et al., 1999;
Toshchakov et al., 2002; Zughaier et al., 2005). The formula φ2 states that subsequent
to a successful immune response, entities of TLR4 signalling pathway will become
inactivated (Akira et al., 2006; Kawai and Akira, 2010; Muzio et al., 1997).
Non-septic case: Logical parameters generated by SMBioNet were used (Table
3.2) to investigate the qualitative properties of the BRN (Figure 3.8) in the case of
non-sepsis. The logical parameters used for the modelling of non-septic behaviour
of the TLR4 and JAK/STAT pathways are presented as dummy tendency graphs in
Figures 3.9 to 3.13. The complete description and evidences for the validation of
logical parameters have been given in Appendix B.
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Description of BRN modelled for non-septic case The abstracted BRN given in
Figure 3.8 is a directed graph, where the entities represent nodes connected to other
via edges, which represent the type of interaction (+ or −). Threshold levels of those
interactions are given as integers. The description of the abstracted BRN is given
below.
Upon the activation of TLR4, it reaches to threshold level “1” and activates
IFN-β and NFκB; IFN-β activates NFκB on reaching a threshold level “1”; IFN-β
on reaching to threshold level “1” activates SOCS-1; NFκB on threshold level “1”
activates PiCyts that on level “1” can induce SOCS-1 and at level “2” can activate
JAK/STAT; NFκB at level “1” negatively regulates IFN-β and TLR4 mediated sig-
nalling; IFN-β inactivates PiCyts at threshold level “1”; SOCS-1 after reaching its
threshold level “1” can inactivate TLR4, IFN-β , NFκB-JAK/STAT and PiCyts.
Septic case: The case of sepsis is constructed by changing the value of logical pa-
rameter “KT LR4({SOCS−1,NFκB}) from “0” to “1” which represents the recurrent
induction of TLR4. This is the only change in the set of logical parameters used in
modelling non-septic case. So, recurrent induction of TLR4 with other logical param-
eters of entities, as presented in Table 3.3, were employed to model the signalling
associated with sepsis.
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Table 3.2. Parameters values. The table shows the logical parameters, their respec-
tive resource sets, and the values that were given as range and generated by SMBioNet.
In the last column, final selected values are shown for each logical parameter.
Parameters Resources
Values
Allowed Generated Selected
KT LR4
{} 0,1 0 0
{NFκB} 0,1 0 0
{SOCS−1} 0,1 0 0
{SOCS−1,NFκB} 0,1 0 0
KNFκB−JAK/STAT
{} 0,1 0 0
{T LR4} 1 1 1
{IFN−β} 1 1 1
{PiCyts} 1 1 1
{SOCS−1} 0,1 0 0
{T LR4, IFN−β} 0,1 1 1
{T LR4,PiCyts} 0,1 1 1
{IFN−β ,PiCyts} 0,1 1 1
{T LR4,PiCyts, IFN−β} 0,1 1 1
{T LR4,SOCS−1} 0,1 1 1
{IFN−β ,SOCS−1} 0,1 1 1
{PiCyts,SOCS−1} 0,1 1 1
{T LR4, IFN−β ,SOCS−1} 0,1 1 1
{T LR4,PiCyts,SOCS−1} 0,1 1 1
{PiCyts, IFN−β ,SOCS−1} 0,1 1 1
{SOCS−1,T LR4, IFN−β ,PiCyts} 0,1 1 1
KPiCyts
{} 0,1 0 0
{NFκB− JAK/STAT} 0,2 0 0
{IFN−β} 0,2 0 0
{SOCS−1} 0,2 0 0
{NFκB, IFN−β} 0 0 0
{NFκB,SOCS−1} 0 0 0
{IFN−β ,SOCS−1} 0,2 0 0
{NFκB, IFN−β ,SOCS−1} 2 2 2
KSOCS−1
{} 0,1 0 0
{PiCyts} 1 1 1
{IFN−β} 1 1 1
{PiCyts, IFN−β} 0,1 1 1
KIFN−β
{} 0,1 0
{T LR4} 0 0 0
{SOCS−1} 0,1 0 0
{NFκB} 0,1 0 0
{T LR4,SOCS−1} 0,1 1 1
{T LR4,NFκB} 1 1 1
{SOCS−1,NFκB} 0,1 0 0
{T LR4,SOCS−1,NFκB} 0,1 1 1
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Figure 3.9. Dummy tendency graphs of TLR4. Dummy tendency graphs of TLR4
used to model non-septic condition. Parameters values for TLR4 (Table 3.2) selected
in the modelling of non-septic signalling are illustrated as dummy tendency graphs
in A-D. Figure adapted from Paracha et al. (2014a)
Figure 3.10. Dummy tendency graphs of IFN-β . Dummy tendency graphs of IFN-
β used to model non-septic condition.Parameters values for IFN-β (Table 3.2) se-
lected in the modelling of non-septic signalling are illustrated as dummy tendency
graphs in A-H. Figure adapted from Paracha et al. (2014a)
62
Chapter 3 3.2 Qualitative Modelling of TLR4 and JAK/STAT Pathway
Figure 3.11. Dummy tendency graphs of NFκB. Dummy tendency graphs of NFκB
used to model non-septic condition. Parameters values for NFκ (Table 3.2) selected
in the modelling of non-septic signalling are illustrated as dummy tendency graphs
in A-P. Figure adapted from Paracha et al. (2014a)
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Figure 3.12. Dummy tendency graphs of PiCyts. Dummy tendency graphs of
PiCyts used to model non-septic condition.Parameters values for PiCyts (Table 3.2)
selected in the modelling of non-septic signalling are illustrated as dummy tendency
graphs in A-H. Figure adapted from Paracha et al. (2014a)
Figure 3.13. Dummy tendency graphs of SOCS-1. Dummy tendency graphs of
SOCS-1 used to model non-septic condition. Parameters values for SOCS-1 (Table
3.2) selected in the modelling of non-septic signalling are illustrated as dummy ten-
dency graphs in A-D. Figure adapted from Paracha et al. (2014a)
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3.2.3 Construction and simulation of BRN
The qualitative model of TLR4 and JAK/STAT signalling pathway is con-
structed using the GENOTECH (Ahmad et al., 2012) and GINSIM (Chaouiya et al.,
2012) which facilitate to construct the logical regulatory signalling network according
to Thomas’ formalism. The output of qualitative model is in the form of state graph,
which represents the dynamical behaviour of the modelled network.
3.2.4 Interventions
Models with interventions/perturbations in the interactions of entities were
constructed by ruling out one or more of the interactions of IFN-β , SOCS-1, PiCyts
and NFκB as depicted in Figure 3.8. Associated logical parameters were, likewise,
altered to conserve integrity of the perturbed model (Table 3.3). These interventions
were employed to detect respective models affect on the normal signalling events
(effects on the cyclic paths and stable states).
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Table 3.3. Intervention studies. CASES of intervention in signalling were derived by removing specific interactions in Figure 3.8 along with
their logical parameters to observe the possible stable states produced due to each condition. Table adapted from Paracha et al. (2014a)
CASE
Evolving
Entity
Target
entity(ies)
Removed parameters Changes in Parameter/s
Removed edge/s
in Figure 3.8
1–N SOCS-1 PiCyts
KPiCyts({SOCS−1})=0
KPiCyts({NFκB,SOCS−1})=0
KPiCyts({NFκB,IFN−β ,SOCS−1})=0
KPiCyts({NFκB,IFN−β})=2
Edge from
SOCS-1 to
PiCyts
1–S SOCS-1 PiCyts
KPiCyts({SOCS−1})=0
KPiCyts({NFκB,SOCS−1})=0
KPiCyts({NFκB,IFN−β ,SOCS−1})=0
KPiCyts({NFκB,IFN−β})=2
KT LR4({SOCS−1,NFκB})=1
Edge from
SOCS-1 to
PiCyts
2–N SOCS-1
PiCyts &
IFN-β
KPiCyts({SOCS−1})=0
KPiCyts({NFκB,SOCS−1})=0
KPiCyts({NFκB,IFN−β ,SOCS−1})=0
KIFN−β ({SOCS−1})=0
KIFN−β ({TLR4,SOCS−1})=1
KIFN−β ({SOCS−1,NFκB})=0
KIFN−β ({TLR4,SOCS−1,NFκB})=1
KPiCyts({NFκB,IFN−β})=2
Edges from
SOCS-1 to
IFN-β and
PiCyts
2–S
SOCS-1,
PiCyts /
IFN-β
KPiCyts({SOCS−1})=0
KPiCyts({NFκB,SOCS−1})=0
KPiCyts({NFκB,IFN−β ,SOCS−1})=0
KIFN−β ({SOCS−1})=0
KIFN−β ({TLR4,SOCS−1})=1
KIFN−β ({SOCS−1,NFκB})=0
KIFN−β ({TLR4,SOCS−1,NFκB})=1
KPiCyts({NFκB,IFN−β})=2
KT LR4({SOCS−1,NFκB})=1
Edges from
SOCS-1 to
IFN-β and
PiCyts
3–N IFN-β PiCyts
KPiCyts({IFN−β})=0
KPiCyts({IFN−β ,NFκB})=0
KPiCyts({IFN−β ,SOCS−1})=0
KPiCyts({NFκB,IFN−β ,SOCS−1})=2
KPiCyts({NFκB,SOCS−1})=2
Edge from IFN-β
to PiCyts
Cont.
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Table 3.3 (finished)
CASE
Evolving
Entity
Target
entity(ies)
Removed parameters Changes in Parameter/s
Removed edge/s
in Figure 3.8
3–S IFN-β
PiCyts &
SOCS-1
KPiCyts({IFN−β})=0
KPiCyts({IFN−β ,NFκB})=0
KPiCyts({IFN−β ,SOCS−1})=0
KPiCyts({NFκB,IFN−β ,SOCS−1})=2
KPiCyts({NFκB,SOCS−1})=2
KT LR4({SOCS−1,NFκB})=1
Edge from IFN-β
to PiCyts
4–N NFκB PiCyts
KPiCyts({NFκB})=0
KPiCyts({NFκB,IFN−β})=0
KPiCyts({NFκB,SOCS−1})=0
KPiCyts({NFκB,IFN−β ,SOCS−1})=2
–
Edge from NFκB
to PiCyts
4–S NFκB PiCyts
KPiCyts({NFκB})=0
KPiCyts({NFκB,IFN−β})=0
KPiCyts({NFκB,SOCS−1})=0
KPiCyts({NFκB,IFN−β ,SOCS−1})=2
KT LR4({SOCS−1,NFκB})=1
Edge from NFκB
to PiCyts
5–N PiCyts
NFκB-
JAK/STAT
KNFκB−JAK/STAT ({PiCyts})=1
KNFκB−JAK/STAT ({TLR4,PiCyts})=1
KNFκB−JAK/STAT({IFN−β ,PiCyts})=1
KNFκB−JAK/STAT ({TLR4,PiCyts,IFN−β})=1
KNFκB−JAK/STAT ({PiCyts,SOCS−1})=1
KNFκB−JAK/STAT ({TLR4,PiCyts,SOCS−1})=1
KNFκB−JAK/STAT ({PiCyts,IFN−β ,SOCS−1})=1
KNFκB−JAK/STAT ({SOCS−1,TLR4,IFN−β ,PiCyts})=1
–
Edge from
PiCyts to NFκB-
JAK/STAT
5–S PiCyts
NFκB-
JAK/STAT
KNFκB−JAK/STAT ({PiCyts})=1
KNFκB−JAK/STAT ({TLR4,PiCyts})=1
KNFκB−JAK/STAT({IFN−β ,PiCyts})=1
KNFκB−JAK/STAT ({TLR4,PiCyts,IFN−β})=1
KNFκB−JAK/STAT ({PiCyts,SOCS−1})=1
KNFκB−JAK/STAT ({TLR4,PiCyts,SOCS−1})=1
KNFκB−JAK/STAT ({PiCyts,IFN−β ,SOCS−1})=1
KNFκB−JAK/STAT ({SOCS−1,TLR4,IFN−β ,PiCyts})=1
KT LR4({SOCS−1,NFκB})=1
Edge from
PiCyts to NFκB-
JAK/STAT
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3.3 Comparative Modelling and Protein-Protein Interactions
The complete work-flow of modelling of PKCδ , structure preparations and
protein-protein interaction has been illustrated in Figure 3.14.
3.3.1 Modelling of phosphorylated PKCδ
In order to study PPIs of PKCδ with MAL, the structure of PKCδ was nec-
essary but unavailable at the time of study for which the comparative modelling
approach was used. In this approach, first the homologous template structure was
identified which was then used in the modelling of PKCδ as given in detail below.
(A) Template selection for the modelling of PKCδ
Protein sequence of the catalytic domain (Phe349-Lys669) of PKCδ was
acquired from Uniprot1 (ID:Q05655) (Consortium et al., 2008). The amino acid
sequence of catalytic domain of PKCδ was employed as query sequence to search
homologous proteins available as three dimensional (3D) structures in Protein Data
Bank (PDB)2 by using PSI (protein specific iteration)-BLAST at NCBI3 (Bernstein
et al., 1977; Jones and Swindells, 2002). The structures of PKCθ were obtained with
minimum distance on the phylogenetic tree and having maximum sequence identity
with respect to the query sequence of PKCδ . These structures are present in PDB with
IDs 2JED (crystal structure of kinase domain of human PKCθ resolved at 2.32Å with
co-crystallized ligand i.e. Nvp-Xaa228 ) and 1XJD (crystal structure of kinase domain
of human PKCθ resolved at 2Å with co-crystallized Staurosporine) (Xu et al., 2004).
Structures of PKCθ were utilized as template structures for the homology modelling
of PKCδ . In order to structurally align sequences of PKCδ with its templates, 3D-
Coffee was utilized (Poirot et al., 2004).
1www.uniprot.org/uniprot/Q05655
2www.rcsb.org/pdb
3www.ncbi.nlm.nih.gov/
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Figure 3.14. Complete work-flow of modelling and protein-protein interaction
analyses.
69
Chapter 3 3.3 Comparative Modelling and Protein-Protein Interactions
(B) Modelling, structural modifications and validations
For the homology modelling of PKCδ , MODELLER (version 9.12) (Eswar
et al., 2002) was used. One hundred homology models were developed and clustered
in accordance with the Root Mean Square Deviation (RMSD) between backbone
residues of structures by utilizing NMRCLUST (Kelley et al., 1996). Models were
selected from every cluster on the basis of the score provided by ERRAT (overall
quality factor of structure 4) (Colovos and Yeates, 1993), Qmean (scoring function
to estimate complete and per residue errors5) (Benkert et al., 2008), PROCHECK
(checks the stereochemical quality of a protein structure 6) (Laskowski et al., 1993),
MODELLER provided scores, possible potential energies, PROSA (checks for over-
all and local quality of the homology model of a protein7) (Wiederstein and Sippl,
2007) and Ramachandran Plot (visualization of backbone dihedral angles ψ against
φ of amino acids in a structure of protein) (Ramachandran et al., 1963). Glycine
rich phosphate-binding loop (GPL) was modelled in an open conformation with the
help of loop refinement module of MODELLER. Serines (Ser) at positions Ser503,
Ser645, Ser654, Ser658 and Ser664, tyrosines (Tyr) at position Tyr374 and Tyr567
and threonine (Thr) at position Thr507 attached to the phosphate group with the help
of Chemistry at HARvard Molecular Mechanics (CHARMM) provided SP2, TP2 and
THP2 patches, respectively, by the help of MODELLER with patch commands (Patel
et al., 2004).
3.3.2 Phosphorylated structure of BTK (pBTK)
Alongside of PKCδ , BTK was the another kinase which was docked with
MAL. The catalytic domain of BTK has already been resolved at 2.1Å and submitted
4For more information visit http://www.doe-mbi.ucla.edu/errat or refer to the paper by Colovos
and Yeates (1993)
5For more information visit http://swissmodel.expasy.org/qmean/cgi/index.cgi?page=help or refer
to the paper by Benkert et al. (2008)
6For more information refer to the paper by Laskowski et al. (1993)
7https://prosa.services.came.sbg.ac.at/prosa.php
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in the PDB (ID:1K2P) (Mao et al., 2001). This structure of BTK was phosphory-
lated at different tyrosine and serine positions including Tyr551, Tyr617, and Ser623
with the help of the same phosphorylation procedure as adopted in Section (B), for
the phosphorylations of PKCδ . Molecular Operating Environment (MOE)(Chemical
computing group’s MOE software, version 2013) CCG (2013) was used for adding
missing hydrogens.
3.3.3 Loop modelling of MAL
The structure of the human TIR domain of MAL (residues 80–221) (PDB ID:
3UB2) is without its AB-loop due to the flexible nature of this loop (Lin et al., 2012).
Therefore, 100 loop models (structures with different conformations of loops) were
developed by utilizing MODELLER. Conformations of AB loop were produced by
utilizing 500 steps in variable target function method (VTFM) with conjugate gra-
dients (CG), and then steady simulations using molecular dynamics (MD) with the
simulated annealing (SA) process as available in MODELLER (Sali and Blundell,
1994). In order to refine the loop models, structure optimizations were performed
thrice, recursively. All models were then clustered on the basis of RMSD between
corresponding backbone residues utilizing NMRCLUST (Kelley et al., 1996). Selec-
tion of the representative models among clusters were assessed with Verify3D (Bowie
et al., 1991), ERRAT (Colovos and Yeates, 1993), Ramachandran plot (Ramachan-
dran et al., 1963), potential energy of complete structure and for AB-loop along with
energy scores determined by MODELLER were utilized as standard.
3.3.4 Preparation of structures
Molecular dynamics packages "Not Another Molecular Dynamics program"
(NAMD) and Visual molecular dynamics (VMD) were utilized to prepare the struc-
tures for analysis (Humphrey et al., 1996; Phillips et al., 2005). NAMD with CHARM22
force field was employed for the minimization, equilibration and heating of structures
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(Patel and Brooks, 2004). In every case, the box of water molecules (TIP3P) was
utilized. The system was neutralized by adding Na+ and Cl− ions at physiologi-
cal concentrations. Initially, minimization of 3000 steps was performed for water
molecules and hydrogen atoms only, fixing the remaining system. This approach
was used so that water molecules could be entered into the pockets of structures. In
the second stage, minimization of 1000 steps was performed to the side chains of
residues to decrease strains. Backbone restraints were minimized by 7000 steps and
for minimization of complete system was performed by 10000 steps. After the stage
of minimization, every structure was heated from 0 Kelvin (K) to 310 K, i.e. about
the same temperature as that of the body, followed by equilibration at 310 K for 300
ps.
3.3.5 Prediction of protein binding areas
Potential interface residues in structures were computed by the help of CPORT
(Consensus Prediction Of interface Residues in Transient complexes) facility (de
Vries and Bonvin, 2011). In CPORT, six interface forecasting algorithms such as
WHISCY (De Vries et al., 2006), PINUP (Liang et al., 2006), cons-PPISP (Chen
and Zhou, 2005), PIER (Kufareva et al., 2007), SPPIDER (Porollo and Meller, 2007)
and ProMate (Neuvirth et al., 2004) have been integrated. It is considered to give
more reliable interpretations for the interface residues that can be utilized in High
Ambiguity Driven bimolecular DOCKing (HADDOCK)8 program (De Vries et al.,
2010) for PPIs.
3.3.6 Protein-protein interactions
To perform the PPI and to explore the interaction regions of both PKCδ (mod-
elled) and BTK were planed to dock with MAL. The GURU interface at HADDOCK
web-server was used to study PPIs of pPKCδ and pBTK with MAL. HADDOCK
8haddock.science.uu.nl
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utilizes biophysical and/or biochemical data of interaction (Dominguez et al., 2003).
Besides, it provides ab initio PPIs based on the centre of mass restraints and ran-
dom patch description. The docking strategy of HADDOCK supports the automatic
definition of semi-flexible regions along with the provision of manual selection of
flexible regions, modified amino acids and solvated docking. Scores are computed on
the basis of desolvation energy term and other related statistical procedures such as
RMSD values of interfaces of every structure and usual contacts among the cluster of
complexes.
3.3.7 Selection of interfaces
Two different regions including the regions around Tyr86 and Tyr106 of MAL
were utilized for docking with PKCδ and BTK. Confining the PPI of kinases with
MAL was endorsed by identified phosphorylation sites at MAL which can be utilized
as sites of interaction with kinases.
3.3.8 Incorporation of ATP in protein complexes
To validate the PPI and interface areas of protein complexes, the ATP mod-
elling in the complexes of pPKCδ and pBTK with MAL was performed. Minimum
distance of γ-phosphate of ATP from phosphorylatable hydroxyl groups in Tyr86 and
Tyr106 of MAL was used as a validaiton criteria. Presently, HADDOCK is not able to
determine PPIs in the presence of any small biological molecule or ligand. Therefore,
modelling of ATP in the structures of pPKCδ and pBTK was done after the PPI with
MAL.
The protein complex of pPKCδ with MAL was aligned with the crystal struc-
ture of PKC iota (PKCι) co-crystallized with ATP (PDB ID: 3A8W) (Takimura et al.,
2010), whereas protein complexes of pBTK and MAL were structurally made into
an alignment with the crystal structure of Abl tyrosine Kinase (PDB ID: 2G2I) co-
crystallized with Adenosine diphosphate (ADP) (Levinson et al., 2006) via structural
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alignments. The molecule of ADP was modified to ATP by constructing a phosphate
group at the β -phosphate of ADP followed by minimizations with MMFF (Merck
Molecular Force Field)94 (Halgren, 1996). The crystal structures of PKCι and Abl
tyrosine kinase utilized for modelling of ATP in pPKCδ and pBTK are homologous
to respective kinases (in terms of maximum sequence identity and on the phylogenetic
tree).
Initially, GPL area of kinases and the neighbouring residues within a 9Å
distance of ATP in protein complexes were minimized for their energies to reduce the
harmonic restraints and local atomic strains. During this procedure, ATP and rest of
structure were maintained in fixed positions. In the second stage, the molecule of ATP
was minimized for energy by allowing the protein structure to be fixed. In this process,
minimization of energy of ATP was done by utilizing MMFF94 force field, whereas
protein structures were energy minimized by utilizing CHARM22 force field.
In addition, other programs were also consulted such as Swiss-PDB Viewer
(Kaplan and Littlejohn, 2001) for sequence-structure analysis, PDBSUM 9 (Laskowski,
2001) for secondary structure analysis, Pymol (Seeliger and de Groot, 2010) for ren-
dered images, Jalview (Clamp et al., 2004) for sequence analysis, PISA server10
(Krissinel and Henrick, 2007) for exploration of macromolecular interfaces and UCSF
Chimera (Pettersen et al., 2004) for hydrophobic surface analysis. Interactions of com-
plexes were analysed using MOE and PISA server using default settings. Delphi (Li
et al., 2012) was utilized to determine the electrostatic charges of proteins.
9www.ebi.ac.uk/pdbsum/
10www.ebi.ac.uk/msd-srv/prot int/pistart.html
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RESULTS
4.1 Qualitative Modelling of TLR4 and JAK/STAT Pathways
This section presents the possible system dynamics of TLR4-JAK/STAT sig-
nalling pathways, produced for two medical conditions i.e. sepsis and non-sepsis
along with perturbed signalling in both cases by using René Thomas’ formalism.
The term “non-septic” here reflects such types of infections that generally do not
induce the recurrent inductions of TLR4, whereas, the blood borne infections that
can frequently induce TLR4 signalling is termed as “septic”. Thus, the case of sepsis
was modelled with the recurrent induction of TLR4, whereas this function was not
modelled in the case of non-sepsis. The computed logical parameters for each entity,
given in Table 3.2, supported the modelling of non-septic case. For the modelling of
perturbed signalling, specific logical parameters (Table 3.3) were eliminated along
with their associated edges between entities in the BRN as depicted in Figure 3.8.
State graphs are produced as result of simulating different cases, as discussed
below. These state graphs represent the signalling events produced in response to
qualitative modelling. In each state graph, there are number of states or nodes con-
nected to each other through trajectories. These nodes represent the set of qualitative
levels i.e. “0, 1 or 2” for the entities particularly in the order TLR4, IFN-β , NFκB,
PiCyts and SOCS-1. Trajectories show probable transition of entities from one state
to another. In state graphs, activation of TLR4 before any entity, i.e. state “10000”
represents the start or first state of state graphs whereas states “00000” and/or “00121”
represent the respective normal and over-active immune responses produced during
the dynamics associated with various conditions.
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4.2 Case of Non-Sepsis
Non-septic case is associated with such type of infections, which do not typ-
ically result in sepsis (Auma et al., 2013). Dummy tendency graphs in Figures 3.9
to 3.13 are the sigmoid curves of every logical parameter utilized in the case of non-
septic signalling (Table 3.2). These logical parameters were computed/inferred using
the model checking approach implemented in SMBioNet (see Section 3.2.2). Quali-
tative modelling of the BRN (Figure 3.8) for the non-septic case produced the state
graph illustrated in Figure 4.1.
TLR4 dependent TRIF activation is presented by the induction of IFN-β
(10000 → 11000), whereas induction of MyD88 and MAL adaptor proteins is pre-
sented by the activation of NFκB (10000 → 10100). The analysis of state graph
highlights that early activation of PiCyts is achieved only in those trajectories where
NFκB activates prior to IFN-β . On the other hand, in those trajectories where IFN-β
activates prior to NFκB, the levels of PiCyts remain compromised for several transi-
tions.
Oval nodes represent the crosstalk mechanism of TRIF and MyD88 dependent
signalling (see Figure 3.6). Downstream to the aforementioned oval nodes, the pres-
ence of IFN-β and/or SOCS-1 compel the system to move towards immunosuppres-
sive states (states with PiCyts level “0” and/or “1”). Much of the crosstalk mechanism
results in the existence of activated TLR4 with successive NFκB or IFN-β inductions.
However, in some of the trajectories where TLR4 is not present, TRIF induces the
activation of NFκB (01001 → 01101) that can be found in transitions labelled with
“β” in Figure 4.1. These transitions are found far from the initial state “10000” which
can stimulate the late phase induction of NFκB mediated pro-inflammatory immune
responses. During system dynamics it is found that transitions “00110→ 00120” and
“10110→ 10120” (tagged with “α” in Figure 4.1) are almost necessary for the higher
levels of PiCyts. These trajectories are found in the absence of IFN-β and SOCS-1
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Chapter 4 4.2 Case of Non-Sepsis
alongside of the elveated levels of PiCyts (depicted by level “2”).
In order to maintain the levels of PiCyts by the regulatory system, SOCS-
1 and/or IFN-β play their important roles at different levels of system dynamics.
Subsequent to the induction PiCyts, gradual inactivation by IFN-β and SOCS-1 down-
regulate the immune responses and lead the system to the stable state “00000”. The
function of IFN-β mediated PiCyts down-regulation is presented by the trajectories
tagged with “γ” illustrated in Figure 4.1. IFN-β reduces the opportunity of PiCyts
induction (trajectories downstream to node “11100”) and results in the delay of hyper-
active immune response. Instead, in the absence of IFN-β , NFκB mediated activation
of PiCyts restores its higher levels.
Trajectories tagged with “ε” and “δ” in Figure 4.1 are depicting the SOCS-
1 dependent down-regulation of PiCyts and IFN-β , respectively. Usually, SOCS-1
is found to be involved in the down-regulation of IFN-β in preference to PiCyts.
Conversely, SOCS-1 first permits the elevated levels of PiCyts in the system and
then down-regulates them in the later stages of the dynamics. Few transitions tagged
with “ζ” show the combined inhibitory actions of SOCS-1 and IFN-β on the levels
of PiCyts that are found mostly during MyD88 and TRIF crosstalk and lead the
system to down-regulated immune response. In this scenario, it can be considered
that SOCS-1 permits additional time for the induction of PiCyts and successively,
SOCS-1 mediated inactivation of PiCyts reduce the exacerbated immune dependent
damage to the host.
Cycles in the state graph are presented as SCC-1 and SCC-2. SCC-1 depicts
the significance of “10100” and “10101” states (Figure 4.2a). Cycle among these two
states represents the repeated induction of PiCyts with successive down-regulation.
As a result of SOCS-1 and IFN-β , system proceeds via the trajectory (10100 →
11100 → 11101 → 10101) and results in the continuous state of immunodepression.
While, SCC-2 depicts the cycle developed after the activation of JAK/STAT signalling
pathway (Figure 4.2b). During SCC-2, only SOCS-1 mediated down-regulation of
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PiCyts is found with the capacity of maintaining the levels of PiCyts, where IFN-β is
absent from the system at this stage.
(a) SCC-1. Cyclic trajectories present the
homoeostatic regulation of PiCyts.
(b) SCC-2. Cyclic trajectories present
the SOCS-1 mediated homoeostasis of
PiCyts.
Figure 4.2. Homoeostasis observed in CASE of non-sepsis. SCCs 1 and 2 observed
in the case of non-sepsis. Figure reproduced from Paracha et al. (2014a).
4.3 Case of Sepsis
State graph of septic case is merged in Figure 4.1 for easy comparison of
trajectories formed in the case of sepsis with that of non-sepsis. Red coloured trajec-
tories in Figure 4.1 represent only the septic one, while the trajectories found in both
cases are presented in black colour.
In contrast to the system dynamics obtained in the case of non-sepsis, sepsis
can be characterized by the events of recurrent TLR4 induction (transitions “00000
→ 10000”, represented with the symbol “η”, and “00010 → 10010”, represented
with the symbol “θ”) along with the absence of any stable state. On the whole, state
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graph illustrates two phases of signalling in which the first phase can be compared to
the case of non-sepsis, whereas second phase of system dynamics presents delayed
phase of signalling dynamics developed as a result of recurrent induction of TLR4.
This is because of the already existing levels of PiCyts (“00010 → 10010”, tagged
with the symbol “θ”). Later on, due to the presence of SOCS-1 and IFN-β , the levels
of PiCyts were tolerated with subsequent degradation. On the whole, it is speculated
that most of the states in delayed phase illustrates the immunodepression as a result
of either IFN-β or SOCS-1 mediated down-regulation of PiCyts.
In the delayed phase of signalling dynamics, induction of NFκB is found
as the only chance for elevating the levels of PiCyts as shown in transition “10010
→ 10110” (tagged with “κ” in Figure 4.1) and can shift the system to over-active
immune response (state “00121”). Finally, all the trajectories lead towards the down-
regulated immune state “00000”. Subsequent to the this state, a new round of TLR4
activation presents the recurrent induction of TLR4 (tagged with “η”). It can be as-
sumed that the activation and deactivation of PiCyts have variability during complete
system dynamics of sepsis, while inactivation of PiCyts in late phase lead towards
immunosuppression.
4.4 Interventions in Signalling
Therapeutic interventions and/or genetic mutations can change the role of
resources alongside bringing variations in the system dynamics (Definition 4 in meth-
ods). Similarly in this study the interventions (perturbations ) were designed by elim-
inating one or more edges of any entity (Figure 3.8). These perturbations generated
a similar effect as could be induced by mutations or therapeutic interventions. The
effects of perturbations in IFN-β , SOCS-1, NFκB and PiCyts mediated signalling
are compared in both cases of non-sepsis and sepsis to further describe the signif-
icance and possible roles of an intact signalling pathway. These perturbations are
described as CASES (CASE 1-CASE 5), which are described later in this chapter.
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Perturbing each signalling event is related with the changes and/or removal of the
logical parameters of entities as presented in Table 3.3 (Chapter 3).
4.4.1 Perturbation in SOCS-1 mediated inactivation of PiCyts (CASE 1)
CASE 1-N represents perturbations in SOCS-1 mediated inactivation of PiCyts
during the case of non-sepsis, whereas CASE 1-S represents the same in case of sep-
sis. As described earlier, modelling of CASE 1-N was carried out with the logical
parameters (Table 3.3) with some variations, as presented in Table 3.2. Figure 4.3
illustrates the state graph generated as a result of the qualitative modelling.
Two stable states including “00000” and “00121” are present in the state
graph (Figure 4.3), representing the immunosuppressive and hyper-activated immune
response, respectively. To much extent, system dynamics of CASE 1-N are compa-
rable to the case of non-sepsis (as presented in Figure 4.1), though some trajectories
comprising of SOCS-1 mediated inactivation of PiCyts are different (trajectories
tagged with “∆ε” in Figure 4.3). In those trajectories, SOCS-1 mediated inactivation
of PiCyts is repressed leading to the elevation in the levels of PiCyts that subsequently
results in the JAK/STAT activation (depicted implicitly in stable state “00121”). These
trajectories are also observed opposite in directions from one state to another as com-
pared to those found in the case of non-sepsis (trajectories tagged with the symbol “ε”
in Figure 4.1), where SOCS-1 mediated inactivation of PiCyts is intact and can lead
the system towards stable state “00000”.
In this case, IFN-β mediated inactivation of PiCyts is observed ineffective,
probably because IFN-β is induced in the earlier phase of the system dynamics (tra-
jectories tagged with “γ” in Figure 4.3). Moreover, PiCyts has the ability to induce
SOCS-1 mediated inactivation of IFN-β during the later stages of the signalling. Thus,
elevated levels of PiCyts caused the system to produce over-active immune reactions
(trajectories tagged with “δ” in Figure 4.3).
It is found that in the absence of activated TLR4, the system leads towards
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Chapter 4 4.4 Interventions in Signalling
stable state “00000”. However, this condition is found in many trajectories except
in those conditions where NFκB and PiCyts are present simultaneously (trajectories
downstream to nodes “10111, 00110, 00111 and 10120” tagged with stars in Figure
4.3). These states has chances for generating an over active immune state, i.e. stable
state “00121”, in the system. One of the homoeostasis trajectories is same to that of
SCC-1 (Figure 4.2a), whereas SOCS-1 mediated regulatory homoeostasis, as given
in Figure 4.2b, which is not observed in CASE 1.
The trajectories and states coloured in red are associated with the CASE 1-S
as illustrated in Figure 4.1. Almost the system dynamics in CASE 1-S is comparable
to the CASE 1-N, however, only the difference is made by the recurrent activation of
TLR4 (transition tagged with the symbol “η” in Figure 4.3). As depicted, two stable
states are present in CASE 1-N although in CASE 1-S, there is only one stable state i.e.
“00121”. Recursive TLR4 induction (transitions “00000 → 10000” tagged with the
symbol “η”, and “00010 → 10010” tagged with the symbol “θ”) are comparable to
the signalling in case of sepsis as presented in Figure 4.1. However, SOCS-1 could not
down-regulate PiCyts levels in late phase of signalling dynamics. Delayed activation
of IFN-β in CASE 1-S is not able to decrease the over-active immune response in the
absence of SOCS-1.
4.4.2 Perturbations in the inhibition of PiCyts and IFN-β (CASE 2)
Perturbations portraying the complete loss-of-function mutation in SOCS-1
abolishes its functions of inactivating PiCyts and IFN-β and subsequently lead to
the over-active immune response. CASE 2-N represents the perturbation in SOCS-1
mediated inactivation of PiCyts and IFN-β in case of non-sepsis, whereas CASE 2-S
represents this intervention in case of sepsis. The logical parameters presented in
Table 3.2 with some exceptions as shown in Table 3.3 were used to model CASE
2 along with eliminating the edges of SOCS-1 mediated inactivation of PiCyts and
IFN-β (see Figure 3.8). State graph produced for CASE 2 is illustrated in Figure 4.4.
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System dynamics generated in CASE 2-N are almost comparable to those
found in the case of non-sepsis (Figure 4.1) except some trajectories that are related
to SOCS-1 mediated inactivation of IFN-β (trajectories bearing the symbol “∆δ”)
and PiCyts (trajectories with the symbols “∆ε”). These trajectories are opposite in
direction as compared to those presented in the case of non-sepsis (Figure 4.1). Stable
states “00000” and “00121” are found comparable to those observed in CASE 1-N.
Similar to other state graphs, as mentioned above, the concurrent existence of NFκB
and PiCyts are found to be associated with higher levels of PiCyts, even in the absence
of SOCS-1 mediated inactivation of IFN-β . Homoeostatic regulation of entities is
found comparable to that present in SCC-1 (Figure 4.2a), whereas SOCS-1 mediated
regulatory homoeostasis is absent.
Figure 4.4 depicts the system dynamics in CASE 2-S (state and trajectories
are coloured red in this case). In this CASE, many of the sepsis related trajectories and
states were observed comparable to those, which are present in CASE 2-N. However,
state “00121” is the only stable state in CASE 2-S, where a transition from state
“00000” leads towards the recurrent induction of TLR4. New trajectories of recurrent
induction of TLR4 (trajectories “00000 → 10000” tagged with the symbol “η” and
“00010 → 10010” tagged with the symbol “θ”) are comparable to signalling in the
case of sepsis as shown in Figure 4.1. However, SOCS-1 has no regulatory role
in the late phase signalling dynamics. It is interesting to note that perturbations in
SOCS-1 mediated regulation of IFN-β is similar to those in CASE 1-S. This depicts
that inactivation of IFN-β in late stages of signalling or down-regulation of TRIF
dependent pathway may have significant role in the induction of over active immune
responses.
4.4.3 Perturbation in the IFN-β mediated inactivation of PiCyts (CASE 3)
CASE 3-N represents the perturbations in IFN-β mediated regulation of
PiCyts during the case of non-sepsis, whereas CASE 3-S represents this perturba-
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tion during the case of sepsis. These CASES helped in the determination of system
dynamics and resulting immunologic response in the absence of IFN-β mediated
inactivation of PiCyts. Perturbation was carried out by eliminating the regulatory role
of IFN-β for PiCyts as portrayed in Figure 3.8. Modelling was carried out with the
logical parameters with some variations as presented in Table 3.2 and Table 3.3 for
CASE 3-N and CASE 3-S. Figure 4.5 depicts the state graph of CASE 3-N and CASE
3-S (trajectories and states coloured red). State “00000” is the only stable state that
is observed during the signalling dynamics. It is found that IFN-β mediated inactiva-
tion of PiCyts, during earlier stages of system dynamics, is revoked from the system
(trajectories tagged with the symbol “∆γ” in Figure 4.5), which is providing support
to reduce the levels of PiCyts as seen in preceding Figures 4.1 to 4.4. Role of SOCS-1
mediated inactivation of PiCyts is found same as in the case of non-sepsis.
Homoeostatic signalling in CASE 3-N (SCC-3) can be compared to that of
the case of non-sepsis signalling (SCC-1), although cycling of trajectories is found to
be slightly shifted towards higher levels of PiCyts (Figure 4.6a). Presence of SOCS-1
(SCC-4 and SCC-5 shown in Figure 4.6b and Figure 4.6c, respectively) results in
homoeostasis at level of over active immune response (state “00121”) showing that
even in the absence of IFN-β , levels of PiCyts may be regulated by SOCS-1.
System dynamics obtained in CASE 3-S is integrated with those produced by
CASE 3-N (Figure 4.5). Almost all of the trajectories and states are shared between
two CASES of 3-S and 3-N, except those trajectories, which are found to be involved
in the recurrent induction of TLR4. IFN-β mediated inactivation of PiCyts during
late stages of CASE 3-S is not observed.
4.4.4 Perturbation in NFκB mediated induction of PiCyts (CASE 4)
CASE 4-N represents the perturbation in NFκB mediated induction of PiCyts
during the case of non-sepsis, whereas CASE 4-S represents this perturbation during
sepsis. Different studies have reported the inhibition of NFκB mediated induction of
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(a) SCC-3. This cyclic graph repre-
sents the homoeostasis by IFN-β me-
diated regulation of PiCyts during
CASE 3.
(b) SCC-4. This
cyclic graph
represents the
homoeostasis by
SOCS-1 mediated
regulation of
PiCyts during
CASE 3
(c) SCC-5. This
cyclic graph
represents the
homoeostasis by
SOCS-1 mediated
regulation of
PiCyts during
NFκB down-
stream signalling
in CASE 3.
Figure 4.6. Homoeostasis observed in CASE 3 SCC-3 to SCC-5 observed in CASE
3. Figures reproduced from Paracha et al. (2014a).
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PiCyts that were performed either by degrading the NFκB complex or by inhibiting
the resultant gene transcription pathway (Baeuerle and Henkel, 1994; Shi et al., 2006).
The model was modelled in such to way to study this intervention by eliminating the
NFκB mediated induction of PiCyts as shown in Figure 3.8. In order to model this
perturbation, logical parameters presented in Table 3.2 were employed with a few
exclusions as presented in Table 3.3. CASE 4 results in a single normal stable state,
i.e. “00000”, along with the absence of PiCyts in the complete state graph as shown
in Figure 4.7. Homoeostasis is found only between SOCS-1 and IFN-β as rendered
in Figure 4.8.
System dynamics of both CASE 4-N and CASE 4-S are almost similar ex-
cept for the continual recruitment of TLR4. Results illustrated that immunologic
response does not consider the promoted levels of endotoxemia and permitted the
micro-organisms to cause infection within the immunodepressed host due to the ab-
sence of PiCyts.
4.4.5 Perturbations in PiCyts mediated induction of NFκB-JAK/STAT (CASE
5)
Perturbation in PiCyts mediated activation of NFκB-JAK/STAT pathway dur-
ing the conditions of non-sepsis and sepsis are discussed as CASE 5-N and CASE
5-S, respectively. In order to model perturbations, logical parameters as mentioned
in Table 3.2 were employed with some exceptions as presented in Table 3.3. Further-
more, interaction (edge) arising from PiCyts towards NFκB-JAK/STAT, as presented
in Figure 3.8, was eliminated as well. Figure 4.9 represents the system dynamics
of both CASES. Events in CASE 5-N are somewhat contrasting to those found in
the case of non-sepsis as presented in Figure 4.1, in terms of depletion of PiCyts
mediated activation of JAK/STAT pathway. Additionally, the over-active levels of
PiCyts are not found in all of the system dynamics. Stable state, i.e. “00000”, was
found in CASE 5-N, however in CASE 5-S, this state led to the recurrent activation of
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Figure 4.7. Merged state spaces of CASE 4-N and 4-S. Each node symbolizes a
specific qualitative state noticed in the system dynamics of CASE 4-N and CASE 4-S.
Set of 5 values i.e. “0” or “1” given inside the nodes constitute the qualitative levels
of 5 entities modelled in the BRN shown in the order of TLR4, IFN-β , NFκB, PiCyts
and SOCS-1. Inactive or dormant entities are symbolised by value “0”and active
entities are symbolised by value “1”. Trajectories, which were specifically observed
during signalling dynamics associated with CASE 4-S, are indicated in red colour,
while the shared nodes and trajectories in both CASES are depicted in black colour.
All the trajectories arise from a node with values “10000”, comprising the induction
of TLR4, and finally trail toward the node of value “00000” that is the stable state
in the case of CASE 4-N. In contrast, a transition tagged with η from node “00000”
back to originating state “10000” results in a cycle in CASE 4-S. State “00121” which
represents the immune response was absent in state graph and not shown in this figure.
TRIF and MyD88 mediated cascades are displayed as dashed arrows and black lines,
respectively. Nodes that make up a crosstalk of both cascades i.e. NFκB and IFN-β
with value “1” are shown in oval shapes. Arrows marked by small Greek letters are
utilized to present trajectories affiliated with distinct signalling processes (cf. legend
in figure). The conditions essential to generate state graph depicted in this figure are
presented in Table 3.2 and Table 3.3. Figure reproduced from Paracha et al. (2014a).
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Figure 4.8. Homoeostasis observed in CASE-4 (SCC-6). This cyclic graph repre-
sents the homoeostasis between IFN-β and SOCS-1 during CASE 4. Figure repro-
duced from Paracha et al. (2014a).
TLR4 (trajectories 00000 → 10000, represented with the symbol “η”). Homoeosta-
sis as a result of cyclic trajectories termed as SCC-7 and SCC-8 in CASE 5-N are
almost comparable to SCC-1 and SCC-2 shown in Figures 4.10-A and Figure 4.10-B,
respectively, though elevated levels of PiCyts could not be observed.
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A B
Figure 4.10. Homoeostasis observed in CASE 5 (A) SCC-7 represents the ho-
moeostasis between IFN-β and SOCS-1. (B) SCC-8 represents the homoeostasis
due to SOCS-1 during CASE 5. Figures reproduced from Paracha et al. (2014a).
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4.5 Modelling of pPKCδ
Kinase domain of PKCδ (residues from position 349 to 603) was modelled
in the phosphorylated form (termed as pPKCδ ) to analyse its site specific interaction
with MAL. Available crystal structures of PKCθ (PDB IDs:1XJD and 2JED) were em-
ployed as template structures to make the models of pPKCδ . The structures of PKCθ
are deposited in the active conformations with co-crystallized ligands (Staurosporine
and Nvp-Xaa228) in the active site which caused the conformational change of GPL.
Therefore, the selected models of pPKCδ were further posed to GPL conformational
search that can effectively allow for the recruitment of ATP in complexes.
With the help of MODELLER, 100 models of catalytic domain of PKCδ were
developed. Figure 4.11-A illustrates the energies provided by MODELLER for all
models. These models were grouped with the help of NMRCLUST and finally 10
models were selected. These models were selected for further study on the basis of
scores provided by MODELLER, Qmean and ERRAT. The Qmean scores of these
models lie in the range 0.5 to 0.6, while ERRAT scores for models lie in the range
70 to 80. Therefore, the finest models on the basis of higher ERRAT score and the
lowest energy values were picked out for preparation. Subsequently, models were
again appraised for the scores of Qmean, ERRAT and their plausible energies. Final
selection of the model was made out on the grounds of the maximum Qmean score
(0.738), ERRAT score (95%) (Figure 4.12) and potential energy that was relatively
less than other constructed models of pPKCδ (Figure 4.11-B).
Multiple sequence alignment (Figure 4.13-A) and superimposed structures of
pPKCδ and pPKCθ (template structure) depict similar structural features present in N
(349–431) and C-terminal (435–603) domains (Figure 4.13-B). N-terminal of pPKCδ
consists of 2 α-helices (αB and αC) and 5 β -sheets (β1–β5), whereas relatively
bigger C-terminal domain is comprised of 8 α-helices (αD–αK) and 3 strands of β -
sheets (β6–β8). Amino acids of hinge linker domain (432–435) help in the connecting
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Figure 4.11. Energy profile for the modelled structures of pPKCδ . (A) The DOPE
scores against molpdf energies for 100 models of pPKCδ .(B) Potential energies ex-
hibited by the top ten models of pPKCδ . Figure adapted from Paracha et al. (2014b).
both N and C-terminals. Some of the prominent domains such as GPL, hydrophobic
groove at N-terminal, helix-αC, activation loop (522–544), hydrophobic motif (HM)
FXXFS and turn motif (662–685) at C-terminal are evaluated to compare pPKCδ
with its template structure.
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*On the error axis, two lines are drawn to indicate the condence with
which it is possible to reject regions that exceed that error value.
#Expressed as the percentage of the protein for which the calculated error value falls below the 95% rejection limit. Good high resolution 
structures generally produce values around 95%or higher. For lower resolutions (2.5 to 3Å) the average overall quality factor is around 91%.
Overall Quality factor: 95.86#
X
Figure 4.12. Quality profile for the selected model of pPKCδ . Qmean (A) and
ERRAT (B) scores are shown for the selected model of pPKCδ . Figure reproduced
from Paracha et al. (2014b).
Almost all the contacts present between the residues of pPKCδ can be com-
pared to those present in the template structure. The only difference in residue to
residue interactions were present in GPL of modelled and template structures. The
GPL joins β1 and β2 sheets of the protein (356–361) and produces a ridge over
ATP binding cavity. In the crystal structures of PKCθ , GPL is inclined towards co-
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crystallized ligands stabilized by the interaction of Lys378 with Phe360 (residues are
numbered according to that of pPKCδ ). This interaction clashed with γ-phosphate
group of ATP during the stage of ATP modelling in pPKCδ -MAL complex (cf. Sec-
tion 3.3.8). So loop refinement of GPL in pPKCδ was performed to alter the interac-
tion of Lys378 with Phe360. Analysis of loop modelling establishes that GPL may
undergo huge number of orientations from closed to open in relation to the ATP
binding site. In order to acquire the correct placement of ATP within the complexes,
various GPL orientations are utilized in parallel to the modelling of ATP in the active
site. The selected model of pPKCδ with optimized GPL orientation is further used in
the further study.
The activation loop and central helix αC are important domains for the cat-
alytic function of kinases. The extended orientation of activation loop (carrying the
vital phosphorylatable Thr507 (pThr507)) and appropriate alignment of helix αC
supports the model to be in active conformation. Oxygen present in pThr507 exhibits
preserved contacts with its environment except with Ala505. Furthermore, the cationic
cluster between pThr507, Arg472 and Lys496 is intact in the model of pPKCδ along
with the correct orientation of catalytic base Asp473, as seen in the template structures.
Catalytically important residues such as Lys378, Asp473 and Asp491 exhibit similar
contacts as in template structures. Inter-domain interactions between Arg399 and
Glu392 of helix-αC and Glu497 of activation loop creates same double salt bridges
as shown in the structures of PKCθ . The orientation of HM is similar to that in tem-
plate structures. Turn motif in pPKCδ (631-654) is extended across the ATP binding
pocket similar to its conformation in template structures. The C-terminal HM domain
has pSer64, located in the same position as observed in the structures of PKCθ that
are probably performing comparable functions.
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4.6 Loop Models of MAL
The secondary structure of TIR-domain of MAL (PDB ID: 3UB2) (Figure
2.3), consists of 5 parallel β -strands having βA-βE and 4 α-helices (αA and αC–αE)
(naming conventions of sheets and strands are used as in the study (Lin et al., 2012)).
Two significant residues including Tyr86 and Tyr106 are located in the strand βA and
helix αA, respectively. These protein secondary structures are joined through a long
loop referred to as AB-loop. Crystallized structure of TIR-domain of MAL lacks AB-
loop due to its elastic nature (Lin et al., 2012). In this case, loop modelling approach
was used to build AB-loop utilizing the 3D structure of TIR-domain of MAL (PDB
ID: 3UB2) as template structure.
One hundred loop models of TIR-domain of MAL were developed with the
help of MODELLER. AB-loop was modelled so that the disulphide bonds between
Cys89-Cys134 and Cys142-Cys174, skeleton of protein, orientations and residue ori-
entations of models would not be disturbed. Figure 4.14-A illustrates the MOD-
ELLER reported molecular PDF (molpdf) and discrete optimized protein energy
(DOPE) scores, while Figure 4.14-B depicts the potential energies (PE) of complete
structure against PE of AB-loop. Clustering of the models based on RMSD produced
12 clusters in which 10 models have most favourable MODELLER provided energy
and RMSD values. ERRAT scores for the selected 10 models have the range 70 to 90
as compared to 94 for the template structure. The potential energies of the AB-loop
and the whole structure which are better than other than other prepared models are
presented in Figure 4.14-B.
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Figure 4.14. Energy profile for the modelled structures of MAL. (A) The DOPE
scores against molpdf energies for 100 loop models of MAL. (B) Potential energies of
different conformations of AB-loop against complete models of MAL. (C) Potential
energies of 10 selected models of MAL against its template structure. Figure adapted
from Paracha et al. (2014b).
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The MD refinement of loop models produced two conformational modes of
AB-loop. Figure 4.15 illustrates the superimposed conformations of loop models of
MAL. In first conformational mode (Figure 4.15-A), the AB-loop is tilted towards
the helix-αE helix and makes interaction with it (Figure 4.16). Hydrophobic and hy-
drogen interactions results in the stabilization of AB-loop with helix-αE. So, Tyr86
and Tyr106 are exposed to solvent and participate in interacting with kinases (dis-
cussed in detail below). Furthermore, electrostatic charge analysis on the surface of
MAL presented that Tyr86 and Tyr106 are protruded as putative sites for interaction
with kinases (discussed in detail below). On the other hand, in second conformational
mode, (superimposed models 3-10 are shown in Figure 4.15-B), AB-loop is slanted
in the opposite direction as compared to the first conformational mode of AB-loop
and scattered away from helix-αE. Moreover, in second conformational space, in-
teractions of AB-loop with nearby residues are relatively fewer which increased the
flexibility of AB-loop. Solvent accessible surfaces analysis of models 3-10 presents
that the AB-loop overshadow Tyr86 and cause non-functional models that cannot be
used further for PPI analysis.
Study of models, in terms of energies, illustrates that model 1 and 2 have
minimal energy levels comparable to the crystal structure of MAL along with their
ERRAT scores. As this study is concerned with the PPI of MAL from the sides of
Tyr86 and Tyr106 with kinases, so model 1 with exposed Tyr86 and Tyr106 is used
for further analysis.
4.7 Conserved Domains of Proteins
pBTK: ConSurf analysis (Figure 4.17-B) discloses (as anticipated) that the func-
tional domains of pBTK are highly conserved (depicted in intense pink colour). For
example, all the residues that form the possible interface obtain the highest conserva-
tion scores. Likewise, active site, that is known to be central for ATP binding is also
highly conserved.
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180°
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Figure 4.15. Superimposed structures of 10 selected models of MAL. (A) Struc-
tural representation of superimposed models 1 and 2 of MAL depicting the correct
orientation of AB-loop (tilted towards αE helix)(upper left corner) along with the
solvent exposed ridges of Tyr86 and Tyr106 (upper right corner) (B) Structural repre-
sentation of superimposed models 3-10 of MAL depicting the incorrect orientation of
AB-loop (tilted against αE helix)(lower left corner) along with the shadowed Tyr86
and Tyr106. Figure adapted from Paracha et al. (2014b)
pPKCδ : Similarly ConSurf analysis (Figure 4.17-B) imparts, that the functional
domains are highly preserved. However, the conservation of residues in pPKCδ is
not up to that level as seen in pBTK.
MAL: ConSurf analysis (Figure 4.17-A) discloses that conserved areas are present
inside of the protein, where highly non-conserved residues are present at surface of
MAL.
4.8 PPI of pBTK with MAL within Tyr86 region.
The prepared structure of pBTK was interacted with model-1 of MAL using
HADDOCK. Default settings were used for PPIs. CPORT interpretations for active
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Figure 4.16. Orientation of AB-loop and its non-covalent contacts with nearby
atoms of residues in 2 loop models of MAL. List of interactions made by the AB-
loop of MAL with nearby residues in model-1 (upper Left) along with the graphical
representation of the orientation of AB-loop in the model (upper right) are illustrated
in (A). List of interactions made by the AB-loop in model-2 (lower left) along with
its graphical representation (lower right) are illustrated in (B). Hydrophobic and
hydrogen bond interactions are termed as “HYD” and “HB”, respectively. Amino
acids are depicted as sticks and labelled. Interaction within residues is presented as
thin lines. Figure adapted from Paracha et al. (2014b)
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and passive interface residues of pBTK and MAL within Tyr86 region are presented
in Figure 4.18 and 4.20, respectively. Active residues are those residues that may
directly involved in the PPI, whereas passive residues only support the active residues.
HADDOCK produced 166 pBTK-MAL complexes grouped into 9 clusters based on
HADDOCK score. Statistical analysis for the 9 clusters is illustrated in Figure 4.19.
HADDOCK score for the potential complex of pBTK within Tyr86 region of MAL
(described as pBTK-Tyr86:MAL) is “-13.4 ± 2.7”, depicting the utmost possible
complex in other interpretations. Figure 4.21 presents the cluster size, Van der Waals
energy, desolvation energy, RMSD from the overall lowest-energy structure, restraints
violation energy (RVE), electrostatic energy (EE), buried surface area (BSA) and Z-
score of 9 clusters. In order to further refine the complex, the most probable complex
(having lowest HADDOCK score) among the other predicted complexes was treated
for the refinement of protein orientations against one another. Figure 4.22 presents the
statistics for the refined complexes. Refined complex of pBTK–Tyr86:MAL (Figure
4.23) was further used in the analysis of PPI. Study of deformation of structures
regarding atomic clashes, bond lengths, bond angles, contact energies and dihedrals
of pBTK-Tyr86:MAL demonstrates that structures conserves their quality after PPIs.
Inter-molecular interaction analysis of pBTK–Tyr86:MAL establishes that 21
non-covalent interactions adhere proteins with one another. Out of these 21 interac-
tions 5 ionic, 7 hydrophobic and 9 hydrogen bonds are found within the residues of
MAL and pBTK discussed in detail below.
The selected complex of pBTK–MAL illustrates prominent conformations of
pBTK against MAL in which γ-phosphate of ATP modelled in pBTK (ATP:pBTK)
is found within a distance of 3.1Å from the phosphorylatable atom of Tyr86:MAL
(Figure 4.23-B). Furthermore, the atoms of GPL are making contacts with strand
βB:MAL in vicinity of Tyr86 of MAL (Tyr86:MAL). Interaction of Gln412:GPL of
pBTK with the Tyr86:MAL can stabilize its position and help in the flexible transition
of γ-phosphate of ATP:pBTK towards its phosphorylatable atom. AB-loop of MAL is
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Figure 4.18. Implication of probable interacting surface of pBTK. (A) Ribbon
plot of pBTK depicting the region close to GPL (Left side) and helix αC (right
side). (B) Protein sequence of pBTK. Amino acids in the ribbon plots and in protein
sequence are shaded in red for active and blue for passive residues, whereas white
shaded residues represent inactive amino acids as anticipated by CPORT. Figure
adapted from Paracha et al. (2014b).
stabilized as a result of interaction of β3:pBTK involving Lys433 with Gly126:MAL.
Helix-αA of MAL is stabilized with pBTK by salt bridges between Glu94:MAL
with Arg487and Lys595 of pBTK along with Leu97:MAL with Leu483:pBTK. Loop
among βB and βC strands in MAL makes additional interactions with pBTK to
stabilize the complex. In this interaction, a salt bridge is found between Gln135
and Glu132 of MAL and the catalytic residue Arg525:pBTK. Moreover, Ser138 and
Ser139 of MAL form salt bridges with Lys558: pBTK. Furthermore, Leu133, Ala136
and Leu137 of MAL are found in making interactions with Leu483, Asn603 and
Trp563 of pBTK, respectively, to strengthen the complex. Helix-αC of MAL also
interacts with pBTK on the loop between helix-αE and αF. In this area, Asp154:MAL
is producing salt bridges with Lys595:pBTK. The interaction of Pro155:MAL and
Trp156:MAL with Arg600:pBTK and Met596: BTK respectively, further stabilise the
helix-αC of MAL with loop between helix-αE and αF of pBTK, respectively.
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Figure 4.19. Statistics for the complex of pBTK-Tyr86:MAL. Statistics obtained
after PPI of pBTK with MAL within Tyr86 region. (A-G) Scatter plots of HADDOCK
score (arbitrary units(a.u.)), interface (i) RMSD (Å), interface-ligand (i-l) RMSD (Å),
ligand (l) RMSD (Å), EE (kcal/mol), Van der Waals energy (kcal/mol), ambiguous
interaction restraint energy (AIR) (kcal/mol) and fraction of common contacts (FCC)
(a.u.). Definitions of mentioned statistics can be learned from (De Vries et al., 2010;
Méndez et al., 2003; Rodrigues et al., 2012). These scores were estimated for different
complexes with reference to the most probable complex. The clusters were derived
on the basis of RMSDs within the interfaces that are specified by HADDOCK. Mean
and standard deviations of scores of complexes are depicted by coloured points and
related error bars, respectively. Figure adapted from Paracha et al. (2014b).
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Figure 4.20. Implication for probable interacting surface of MAL.(A) Ribbon
plot of pBTK depicting the region close to Tyr86 (Left side) and Tyr106 (right side)
(B) Protein sequence of MAL. Amino acids in the ribbon plots and in protein sequence
are shaded in red for active and blue for passive residues, whereas white shaded
residues represent inactive amino acids as anticipated by CPORT. Figure adapted
from Paracha et al. (2014b).
4.9 PPI of pBTK with MAL within Tyr106 region
The prepared structure of pBTK was docked with model-1 of MAL using
HADDOCK. Default settings were used for PPI. CPORT interpretations for active
and passive residues of pBTK and MAL within Tyr106 region are illustrated in Fig-
ure 4.18 and 4.20, respectively. HADDOCK produced 191 pBTK-MAL complexes
grouped into 4 clusters based on HADDOCK score. Statistical analysis for the 4 clus-
ters is illustrated in Figure 4.24. HADDOCK score for the potential complex of pBTK
within Tyr106 of MAL (described as pBTK-Tyr106:MAL) is “-65.2 ± 5.8”, repre-
senting the most possible complex among other interpretations. Figure 4.25 presents
the cluster size, Van der Waals energy, desolvation energy, RMSD from the overall
lowest-energy structure, RVE, EE, BSA and Z-score of 4 clusters. The most probable
complex was refined and its statistics are illustrated in Figure 4.26. Refined complex
of pBTK-Tyr106:MAL is depicted in Figure 4.27, which is further used in the analysis
of PPI. Study of deformation of structures regarding atomic clashes, bond lengths,
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Figure 4.21. PPI scores for clusters 1-9 of pBTK-Tyr86:MAL. (A) Chart of PPI
scores for the top 9 clusters of the most probable complexes of pBTK-Tyr86:MAL .
(B) Superimposed structural representation of top four probable complexes of pBTK-
Tyr86:MAL from clusters 1-9. Structures of MAL are illustrated in khaki shade,
whereas structures of pBTK are depicted in blue shade. Figure adapted from Paracha
et al. (2014b).
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Figure 4.22. Statistics for the complex pBTK-Tyr86:MAL after refinement.
Statistics obtained after the refinement of pBTK with MAL within Tyr86 region.
(A-G) Scatter plots for the HADDOCK score (a.u.), i-RMSD (Å), i-l-RMSD (Å),
l-RMSD (Å), Electrostatic energy (kcal/mol), Van der Waals energy (kcal/mol), AIR
(kcal/mol) and FCC (a.u.) against one another. Definitions of mentioned statistics can
be learned from (De Vries et al., 2010; Méndez et al., 2003; Rodrigues et al., 2012).
These scores were estimated for different complexes with reference to the most prob-
able complex. The clusters were derived on the basis of RMSDs within the interfaces
that are specified by HADDOCK. Mean and standard deviations of scores of com-
plexes are depicted by coloured points and related error bars, respectively. Figure
adapted from Paracha et al. (2014b).
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Figure 4.23. Protein complex of pBTK with MAL within Tyr86 region.(A) The
structural representation of pBTK-Tyr86:MAL. ATP:pBTK and Tyr86 of MAL are
shaded red and green, respectively. Loop model of MAL is in khaki shade, whereas
pBTK is demonstrated in sea green shade. (B) The ATP of pBTK and Tyr86 of MAL,
presented as sticks, are situated in a proximity of 3.1Å. Figure adapted from Paracha
et al. (2014b).
bond angles, contact energies and dihedral of pBTK-Tyr106:MAL demonstrates that
structures conserves their quality after PPIs.
Inter-molecular interaction analysis of pBTK–Tyr106:MAL establishes that
29 non-covalent interactions adhere the proteins with one another. Out of these 29
interactions; 4 ionic, 4 hydrophobic and 21 hydrogen bonds are found within the
residues of MAL and pBTK, briefly discussed in detail below.
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Figure 4.24. Statistics for the complex of pBTK-Tyr106:MAL Statistics obtained
after PPI of pBTK with MAL within Tyr86 region. (A-G) Scatter plots for the HAD-
DOCK score (a.u.), i-RMSD (Å), i-l-RMSD (Å), l-RMSD (Å), Electrostatic energy
(kcal/mol), Van der Waals energy (kcal/mol), AIR (kcal/mol) and FCC (a.u.) against
one another. Definitions of mentioned statistics can be learned from (De Vries et al.,
2010; Méndez et al., 2003; Rodrigues et al., 2012). These scores were estimated for
different complexes with reference to the most probable complex. The clusters were
derived on the basis of RMSDs within the interfaces that are specified by HADDOCK.
Mean and standard deviations of scores of complexes are depicted by coloured points
and related error bars, respectively. Figure adapted from Paracha et al. (2014b).
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Figure 4.25. PPI scores for clusters 1-4 of pBTK-Tyr106:MAL. (A) Chart of PPI
scores for the top 4 clusters of the most probable complexes of pBTK-Tyr106:MAL .
(B) Superimposed structural representation of top four probable complexes of pBTK-
Tyr106:MAL from clusters 1-4. Loop model of MAL is illustrated in khaki shade,
whereas structure of pBTK is depicted in green shade. Figure adapted from Paracha
et al. (2014b).
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Figure 4.26. Statistics for the complex pBTK-Tyr106:MAL after refinement.
Statistics obtained after the refinement of pBTK with MAL within Tyr106 region.
(A-G) Scatter plots for the HADDOCK score (a.u.), i-RMSD (Å), i-l-RMSD (Å),
l-RMSD (Å), Electrostatic energy (kcal/mol), Van der Waals energy (kcal/mol), AIR
(kcal/mol) and FCC (a.u.) against one another. Definitions of mentioned statistics can
be learned from (De Vries et al., 2010; Méndez et al., 2003; Rodrigues et al., 2012).
These scores were estimated for different complexes with reference to the most prob-
able complex. The clusters were derived on the basis of RMSDs within the interfaces
that are specified by HADDOCK. Mean and standard deviations of scores of com-
plexes are depicted by coloured points and related error bars, respectively. Figure
adapted from Paracha et al. (2014b).
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The selected complex of pBTK–Tyr106:MAL provides putative conformation
of pBTK against MAL in which γ-phosphate of ATP modelled in pBTK (ATP:pBTK)
lies within a distance of 3.5Å from the phosphorylatable hydroxyl of Tyr106:MAL
(Figure 4.27). Lys558 of pBTK interacts with Tyr106, Gly109, Leu107, and Ser110
of MAL to stabilize the Tyr106 in place. On the other hand, Tyr86 is interacting with
the β2 strand of pBTK. The main domains of MAL such as αA, αB and αE helices
interact with GPL, the loop between β3 and αA, the loop between αE and αF and
activation loop of pBTK. Within the area of helix-αA:MAL, Val98 and Ala99 inter-
acts with the activation loop of pBTK that limit the activation loop in place. Gln101 is
found to interact with Gln412, Arg520 and Arg544 of pBTK. Furthermore, Asp102 of
MAL makes salt bridge with Arg520:pBTK to further stabilize and strengthen the αA
helix:MAL against pBTK. Area of αB helix of MAL interacts with Lys433 of pBTK.
Area of αE helix:MAL relating to Asp203 and Arg207 interacts with Glu599-Asn603
of pBTK that form a loop between αE and αF.
4.10 PPI of pPKCδ with MAL within Tyr86 region
The prepared model of pPKCδ was docked with model-1 of MAL using de-
fault settings of HADDOCK. CPORT interpretations for active and passive residues
of pPKCδ and MAL within Tyr86 region (described as pPKCδ -Tyr86:MAL) are
illustrated in Figures 4.28 and 4.20, respectively. HADDOCK produced 176 pPKCδ -
Tyr86:MAL complexes grouped into 10 clusters based on HADDOCK score. Statisti-
cal analysis for the 10 clusters is portrayed in Figure 4.29. HADDOCK score for the
potential complex of pPKCδ -Tyr86:MAL is “-96.4 ± 3.0”, representing the highly
possible complex in other interpretations. Figure 4.30 presents the cluster size, Van
der Waals energy, desolvation energy, RMSD from the overall lowest-energy structure,
RVE, EE, BSA and Z-score of 10 clusters. The most probable complex was refined,
its statistics are illustrated in Figure 4.31. Refined complex of pPKCδ -Tyr86:MAL
is depicted in Figure 4.32, which is further used in the analysis of PPI. Study of
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deformation of structures regarding atomic clashes, bond lengths, bond angles, con-
tact energies and dihedrals of pPKCδ -Tyr86:MAL demonstrate that the quality of
structures is retained in the stage of PPIs.
Inter-molecular interaction analysis of pPKCδ -Tyr86:MAL establishes that
21 non-covalent interactions adhere the proteins with one another. However, the γ
phosphate of ATP in pPKCδ -Tyr86:MAL complex is found to be within a distance of
25.6Å from Tyr86:MAL. Major interactions are observed within GPL and activation
loop of pPKCδ with αC-βD region of MAL.
F I F H K V L G K G S F G K V L L G E L K G R G E X F A I K A L K K D V V L I D D D V E C T M V E K349 
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R A T F Y A A E I M C G L Q F L H S K G I I Y R D L K L D N V L L D R D G H I K I A D F G M C K E N449
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>pPKCδ
A
B
Glycine rich loop
αC helix
Figure 4.28. Implication for probable interacting surface of pPKCδ (A) Ribbon
plot of pBTK depicting the region close to GPL (Left side) and helix αC (right side).
(B) Protein sequence of pPKCδ . Amino acids in the ribbon plots and in protein
sequence are shaded in red for active and blue for passive residues, whereas white
shaded residues represent inactive amino acids as anticipated by CPORT. Figure
adapted from Paracha et al. (2014b).
4.11 PPI of pPKCδ with MAL within Tyr106 region
The prepared structure of pPKCδ was docked with model-1 of MAL using
default settings of HADDOCK. Interpretations for active and passive residues pro-
duced by CPORT for pPKCδ and MAL within Tyr106 region (described as pPKCδ -
Tyr106:MAL) are illustrated in Figures 4.28 and 4.20-B, respectively. HADDOCK
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Figure 4.29. Statistics for the complex of pPKCδ -Tyr86:MAL Statistics obtained
after PPI of pPKCδ with MAL within Tyr86 region. (A-G) Scatter plots for the HAD-
DOCK score (a.u.), i-RMSD (Å), i-l-RMSD (Å), l-RMSD (Å), Electrostatic energy
(kcal/mol), Van der Waals energy (kcal/mol), AIR (kcal/mol) and FCC (a.u.) against
one another. Definitions of mentioned statistics can be learned from (De Vries et al.,
2010; Méndez et al., 2003; Rodrigues et al., 2012). These scores were estimated for
different complexes with reference to the most probable complex. The clusters were
derived on the basis of RMSDs within the interfaces that are specified by HADDOCK.
Mean and standard deviations of scores of complexes are depicted by coloured points
and related error bars, respectively. Figure adapted from Paracha et al. (2014b).
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Scores for Clusters produced by HADDOCK
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Figure 4.30. PPI scores for clusters 1-10 of pPKCδ -Tyr86:MAL. (A) Chart of PPI
scores for the top 10 clusters of the most probable complexes of pPKCδ -Tyr86:MAL .
(B) Superimposed structural representation of top four probable complexes of pPKCδ -
Tyr86:MAL from clusters 1-10. Structure pf MAL is illustrated in blue shade, whereas
structure of pPKCδ is depicted in green shade. Figure adapted from Paracha et al.
(2014b).
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Figure 4.31. Statistics for the complex pPKCδ -Tyr86:MAL after refinement.
Statistics obtained after the refinement of pPKCδ with MAL within Tyr86 region.
(A-G) Scatter plots for the HADDOCK score (a.u.), i-RMSD (Å), i-l-RMSD (Å),
l-RMSD (Å), Electrostatic energy (kcal/mol), Van der Waals energy (kcal/mol), AIR
(kcal/mol) and FCC (a.u.) against one another. Definitions of mentioned statistics can
be learned from (De Vries et al., 2010; Méndez et al., 2003; Rodrigues et al., 2012).
These scores were estimated for different complexes with reference to the most prob-
able complex. The clusters were derived on the basis of RMSDs within the interfaces
that are specified by HADDOCK. Mean and standard deviations of scores of com-
plexes are depicted by coloured points and related error bars, respectively. Figure
adapted from Paracha et al. (2014b).
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ATP
Tyr106
Tyr86
25.6Å
Figure 4.32. Protein complex of pPKCδ with MAL within Tyr86 region. The
structural representation of pPKCδ -Tyr86:MAL. ATP of pPKCδ and Tyr86 of MAL
are shaded red and aquamarine, respectively. Loop model of MAL is in aquamarine
shade, whereas pPKCδ is demonstrated in green shade. The ATP of pPKCδ and Tyr86
of MAL, presented as sticks, are situated in a proximity of 25.6Å. Figure adapted
from Paracha et al. (2014b).
produced 185 pPKCδ -Tyr106:MAL complexes grouped into 8 clusters based on
HADDOCK score. Statistical analysis for the 8 clusters is portrayed in Figure 4.33.
HADDOCK score for the potential complex of pPKCδ -Tyr106:MAL is “-72.4 ±
4.0”, representing the highly possible complex in other interpretations. Figure 4.34
presents the cluster size, Van der Waals energy, desolvation energy, RMSD from the
overall lowest-energy structure, RVE, EE, BSA and Z-score of 8 clusters. The most
probable complex among the other predicted complexes was refined in the orien-
tations of proteins against one another. Figure 4.35 portrays the statistics for the
refined complexes. Refined complex of pPKCδ -Tyr106:MAL is depicted in Figure
4.36, which is further used in the analysis of PPI. Study of deformation of structures
regarding atomic clashes, bond lengths, bond angles, contact energies and dihedrals
of pPKCδ -Tyr106:MAL demonstrate the reliability and quality of structures after
PPIs.
Inter-molecular interaction analysis of pPKCδ -Tyr106:MAL establish that
33 non-covalent interactions adhere the proteins with one another. Out of these 33
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interactions; 3 hydrophobic, 10 ionic and 20 hydrogen bonds are found within the
residues of MAL and pPKCδ discussed in detail below
Figure 4.33. Statistics for the complex pPKCδ -Tyr106:MAL. Statistics obtained
after PPI of pPKCδ with MAL within Tyr106 region. (A-G) Scatter plots for the HAD-
DOCK score (a.u.), i-RMSD (Å), i-l-RMSD (Å), l-RMSD (Å), Electrostatic energy
(kcal/mol), Van der Waals energy (kcal/mol), AIR (kcal/mol) and FCC (a.u.) against
one another. Definitions of mentioned statistics can be learned from (De Vries et al.,
2010; Méndez et al., 2003; Rodrigues et al., 2012). These scores were estimated for
different complexes with reference to the most probable complex. The clusters were
derived on the basis of RMSDs within the interfaces that are specified by HADDOCK.
Mean and standard deviations of scores of complexes are depicted by coloured points
and related error bars, respectively. Figure adapted from Paracha et al. (2014b).
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The complex of pPKCδ and MAL has significant orientations of protein
against each another, in which γ-phosphate of ATP:pPKCδ is found within an area of
3.9Å around hydroxyl group of Tyr106 of MAL (Figure 4.36-B). Many interactions
among MAL and pPKCδ exists between pPKCδ and helices αA and αE of MAL.
Among them, three residues including Val384, Asp648 and Leu651 of pPKCδ inter-
act within helix-αA of MAL at position Val98. Moreover, Asp648 located in the Turn
motif of pPKCδ interacts with Leu97 and Val98 of MAL to limit the flexibility of
Turn motif and thus decrease the probability of its clash within the interaction sites of
proteins. Moreover, Lys357 and Lys362 of pPKCδ develop salt bridges with Asp102
of MAL that braces GPL in correct order. Two residues including Asp635 and Glu637
of pPKCδ interacts with Arg115 that is present in the area of AB-loop:MAL, where,
Asp388 of pPKCδ interacted with Ser180 and Gly181 located in the region of loop
after strand-βD and Arg200 of helixαE of MAL to further stabilise the complex of
pPKCδ and MAL.
Helix-αE is projected into the channel between N and C terminals of pPKCδ
underneath the binding cavity of ATP and allows the γ-phosphate of ATP near Tyr106
of MAL. Five salt bridges are found between pPKCδ and Asp203, Arg207, Gln208
and Arg215 of MAL that braces the orientation of Helix-αE.
4.12 Physicochemical Properties of Interfaces
Various methods were utilized for the interpretation and validation of PPIs
and it was established that charge dispersion and hydrophobicity of protein surfaces
can explicitly explain the rationality of PPIs of MAL with pPKCδ and pBTK. In
this portion of the study, the physicochemical quality of protein binding surfaces of
MAL, pPKCδ and pBTK are discussed. Delphi (Li et al., 2012) was used to compute
the dissemination of electrostatic charges and Kyte–Doolittle algorithm (Kyte and
Doolittle, 1982) was used for the determination of hydrophobic character on the
surfaces of MAL, pPKCδ and pBTK.
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Scores of Top 8 Clusters produced by HADDOCK
(PPI of pPKCδ with Tyr106:MAL)
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Figure 4.34. PPI scores for clusters 1-8 of pPKCδ -Tyr106:MAL. (A) Chart of PPI
scores for the top 8 clusters of the most probable complexes of pPKCδ -Tyr106:MAL .
(B) Superimposed structural representation of top four probable complexes of pPKCδ -
Tyr106:MAL from clusters 1-8. Loop model of MAL is illustrated in green shade,
whereas structure of pPKCδ is depicted in blue shade. Figure adapted from Paracha
et al. (2014b).
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Figure 4.35. Statistics for the complex pPKCδ -Tyr106:MAL after refinement.
Statistics obtained after the refinement of pPKCδ with MAL within Tyr106 region.
(A-G) Scatter plots for the HADDOCK score (a.u.), i-RMSD (Å), i-l-RMSD (Å),
l-RMSD (Å), Electrostatic energy (kcal/mol), Van der Waals energy (kcal/mol), AIR
(kcal/mol) and FCC (a.u.) against one another. Definitions of mentioned statistics
can be learned from (De Vries et al., 2010; Méndez et al., 2003; Rodrigues et al.,
2012). These scores were estimated for different complexes with reference to the
most probable complex. The clusters were derived on the basis of RMSDs within the
interfaces that are specified by HADDOCK. Mean and standard deviations of scores
of complexes are depicted by coloured points and related error bars, respectively.
Figure adapted from Paracha et al. (2014b).
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Study of charge complementary at the protein interfaces endorses the PPI of
pBTK pPKCδ within the region of Tyr86:MAL. The interaction surfaces of pBTK
and MAL have substantial charge complementary distribution, where positive inter-
face of pBTK interacts with considerable negatively charged surface of MAL around
Tyr86 (Figure 4.37-F). AB-loop:MAL interacts with N terminal of GPL because of
electrostatic attractions between Glu407:BTK and Arg115:MAL. GPL in pBTK is
positively charged and interacts with negatively charged amino acids of sheets βA
and βB of MAL and orients ATP against Tyr86 of MAL. Furthermore, the area of
helix-αA:MAL has most residues with negative charge, which interacts with posi-
tively charged residues of BTK like Leu483, Arg487 and Lys595 to further support the
complex. Catalytic residue i.e. Arg525 of pBTK develops salt bridges with Glu132
and Gln135:MAL. The charge complementarity is also found in the same area which
supports the interaction. Moreover, helix-αC:MAL interacts within the area of he-
lices αE and αF:pBTK that is further supported by the electrostatic complementation.
Contact formation of pPKCδ in the surroundings of Tyr86 of MAL seems to be
non-functional.This is possibly due to the strong charge dissimilarities on the binding
surfaces (Figure 4.37-G). Probably, due to this reason, optimized pPKCδ -Tyr86:MAL
is not produced.
Area around Tyr106 is an attractive case of heterogeneous distribution of
charges between the proteins. It is observed that pBTK binds with the negative region
of Tyr106 in such an orientation that γ-phosphate can phosphorylate the hydroxyl
group of Tyr106:MAL (Figure 4.37-H). The N-lobe of pBTK interacts with the nega-
tively charged interface of MAL, while C-lobe of pBTK is attracted to the surrounding
of positively charged Tyr106 region. Furthermore, the activation loop:pBTK is also
present in the surrounding of negatively charged region of MAL. On the other hand,
the binding surface of MAL and pPKCδ in the complex pPKCδ -Tyr106:MAL is
different from that in the case of pBTK versus Tyr106:MAL. In the complex pPKCδ -
Tyr106:MAL, the binding surface of pPKCδ is negatively charged whereas MAL
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appealed it with positively charged surface (Figure 4.37 I). The N-lobe of pPKCδ
interacts within the surroundings of negatively charged area of MAL, while C-lobe
of PKCδ binds with the positively charged area of MAL. However, all non-covalent
contacts in the complex pPKCδ -Tyr106:MAL comprises of charge complementarity.
For instance, Lys357 and Lys362 of pPKCδ are attracted by Asp102 in helix-αA
of MAL. Additionally, the compatibly charged residues of pPKCδ are also found in
making interactions with residues of MAL in the area of helix-αE for bracing the
complex.
The hydrophobic regions at the protein interfaces are presented in Figure 4.38.
The complex of pBTK-Tyr86:MAL has several non-polar interactions including: (a)
Phe404 of pBTK with Phe117:MAL; (b) Leu483:pBTK with Val104, Leu97 and
Leu133 of MAL; (c) Val415 of pBTK with Leu107:MAL; (d) Met489:pBTK with
Val98:MAL; and (e) Met596:pBTK with Trp156:MAL. On the other hand, only 3 hy-
drophobic contacts are observed in the complex of pPKCδ -Tyr86:MAL that are Ile387
and Leu651 of pPKCδ with Leu137:MAL and Val384:pPKCδ with Trp156:MAL.
Other areas of hydrophobicity in both protein complexes are found within a region of
over 7Å.
In the complex of pBTK-Tyr106:MAL, 3 hydrophobic contacts are observed
involving: (a) Phe413:pBTK with Leu133:MAL; (b) Val415:pBTK with Val130:MAL;
and (c) Val555:pBTK with Val98:MAL. Likewise, in the case of pPKCδ -Tyr106:MAL,
Val384 and Leu651 of pPKCδ interacts with Val98:MAL and Met436:pPKCδ inter-
acts with Leu114:MAL. The non-polar regions in protein complexes are in a prox-
imity of 7Å. Analysis reveals that the attraction between pBTK and MAL within the
Tyr86 region requires interactions facilitated by non-polar amino acids, while pPKCδ
and pBTK interacts with MAL within the region of Tyr106 by charged amino acids.
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DISCUSSION
In this thesis, a qualitative model for the TLR4 and JAK/STAT signalling path-
ways is developed. The objective of developing a qualitative model was to explore
possible system dynamics of the signalling pathways and to present key interactions
and proteins causing the variation in immune responses during sepsis. As a result
of qualitative analysis, protein-protein interactions of MAL with BTK and PKCδ
(a major event for the initiation of TLR4 signalling) is performed to further explore
the residues, domains and orientation of proteins against each other which could de-
termine the phosphorylation events of MAL at two specific residues i.e. Tyr86 and
Tyr106. The computational approaches and techniques used in this study provided
insights into: (a) unusual functions of the interactions in non-sepsis, sepsis and per-
turbed signalling; (b) roles of IFN-β and SOCS-1 at different stages of sepsis; (c)
extrapolation of TLR4 dependent crosstalk mechanism; (d) the missing structural
features of MAL; (e) the regions and domains of proteins involved in protein-protein
interactions; (f) charges and hydrophobicity at surfaces of proteins necessary to sup-
port the interaction of MAL with kinases at specific regions of Tyr86 and Tyr106; and
(g) BTK as a key kinase of MAL having the ability to phosphorylate both positions
of Tyr86 and Tyr106 unlike PKCδ . Furthermore, it also shaped up a computational
pipeline which can be used to illustrate any signalling event at molecular and even in
to the atomic levels.
The purpose to use qualitative level analysis of TLR4 and JAK/STAT sig-
nalling pathways is due to the reason that quantitative modelling requires various
reaction kinetics which are either unavailable or may produced for any other similar
conditions. Due to this, it was speculated that the usage of logical parameters pro-
duced for any other conditions could produce imitated results in non-septic and septic
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modelling and might neglect their originality. In addition, the objective of this study
was to envisage the roles of interactions between proteins after achieving a minimum
required concentration (referred as threshold levels in this study), which simplify the
overall modelling approach and further its analysis. In further support of qualitative
analysis, the approach used in this work has an additional advantage of producing
state spaces (state graphs), which can represent a system in any dimension as a dis-
crete abstraction, while in other approaches of quantitative modelling, like in ordinary
differential equations, this may be very challenging (Thomas and d’Ari, 1990).
Qualitative modelling approach used in this work is known as René Thomas’
kinetic logic (Demongeot et al., 2000; Snoussi and Thomas, 1993; Thomas, 1978,
1979, 1991, 1998; Thomas and Kaufman, 2001). Kinetic logic is a modified form of
the Boolean logic, initially introduced by Kauffman (1969). Contrary to the Boolean
logic which allows to model the system with values “0” and “1”, Kinetic logic has
the advantage to use qualitative levels from a range of “1” to the outdegree (Defi-
nition 2) of an entity (Thomas and d’Ari, 1990). Therefore, multivalued formalism
has been introduced to cater more qualitative levels than Boolean logic could present.
For example, in the BRN (in Figure 3.8), value "1" is utilised as threshold levels
for all of the interactions among entities except for PiCyts mediated activation of
NFκB-JAK/STAT that is equivalent to "2". Accordingly, PiCyts stimulate SOCS-1 on
achieving the threshold level “1” and further stimulates NFκB-JAK/STAT at another
threshold level “2”. This feature makes the Kinetic logic as one of the significant
approach to model the system dynamics in this study which can be estimated by
the applicability of this approach in various other biological systems studied previ-
ously (Ahmad et al., 2012; Aslam et al., 2014; Mendoza, 2006; Mendoza et al., 1999;
Sanchez and Thieffry, 2003).
Kinetic logic is an asynchronous approach unlike the Boolean modelling ap-
proach which is synchronous in nature Kauffman (1969). As the synchronous transi-
tioning considers the change of more than one entity in a single transition between
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states, therefore it does not accommodate complete cyclic trajectories and may not
predict certain biological behaviours (Dubrova et al., 2005). In contrast, Kinetic logic
as employed in this study produced several successors for each state to generate all
possible orders of states for each component (Thomas et al., 1995). These orders are
important from the modelling point of view as the relative kinetics of the reactions,
and their defined products are usually remain unknown for a specific time. Moreover,
the asynchronous approach accommodates complete cyclic trajectories presented in
this work as strongly connected components (SCCs) (Thomas and d’Ari, 1990). For
example, in case of non-septic signalling shown as the state graph (Figure 4.1), pos-
sibly have two cycles discussed as SCC-1 and SCC-2 as shown in Figures 4.2a and
4.2b, respectively.
The logical modelling approach can be used to model relatively larger BRNs
composed of several entities and interactions (Franke et al., 2008; Saez-Rodriguez
et al., 2007). However, the size of the state space exponentially grows with the number
of nodes and edges. Efficient algorithms have been suggested to describe all possi-
ble stable states through static examination (e.g. Naldi et al. (2007); Dubrova and
Teslenko (2011)). One way to handle this problem is the development of complemen-
tary approach that encompass reduction of the large systems, by concentrating on
the most relevant entities along with redefining the interactions among them in order
to preserve relevant properties of system dynamics (e.g. stable states). In this study,
the concepts of compositionality and modularity, based on the multi-valued logical
formalism, originally defined by Thomas and co-workers (Thomas, 1991) were relied
upon along with the static examination of the system as described by Naldi et al.
(2009) and Saadatpour et al. (2013). The principles of this technique implemented as
a part of GINSIM are employed in the iterative reduction of TLR4 and JAK/STAT
signalling pathways to an abstracted BRN (Figure 3.8), where the significant informa-
tion about the function of entities in the model is retained. Moreover, the reduction of
the signalling pathways was performed to decrease the state spaces (Figures 4.1-4.9)
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and to make them more tractable. The quality of the model presented in this study can
be evaluated by means of results produced with simple modifications in it. Correlation
between results and literature, discussed below, support that the model used in this
study is of high quality and that confidence can be taken in further implications made
from it.
The methodology of model checking for the computation of parameters values
by SMBioNet was based on the experimental observations from the literature in
the form of CTL formulae. It has been successfully employed in the computation
of parameters values for various regulatory networks such as immunity control in
bacteriophage lambda (Richard et al., 2006), tail resorption in tadpole metamorphosis
(Khalis et al., 2009) and type III cytotoxicity in Pseudomonas aeruginosa (Filopon
et al., 2006). The values of logical parameters of the reduced BRN were computed
first for the non-septic condition and after that the modification of value for single
logical parameter provided us the system dynamics of sepsis. The term “non-septic”
reflects such types of infections that generally do not induce the recurrent inductions
of TLR4, whereas, the blood borne infections can frequently induce TLR4 signalling
is termed “septic” (Härter et al., 2004; Remick, 2007).
The qualitative analysis of TLR4 and JAK/STAT signalling cascades during
non-septic condition has established that higher levels of PiCyts can be expressed
at a particular state of infection (such as shown by the state “00121” in Figure 4.1)
to overcome the load of the pathogen, however as soon as the infection is reduced
then the immune system can be successively down-regulated by various inhibitory
mechanisms such as by IFN-β and SOCS-1 up to a particular state, where the immune
response reflect the absence of intermediary factors (such as shown in the state “00000”
in Figure 4.1). The pro-inflammation is considered in those states which have higher
(“2") qualitative levels of PiCyts, while immunodepression is linked with the lower
(“0") qualitative levels of PiCyts.
An important role of the TLR4 signalling observed is the crosstalk mechanism
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of MyD88 and TRIF dependent signalling pathways which elaborates the lagging in
the induction of IFNβ after PiCyts. Previous studies relating the pathogen induced
immune response with the timings for the onset of PiCyts and IFN-β (Pontiroli et al.,
2012; Solodova et al., 2011) also suggested that MyD88 and TRIF mediated sig-
nalling can induce inflammatory responses at relatively different stages of infection.
Another study indicated that IFN-β get stimulated 24 hours after the infection with
Listeria monocytogenes (Pontiroli et al., 2012). Moreover, IFN-β has been found to
reduce the hyper-inflammatory conditions in septic peritonitis in succeeding stages of
disease (Weighardt et al., 2006). This form of the early and late activation of PiCyts
and IFN-β , respectively, have been successfully reproduced in this study. It can be
witnessed that those trajectories in which IFNβ is induced earlier than PiCyts (like
in the trajectories originating from the state “11000”), the inflammatory response
could not be generated until the levels of IFN-β get weakened. This specific pattern
of activation of PiCyts at first instance may allow the system to instantaneously alarm
against the presence of pathogens otherwise the system could be exposed to severe
burden of pathogenic origin. Another interesting phenomenon of the production of
PiCyts through MyD88 independent mechanism late in the system is found consistent
with the previous studies (Adachi et al., 1998; Fitzgerald et al., 2003; Verstak et al.,
2009; Yamamoto et al., 2003). Previously, it has been observed that MyD88 depen-
dent signalling activates PiCyts at earlier stages, whereas TRIF mediated signalling or
known as MyD88 independent signalling is found to be linked with delayed induction
of PiCyts (Adachi et al., 1998; Fitzgerald et al., 2003; Verstak et al., 2009; Yamamoto
et al., 2003).
One important characteristic of the qualitative modelling of non-sepsis is the
production of a specific pattern of PiCyts down-regulation by IFN-β (transitions la-
belled with “γ” in Figure 4.1) and then itself (transitions labelled with “δ” in Figure
4.1) by the inherent property of SOCS-1 for inhibiting both inflammatory response
and IFN-β (Song and Shuai, 1998; Yoshimura et al., 2007). The opportunity of PiCyts
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induction in initial stages of signalling is reduced by the IFN-β (trajectories down-
stream to node “11100”) and results in the delay of hyper-active immune response.
In contrast, SOCS-1 is found to be involved in the down-regulation of IFN-β in pref-
erence to PiCyts. In other words, it can be implicated that SOCS-1 first permits the
gradual elevation of PiCyts levels in the system and then down-regulates them in the
later stages of the system dynamics. This gesture has been established previously that
SOCS-1 preferably regulates the IFN signalling but not the NFκB pathway (Prêle
et al., 2008). In this context, further work is necessary to be performed not only for
the determination of down-regulatory regulatory pattern of involved mechanisms but
also there is a need to determine the potency of inhibitory actions which are allowing
the presence of PiCyts for a specific time period.
Studies have shown the role of recurrent activation of TLRs especially in the
case of sepsis and persistent infections (Netea et al., 2004; Weighardt and Holzmann,
2008). Moreover, severe immune responses are also associated with the recurrent
infections and/or continuous existence of pathogens (Remick, 2007). However, during
the designing of this study, it was tempted to speculate that whether the reduced
BRN with minimal adjustments in the logical parameters could produce a model of
sepsis which would necessarily produce results concordant to the experimental data
obtained specifically for the case of sepsis. In result, the proposed model of sepsis
successfully replicate the data, in part, of previous reports describing the recurrent
signalling through TLR4 in a loop generated with a single modification in a parameter
value that is obtained for the non-septic model.
In the case of sepsis, LPS mediated TLR4 signalling is a prominent inter-
mediary of TH1 or pro-inflammatory responses, while the induction of regulatory
molecules result in decreased levels of inflammation (Stoll et al., 2006). Moreover,
cytokines induced JAK/STAT signalling cause alteration in the levels of gene expres-
sions in a variety of other factors that are significant for the development of pro- as
well as anti-inflammatory immune responses (Schindler et al., 2007). The state graphs
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developed in the case of sepsis (Figure 4.1) almost reflect the similar behaviour, in
terms of continual TLR4 signalling and late phase immunosuppression. Contrary
to the case of non-sepsis, the case of sepsis lack stable state “00000" due to transi-
tion “00000→10000” and this recurring signalling employ higher levels of PiCyts
(state “00121") in a loop every time the system passes through that state. This be-
haviour of the system can be correlated with the SIRS in which the host experience
pro-inflammation throughout this medical condition (Oda et al., 2005).
Sequential induction and down-regulation of PiCyts is found as one of the
significant aspects in the case of sepsis. This phenomenon of swing in the activa-
tion levels of PiCyts has already been reported in terms of pro-inflammation with
subsequent immunodepression (Gogos et al., 2000). Another interesting finding is
the SOCS-1 dependent down-regulation of PiCyts via deactivation of JAK/STAT sig-
nalling. Similarly, down-regulation of TLR4 and NFκB mediated activation of PiCyts
can be related to the anti-inflammatory immune response. This situation may suggest
that treatment options for the management of sepsis should be considered in accor-
dance with the expression levels of IFN-β and SOCS-1 as suggested by other studies
for their roles in case of sepsis (Mahieu and Libert, 2007; Remick, 2007; Scott et al.,
2002).
The peculiar pattern of PiCyts induction at first instance and then deactivation
especially in case of sepsis yielded a cycle of regulatory events which leads the sys-
tem into the immunodepression state. Nevertheless, genetic variations or some other
inhibitory mechanisms involved in the down-regulation of JAK/STAT signalling such
as by SOCS-1 could also lead the system to hyperactive immune response (Yoshimura
et al., 2007). The regulatory role of IFN-β is noticed in the earlier stages of signalling
dynamics, however SOCS-1 probably suppresses the functioning of IFN-β in case of
sepsis along with the levels of PiCyts. It is therefore can be concluded that IFN-β me-
diated down-regulation of PiCyts is probably not a key event to reduce the hyperactive
immune response.
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The analysis of septic case also hypothesised that IFN-β can be induced in
distinct stages of sepsis as presented in Figure 4.1. Apparently, IFN-β down-regulates
PiCyts before SOCS-1 is induced, whereas in later stages, IFN-β and SOCS-1 could
be induced in parallel to down-regulate the higher levels of PiCyts in the system
because at that stage, SOCS-1 becomes also available to the system. This availability
of the IFNβ and SOCS-1 in parallel might be due to the co-infection or presence
of different stages of infection within the same host. Therefore, it is reasonable to
conclude that the chance for the elevated levels of PiCyts is relatively less in the late
phase of signalling dynamics.
In the third phase of qualitative analysis, an integrated approach was adopted
to understand the function of signalling pathways both in non-septic and septic condi-
tions, particularly, the response to perturbations, such as the administration of a drug,
or the inhibition of a reaction in a pathway. This particular objective was to analyse
whether manipulations can alleviate disease severity. In result of perturbations or in-
terventions in the signalling system highlights some significant aspects of the TLR4
and JAK/STAT signalling pathways in this study.
Genetic mutations or therapeutic interference in SOCS-1 dependent down-
regulation of JAK/STAT pathway could lead to non-reversible hyper-inflammation
as compared to any other signalling intervention in this study. This effect is already
experimentally validated thorough genetic modification of SOCS demonstrated that
it has indispensable regulatory role in the cytokines responses (Alexander and Hilton,
2004). From another point of view, the ability of SOCS-1 to bind to JAK2 and IFNγR1
in response to IFN-γ and subsequent down-regulation of STAT1 has been blocked by
mutating the residue Tyr441 of IFNγR1, which increased the downstream activity of
JAK/STAT signalling (Qing et al., 2005). Previously, microarray analysis revealed that
IFN-inducible genes were highly expressed in SOCS-1 deficient mice (Hanada et al.,
2005). These along with many other studies conclude that interrupted or knocked out
SOCS-1 cannot alleviate the hyper-inflammatory conditions which is consistent with
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the presence of stable state “00121” in the CASES of perturbed SOCS-1 mediation
inhibition of PiCyts and IFN-β . Inhibition of IFN and SOCS-1 mediated signalling
has confirmed that the IFN-β may not be ignite the key down-regulatory events in the
hyper-inflammatory conditions. Moreover, SOCS-1 can reduce the levels of PiCyts
even if the IFN-β signalling could not produce its down-regulatory effect.
From therapeutics point of view, this study demonstrated that therapeutic in-
terference in SOCS-1 mediated inhibition of PiCyts may produce beneficial (healthy)
results in case of immunodepressed septic patients. On the other hand, interfering the
TLR4 or PiCyts mediated NFκB-JAK/STAT induction may assist in the treatment
of hyper-inflammatory immunologic response (Gonzales and Orlando, 2008; Jobin
et al., 1999) and if there is the requirement of non-reversible immunosuppression then
intervention in NFκB facilitated PiCyts induction might give competing results.
Overall, it has been hypothesised that in normal infections, i.e. infections not
leading to sepsis, stages of regulatory signalling are dissimilar, in one way or another,
from those of sepsis as presented in Figure 5.1. In this pictorial representation of
hypothesis, it can be observed that the system dynamics proceed in the presence of
sequential activation of down-regulatory factors such IFN-β and SOCS-1 during non-
septic signalling, whereas in the case of sepsis represented here by recurrent signalling,
the activation of regulatory factors may be present at the same time and may inhibit
the activation of PiCyts to a greater extent. This hypothesis is endorsed by previous
literature in which it has been implicated that uninterrupted existence of pathogens
in the host can induce immune responses repeatedly, which subsequently produce
fluctuations in the levels of PiCyts and hence lead the system to immunosuppression
(Netea et al., 2003). The presence of inhibitory molecules in the system at the same
time may be induced possibly either due to a co-infection or in some earlier cycle of
infection. Due to this reason, innate immune response might not efficiently produce
a potent PiCyts outburst to control the pathogen titer. In typical cases of infections,
SOCS-1 and IFN-β show a successive pattern, while in septic infections, this pattern
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is disturbed due to co-occurrence of several inhibitory mechanisms and thus the
immune system could not conceive the higher levels of pathogen load as a result of
decreased PiCyts levels. This computer-aided qualitative analysis might furnished
answers to some of the questions relating to the TLR4 and JAK/STAT signalling,
nevertheless need to be highlighted by further experimental studies. In future, in vitro
experiments may be designed to look into the interpretations in detail and to develop
clear perspectives into the diagnosis and therapy of sepsis accounting IFN-β and
SOCS-1.
So far, this study looks into the signalling dynamics of the TLR4 and JAK/S-
TAT pathways. To look deeply at the atomic level, protein-protein interactions (PPIs)
responsible for the onset of TLR4 signalling are computationally studied to further
elucidate the initial molecular events of the TLR4 signalling. As introduced earlier,
activation of MAL by kinases forms one of the preliminary steps which are neces-
sary for the induction of TLR4 dependent NFκB signalling. Moreover, the recently
crystallized structure of MAL can provide more accurate picture of the mechanism
involved in its activation after interacting with kinases. These structural evaluations
can provide avenues for discovery of new compounds which can be further used as
anti-inflammatory agents. This forms the second major objective of this thesis which
comprise the structural evaluation of MAL and its interactions essentially within the
regions of Tyr86 and Tyr106 with pPKCδ and pBTK. These PPIs are computationally
studied by using the available crystal structures of MAL, BTK and a trustworthy com-
parative model of pPKCδ . The modelling of proteins and protein-protein interactions
(PPI) at atomic level: (i) characterised the missing structural features of MAL and
its interaction with kinases; (ii) provided data that is not yet elucidated by the ex-
perimental techniques such as about the regions and domains of proteins involved in
interactions; (iii) extrapolation of charges and hydrophobicity at surfaces of proteins
necessary to support the interaction of MAL with kinases at specific regions of Tyr86
and Tyr106; and (iv) presented BTK as a key kinase of MAL, which has the ability
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to phosphorylate both positions of Tyr86 and Tyr106, as compared to the PKCδ that
can phosphorylate only Tyr106.
The TIR-domain of MAL has an essential role in TLR2 and TLR4 mediated
MyD88 dependent signalling that can lead to the induction of NFκB signalling path-
way (Gray et al., 2006; Horng et al., 2002; Yamamoto et al., 2002). It has also been
associated with multiple other regulatory events after interacting with plasma mem-
brane, IRAK-1, IRAK-2, IRAK-4, TRAF6, SOCS-1, BTK and PKCδ . MAL interacts
with plasma membrane through phosphatidylinositol-4,5-biphosphate (PIP2) binding
motif at N-terminal (Kagan and Medzhitov, 2006). TRAF6 mediated activation of
NFκB is facilitated by interaction with MAL (Verstak et al., 2009). IRAKs have been
associated with the phosphorylation and ubiquitination of MAL followed by its degra-
dation (Dunne et al., 2010; Muzio et al., 1997). SOCS-1 has been associated with the
degradation of MAL and provide a negative feedback loop to the induction of PiCyts
(Mansell et al., 2006).
The BB-loop present in the cytosolic portions of TLR2, TLR4 and TIR do-
mains of adaptor proteins such as MyD88, TRIF, TRAM whereas AB-loop in MAL
provide specificity to the TLR2 and TLR4 dependent signalling through specific
adaptor proteins and ultimately result in the variation in immune responses (Gangloff
et al., 2005; Snyder et al., 2013; Toshchakov et al., 2005). The crystal structure of
TIR-domain of MAL did not resolve with the AB-loop which could lead to the un-
determined functions of this loop during the study of PPI with kinases. To study the
complete structure in terms of presence of AB-loop, modelling of AB-loop in the
available structure is performed which contributes to the elucidation of its elastic na-
ture. Different orientations of AB-loop present possible effects on PPIs with kinases.
It has been observed that the phosphorylations of MAL probably take place in the
presence of interaction of the AB-loop with αE-helix that shows the first type of
orientation for flexible AB-loop presented herein, and when Tyr86 would get phos-
phorylated then the 2nd type of orientation may allow MAL for further interaction
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with other proteins of TLR2/4 signalling cascades. This is supported by previous stud-
ies that the interaction of the AB-loop with phosphorylated Tyr86 (pTyr86) is crucial
for interaction with MyD88 and consequent downstream signalling. Moreover, it is
also important for its degradation by SOCS-1 (Niazi et al., 2011). These two types of
conformational selection also exist in BB-loops of other proteins. For instance, if the
case of monomeric TLR2 is considered, a loop is stretched outside of the rest of the
region, while the closeness of loop against the TIR-domain of TLR2 is observed to
be essential for the TLR2 dimerization (Tao et al., 2002).
As proposed by earlier studies and observation in this study in that the accu-
racy of comparative modelling of proteins is associated with the percentage sequence
identities of the template and query proteins (Daga et al., 2010). Homology mod-
elling with higher accuracy has nearly 1Å root mean square (RMS) error for the
backbone atoms and may be related to a structure that is determined by medium reso-
lution NMR (nuclear magnetic resonance). Such precision of comparative model is
achieved if 50% sequence of the query protein is identical to the template one (Baker
and Sali, 2001). Comparative modelling of biological entities is found to be a rapid,
authentic and precise method and can be compared to any other empirical technique
(Kryshtafovych et al., 2014). In this context, the amino acid sequence of pKCδ is
nearly 76% identical without any gaps to that of PKCθ (PDB IDs: 1XJD and 2JED)
which is demonstrating that the comparative model of pPKCδ used in this study may
have provided significant results. In order to endorse the quality of comparative mod-
els of pPKCδ for final consideration, several parameters, including ERRAT, Qmean,
Ramachandran, PROCHECK and PROSA were utilized to assess the errors in the ge-
ometry of models and for the improvement in backbone, conformation of side chains,
rotamers selection and to decrease the atomic clashes. Finally, the selected compar-
ative model of pPKCδ demonstrates dihedral, lengths, bond angles and interaction
energies inside the permitted boundaries without any atomic clashes. Moreover, 0.738
Qmean scores (-0.43 Z-score), 95% ERRAT score, and comparatively lower potential
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energy constitutes some of the additional features supporting the final selection of a
comparative model of pPKCδ in further studies of PPI.
At the molecular level the interaction of proteins have a significant role in
maintaining the activities of the cell and life. It is therefore important to get insights
into the detailed information i.e. atomic level to understand certain features of interac-
tions such as binding area, structural flexibility and residue interactions. Sometimes,
the restrictions in the analysis of protein complexes are posed by the complexity
of experimental techniques. Computational approaches of PPIs can be proved to be
helpful in such conditions. The basic scheme of computational methodology in PPI
is the generation of numerous feasible orientations of the protein complexes with
a precise scoring for all of them, so that a complex could be highly scored that is
similar to a native one. Familiar sampling techniques include fast Fourier transform
algorithms (e.g., as used in PIPER (Kozakov et al., 2006), ZDOCK (Chen et al., 2003),
GRAMM-X (Tovchigrechko and Vakser, 2006), DOT (Mandell et al., 2001), CLUS-
PRO (Comeau et al., 2004) and MolFit (Katchalski-Katzir et al., 1992)) and Monte
Carlo minimization (e.g., as used in ICM-DISCO (Fernández-Recio et al., 2003) and
RosettaDock (Lyskov and Gray, 2008)). The scoring generally comprises of a combi-
nation of numerous empirical and/or biophysical energy terms, including electrostatic
energy, geometric surface matching, buried surface area, van der Waals energy, des-
olvation energy and so on. A number of scoring strategies could be used depending
upon the complexity level, with more simple terms frequently employed in the earlier
stage (during exhaustive search for conformations) subsequently with more advanced
(computational expensive) in the stage of refinement. Depending upon the docking
process, several models can be produced and clustered to decide the finest predic-
tions. HADDOCK (De Vries et al., 2010; Dominguez et al., 2003; Schmitz et al.,
2012) is among a couple of other docking programmes that explicitly deals with the
flexibility of both the backbone and side-chains of the complex. Additionally, large
conformational modifications can be modelled by taking ensembles of initial orienta-
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tions or treating residues as an aggregation of sub-domains. To focus the sampling of
orientations about the interaction surfaces, HADDOCK offers a hybrid approach that
can apply a variety of nuclear magnetic resonance (NMR) and non-NMR empirical
knowledge to direct the docking approach.
During the process of PPI, the regions of Tyr86 and Tyr106 MAL were se-
lected to be docked with BTK and PKCδ . The reason is that the residues of MAL
under study are already known and can be used to reduce the conformational sam-
pling of each protein during processing. This strategy is further supported by previous
literature in which Kenyon et al. (2012) studied the chemical mechanism of phospho-
ryl group transfer among kinases and substrate to phosphorylate Tyr residues. This
method of reducing the conformational space by selecting already known regions of
proteins has been conclusively demonstrated by the blindfold predictions of PPI in
various rounds of critical assessment of predicted interactions (CAPRI) (Janin et al.,
2003). As a result of PPI of pBTK against the Tyr86 of MAL, both proteins are found
in accurate orientation against each other, which can easily allow to phosphorylate
Tyr86 of MAL. This adjustment in the orientation of each protein against one another
drives Tyr86 of MAL to the closest proximity of γ-phosphate of ATP modelled in
pBTK. The analysis of the interface of MAL demonstrates that an interface area has
substantial hydrophobic nature and could be unique with respect to BTK. The hy-
drophobic nature that was present in PPIs between MAL and pBTK is found around
1/3rd of the surfaces of proteins encircled with polar contacts. All the other complexes
provided a difference of 9-35Å within the γ-phosphate of ATP and the hydroxyl group
of Tyr86 of MAL, which is not feasible for the transfer of phosphoryl group (Kenyon
et al., 2012) so were not selected for any analysis. The surfaces of MAL and pBTK in
selected complex exhibited numerous contacts among them alongside of complement
charges at the interface. Some of the residues of MAL making contacts with pBTK
have been studied using point mutations, including Tyr86Ala, Tyr106Ala, Pro125His
and Tyr159Ala (Piao et al., 2008). These mutations have been considered as puta-
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tive mutations with complete loss of function. In contrast, mutations at sites Tyr187,
Tyr195 and Tyr196 have been associated with relatively depressed functions of MAL
or with no changes at all. This study confirms all the above-mentioned results, though,
Pro125 of MAL is not found as a putative site required for making contacts with
pBTK or pPKCδ . This site may be dynamically involved in the interaction with other
proteins, which are significant for the signalling cascades of TLRs.
The best pose of the proteins making complex with one another in this study
are evaluated using the distance between γ-phosphate of ATP (modelled in kinases)
and one of the Tyr86 or Tyr106 of MAL. It is found that pPKCδ and pBTK could com-
petitively phosphorylate Tyr106 of MAL. Selected complex of pPKCδ -Tyr106:MAL
exhibited closer proximity of Tyr106 with ATP (modelled in pPKCδ ) within a space
of 3.9Å. From 3D structural point of view, pPKCδ is in the best posture to bind to
MAL for phosphorylation at position Tyr106. However, pPKCδ cannot adopt the
required orientation for Tyr86 that is also present in an accessible position at the
surface of MAL. The hydrophobicity at the interfaces of pPKCδ and around Tyr106
of MAL is nearly 1/8th of the interfaces that is comparatively less than the case of
interfaces between pBTK and MAL complexed around the same region of MAL.
The orientation of pPKCδ against MAL, around the region of Tyr106, was transient,
probably because of less hydrophobic nature of MAL around the region of Tyr106;
hence, it is plausibly an artefact of crystal packing. In the similar manner, the complex
of pBTK-Tyr106:MAL imparted the comparative results for interfaces. The crystal
packing is generally found on the crystallization of proteins and forces of interaction
are exhibited within the complexes that are implicated to be too weak to form a stable
complex at normal concentrations (Carugo and Argos, 1997). As an opinion, the crys-
tal packing values for MAL are actually demonstrating the transient PPI with pPKCδ
and pBTK at area of Tyr106 that is probably important for the phosphorylation of
MAL just like transition reactions (Nooren and Thornton, 2003). Furthermore, the
BSA of pPKCδ /pBTK with MAL at position of Tyr106 endorses the presence of
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such protein complexes as anticipated by the data of Chakrabarti and Janin (2002)
previously computed by Conte et al. (1999) on a subset of protein complexes.
A linear relationship between the BSA and binding free energies of a set of
protein complexes, mainly enzyme-inhibitor complexes was established by Horton
and Lewis (Horton and Lewis, 1992). They interpreted huge binding free energies
for most of the protein complexes having BSA > 20002. Every investigated complex
in this study has nearly same BSA and can be compared to them. However, the
relation between binding free energies and BSA concerning kinase with its substrate
for phosphoryl transfer is suggested to be further investigate.
An important feature for accurate interpretations of interfaces in PPI is the
study of electrostatic characteristics (Aziz et al., 2011; Maleki et al., 2013). Elec-
trostatics offer non-covalent interactions causing attraction of compatible charged
amino acids. The charge dispersion at the interacting surfaces of pBTK (compara-
tively +ively charged) and pPKCδ (comparatively −ively charged) differ from one
another. The area around the Tyr86 is negatively charged and thus indicated a major
ground for which pBTK can exclusively phosphorylate Tyr86 subsequent to binding
with MAL. However, the region of Tyr106:MAL exhibited charge heterogeneousness
and portrayed the charge complementary for both pPKCδ and pBTK. The orientation
of both kinases against MAL indicates that both kinases attach to different regions
of MAL in different orientations from one another, but accurately orient their ATPs
within a reasonable distance of Tyr106 to phosphorylate it.
Several variants of MAL have been reported, including Asp96Asn, Ala100Thr,
Glu108Ala Arg115Ala Phe117Ala, lu132Lys, Arg184Thr, Arg121Ala, Leu165Ala
Arg143GIn Arg143Trp, Ser180Leu, Glu190Asp and Val197Ile (An et al., 2011; Dis-
sanayeke et al., 2009; George et al., 2010; Nagpal et al., 2009; Valkov et al., 2011).
These variants affect the population differently regarding their immune responses to
microbes, diseases and inflammation, etc. Out of these variants, Asp96Asn, Glu132Lys,
Arg143GIn and Glu190Asp are loss of function mutations of MAL, while Glu108Ala
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and Phe117Ala decrease the interaction of TIR-domains of MAL with MyD88. These
studies generally report the binding of TIR-domain MAL with other proteins, in-
cluding MyD88 and TLR4. This study is probably the foremost one to propose the
function of these amino acids in PPI of MAL with kinases. Among these, Asp96,
Ala100 and Glu108 lie in the αA-helix of the TIR-domain of MAL and found in
the complex of MAL with pBTK and pPKCδ . Multiple amino acids present in this
domain, including Glu94, Leu97, Val98 and Asp102 of MAL also found in making
interactions with the residues of pPKCδ and pBTK. Furthermore, Arg115, Phe117A,
Arg121 related to the AB-loop of MAL among which Arg115 and Phe117 interacts
with pBTK and pPKCδ . Glu132 is part of the βB-strand of MAL and has a role in
forming salt bridges with pBTK, however not with pPKCδ . In contrast, Ser180 is
found to have a role in associating with pPKCδ and not with pBTK. Therefore, these
amino acids could cooperatively play a role in making interactions with TIR-domains
of MyD88, TLR4, pBTK and/or pPKCδ . Alterations or therapeutically targeting these
regions could weaken the phosphorylation of Tyr86 and Tyr106 making the loss of
activation with subsequent loss of interaction with TLR4 and MyD88. Other muta-
tions such as Arg143, Arg143, Leu165, Arg184, Glu190 and Val197 cannot impair
the interaction of MAL with pBTK and/or pPKCδ as these residues are not found in
the interfaces.
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CONCLUSION AND FUTURE
PERSPECTIVES
The modelling of TLR4 and JAK/STAT pathway presented in this thesis im-
plies that TLR4, JAK/STAT, IFN-β and SOCS-1 facilitate the homoeostasis by per-
forming their responsibilities in a consecutive manner. Intervention in SOCS-1 depen-
dent down-regulation of PiCyts caused the hyper-inflammatory responses, whereas,
in TLR4, NFκB and JAK/STAT signalling can be associated with immunomodulation.
In addition, IFN-β may inhibit PiCyts in the earlier stages of sepsis, which is still need
to be experimentally validated. However, the down-regulatory molecules of JAK/S-
TAT signalling like SOCS-1 can govern the inflammatory responses in later stages
of sepsis. Thus, fluctuations are present in the levels of PiCyts and AiCyts along
with other down-regulatory molecules like IFN-β and SOCS-1 in distinct stages
of sepsis and might furnish the basis for the controversies in the role of pro- and
anti-inflammatory immune responses. Nevertheless, these anticipations require wet
laboratory experimental studies for further validations.
Protein-protein interactions responsible for the onset of TLR4 signalling are
computationally studied to further elucidate the initial molecular events of the TLR4
signalling. Phosphorylations at tyrosines (especially Tyr86 and Tyr106) of MAL are
proposed to be crucial for the activation of MAL and its subsequent functions in the
downstream signalling of TLR4. It is found that PKCδ and BTK could competitively
phosphorylate Tyr106 of MAL. However, pPKCδ could not adopt the required ori-
entation for Tyr86 which is also exposed at the surface of MAL. In this aspect, BTK
could interact with MAL in such a position which is suitable for the phosphorylation
of Tyr86. Further experimental analysis of structural complexes of pPKCδ and pBTK
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with MAL may furnish exclusive evidences for the relation of MAL with interacting
kinases, nevertheless, the data presented in this study have provided basic information
to understand initial molecular events essential for the activation of TLR4 signalling
pathway.
In future, experimental studies will be carried out to study the sensitivity anal-
ysis of TLR4 and JAK/STAT signalling pathways with the purpose of validation of
significant proteins and interactions which could further be experimentally studied to
provide putative information for the treatment of sepsis. In addition to this, experi-
mental studies will be carried out to examine the significance of BTK in comparison
to PKCδ for MAL in order to design new or improve existing inhibitors of kinases
to block the pathological signalling of TLR4 and to treat the hyper-inflammatory
conditions in sepsis.
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APPENDIX A
Code given as Input to SMBioNet and its resultant
output
############ INPUT FOR SMBioNet.############
#For complete information about the generation of an input for SMBioNet, the readers
#are referred to the [1,2]. Briefly the sections of INPUT are discussed here:
# The VAR section defines the variables/entities that are being used in the model.
#The two numbers after the '=' sign indicate minimum and maximum levels of the
#discrete level range for each entity.
VAR
IFNb = 0 1 ;
SOCS1 = 0 1 ;
TLR4 = 0 1 ;
NFkB = 0 1 ;
PICyts = 0 2 ;
# The REG section below defines the Biological Regulatory Network through its interactions.
#Each statement comprises of three parts, the first representing the entity causing the interaction,
#the second part within the '[()]' indicating the level that the entity causing the reaction should have,
# and the third part after '=>' indicates the entities being affected. The definition only allows activation
# interactions to be defined, therefore the cases where the second part occurs as [(Entity>=n)] for
#some arbitrary discrete value 'n' indicates that the Entity is activating the affected entities at or above
#the level 'n'. Likewise, inhibition interactions are shown as [(Entity<n)] indicating that the Entity is only
#acting as a resource for the affected entities when its level is below 'n', thus by implication, inhibiting them
# at or above the level 'n'.
REG
SOCS1 [(SOCS1<1)]=> IFNb TLR4 NFkB PICyts ;
TLR4 [(TLR4>=1)]=> IFNb NFkB ;
NFkB [(NFkB<1)]=> IFNb TLR4 ;
IFNb [(IFNb>=1)]=> SOCS1 NFkB ;
PICyts [(PICyts>=1)]=> SOCS1 ;
PICyts [(PICyts>=2)]=> NFkB ;
IFNb [(IFNb<1)]=> PICyts ;
NFkB [(NFkB>=1)]=> PICyts ;
# SMBioNet selects parameter values of an entity from a range, which starts from the lowest expression
# level (0) and goes to the maximum expression level i.e. highest threshold.
# The values of some parameters could be fixed as single values since they are well-known observations
# reported in the literature. Each fixed parameter in the below section is linked to its respective evidences
# discussed in detail in Appendix \ref{AP2_1}.
PARA
# Range of Parameters for TLR4
K_TLR4 = 0 1;
K_TLR4+NFkB = 0 1 ;
K_TLR4+SOCS1 = 0 1 ;
K_TLR4+NFkB+SOCS1 = 0 1 ;
# Parameter ranges for IFN-beta (IFNb)
K_IFNb = 0 1;
K_IFNb+NFkB = 0 1 ;
K_IFNb+SOCS1 = 0 1 ;
K_IFNb+TLR4 = 0 ;
K_IFNb+NFkB+SOCS1 = 0 1 ;
K_IFNb+SOCS1+TLR4 = 0 1 ;
K_IFNb+NFkB+TLR4 = 1 ;
K_IFNb+NFkB+SOCS1+TLR4 = 0 1 ;
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# Parameters for SOCS1
K_SOCS1 = 0 1;
K_SOCS1+IFNb = 1 ;
K_SOCS1+PICyts = 1 ;
K_SOCS1+IFNb+PICyts = 0 1 ;
# Parameters for NFkB
K_NFkB = 0 1;
K_NFkB+IFNb = 1 ;
K_NFkB+PICyts = 1 ;
K_NFkB+SOCS1 = 0 1 ;
K_NFkB+TLR4 = 1 ;
K_NFkB+IFNb+PICyts = 0 1 ;
K_NFkB+PICyts+SOCS1 = 0 1 ;
K_NFkB+PICyts+TLR4 = 0 1 ;
K_NFkB+IFNb+SOCS1 = 0 1 ;
K_NFkB+SOCS1+TLR4 = 0 1 ;
K_NFkB+IFNb+TLR4 = 0 1 ;
K_NFkB+IFNb+PICyts+TLR4 = 0 1 ;
K_NFkB+IFNb+PICyts+SOCS1 = 0 1 ;
K_NFkB+IFNb+SOCS1+TLR4 = 0 1 ;
K_NFkB+PICyts+SOCS1+TLR4 = 0 1 ;
K_NFkB+IFNb+PICyts+SOCS1+TLR4 = 0 1 ;
# Parameters for PICyts
K_PICyts = 0 1;
K_PICyts+IFNb = 0 2 ;
K_PICyts+NFkB = 0 2 ;
K_PICyts+SOCS1 = 0 2 ;
K_PICyts+IFNb+NFkB = 0 ;
K_PICyts+NFkB+SOCS1 = 0 ;
K_PICyts+IFNb+SOCS1 = 0 2 ;
K_PICyts+IFNb+NFkB+SOCS1 = 2 ;
# The CTL section lists out the CTL logic constructs used to test each parameter set in order to
#test whether it holds true in them or not. Starting from the initial state (1,0,0,0,0), that is only TLR4
# is active and the rest are inactive, NFkB and IFNb eventually activate under the influence of TLR4
#(1,1,1,0,0), leading the system towards the clearance of the infection indicated by the state (0,0,0,0,0).
CTL
((TLR4=1&IFNb=0&NFkB=1&PICyts=0&SOCS1=0)->EF(TLR4=1&IFNb=1&NFkB=1))
&
((TLR4=1&IFNb=0&NFkB=0&PICyts=0&SOCS1=0)->EF(AG(TLR4=0&IFNb=0&NFkB=0&PICyts=0&SOCS1=0)))
############ OUTPUT OF SMBioNet.############
# The initial part is the same as the input file, up to the CTL section. SMBioNet appends the input
#file before the output. This section is the output section generated by SMBioNet, with each 'Model
#<n>' indicating the number of the parameter set generated by SMBioNet that satisfies the CTL
#given above. In this case, only one model (MODEL 1) with set of parameters was selected by
#SMBioNet, out of the 288 that were generated.
# MODEL 1
# K_IFNb = 0
# K_IFNb+NFkB = 0
# K_IFNb+SOCS1 = 0
# K_IFNb+TLR4 = 0
# K_IFNb+NFkB+SOCS1 = 0
# K_IFNb+SOCS1+TLR4 = 1
# K_IFNb+NFkB+TLR4 = 1
# K_IFNb+NFkB+SOCS1+TLR4 = 1
# K_SOCS1 = 0
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# K_SOCS1+IFNb = 1
# K_SOCS1+PICyts = 1
# K_SOCS1+IFNb+PICyts = 1
# K_TLR4 = 0
# K_TLR4+NFkB = 0
# K_TLR4+SOCS1 = 0
# K_TLR4+NFkB+SOCS1 = 0
# K_NFkB = 0
# K_NFkB+IFNb = 1
# K_NFkB+PICyts = 1
# K_NFkB+SOCS1 = 0
# K_NFkB+TLR4 = 1
# K_NFkB+IFNb+PICyts = 1
# K_NFkB+PICyts+SOCS1 = 1
# K_NFkB+PICyts+TLR4 = 1
# K_NFkB+IFNb+SOCS1 = 1
# K_NFkB+SOCS1+TLR4 = 1
# K_NFkB+IFNb+TLR4 = 1
# K_NFkB+IFNb+PICyts+TLR4 = 1
# K_NFkB+IFNb+PICyts+SOCS1 = 1
# K_NFkB+IFNb+SOCS1+TLR4 = 1
# K_NFkB+PICyts+SOCS1+TLR4 = 1
# K_NFkB+IFNb+PICyts+SOCS1+TLR4 = 1
# K_PICyts = 0
# K_PICyts+IFNb = 0
# K_PICyts+NFkB = 0
# K_PICyts+SOCS1 = 0
# K_PICyts+IFNb+NFkB = 0
# K_PICyts+NFkB+SOCS1 = 0
# K_PICyts+IFNb+SOCS1 = 0
# K_PICyts+IFNb+NFkB+SOCS1 = 2
# SELECTED MODELS / CHECKED MODELS = 1 / 288 (2s154ms)
# These papermeters were taken for simulation of the BRN and provided in Table 1
#References:
#1. Khalis Z, Comet J-P, Richard A, Bernot G (2009) The SMBioNet method for discovering
# models of gene regulatory networks. Genes, Genomes and Genomics 3: 15-22.
#2. Richard A, Comet J, Bernot G SMBioNet: Selection of Models of Biological Networks.
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APPENDIX B
Description of logical parameters with relevant
evidences
Description of the logical parameters with relevant evidences.
Below, is the list of entities as shown in Figure 3.8 with informal description
of each logical parameter with relevant evidences based on the previous experimental
studies and values given to SMBioNet. The values of some parameters were fixed as
single values since they are well-known observations reported in the literature. The
output values of SMBioNet have been discussed with their implications in this study.
The input and output of SMBioNet can be seen in Appendix A.
1. TLR4
(a) Logical Parameter: KT LR4({}) = 0
i. Description of the logical parameter: NFκB and SOCS-1 are active for the TLR4 (see Definition 4
in the methods section for the description of activators or inhibitors as resources for target entity).
ii. Evidence: The TLR4 signal is inhibited either due to the absence of an activator entity such as LPS [1]
or presence of inhibitors such as SOCS-1 and A20. MAL, an adaptor protein in the MyD88 dependent
signalling pathway of TLR4 is an important protein (modelled implicitly in the BRN), which is nec-
essary for the activation of NFκB [2]. This protein is inhibited by the SOCS-1 [3,4]. Moreover, A20
protein, which has been implicitly modelled in the BRN by an inhibitory edge from NFκB towards
TLR4, is transcribed by NFκB, which can in turn form a negative feedback loop to inhibit the NFκB
signalling and the ubiquitination process of TRAF6 [5-8].
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “0” was given as output, which
implies that TLR4 would inactivate in the presence of SOCS-1 and NFκB.
(b) Logical Parameter: KT LR4({NFκB}) = 0
i. Description of the logical parameter: SOCS-1 is active and NFκB is inactive for the TLR4.
ii. Evidence: MAL, an adaptor protein in the MyD88 dependent signalling pathway of TLR4 is an impor-
tant protein, which is necessary for the activation of NFκB [2]. This protein is inhibited by the SOCS-1
[3,4].
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “0” was given as output, which
implies that TLR4 would inactivate in the presence of SOCS-1.
(c) Logical Parameter: KT LR4({SOCS−1}) = 0
i. Description of the logical parameter: NFκB is active and SOCS-1 is inactive for the TLR4.
ii. Evidence: A20 protein has been explicitly modelled in the BRN by an inhibitory edge from NFκB
towards TLR4. This represents that as soon as the NFκB activates, it transcribes the A20 along with
other genes, which can in turn form a negative feedback loop to inhibit the NFκB signalling and the
ubiquitination process of TRAF6 [5-8]. TRAF6 has also been modelled in an explicit manner.
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “0” was given as output, which
implies that TLR4 would inactivate in the presence of active NFκB.
(d) Logical Parameter: KT LR4({SOCS−1,NFκB}) = 0
i. Description of the logical parameter: SOCS-1and NFκB are inactive for the TLR4.
ii. Evidence: As mentioned in point 1.a and 1.b.
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “0” was given as output, which
represents that TLR4 would inactivate in the absence of active SOCS-1 and NFκB due to the absence
of activating factor.
2. NFκB and JAK/STAT
(a) Logical Parameter: KNFκB−JAK/STAT ({}) = 0
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i. Description of the logical parameter: SOCS-1 is active while activating factors are inactive for the
NFκB-JAK/STAT.
ii. Evidence: The NFκB or JAK/STAT cannot be activated in the absence of an activator protein or en-
tity [9,10]. Moreover, SOCS-1 has been presented as a negative regulator of NFκB and JAK/STAT
pathways in a number of studies [11-17].
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “0” was returned as output,
which implies that NFκB-JAK/STAT would inactivate in the absence of activators and in the presence
of SOCS-1, which is a negative regulator.
(b) Logical Parameter: KNFκB−JAK/STAT ({T LR4}) = 1
i. Description of the logical parameter: TLR4 and SOCS-1 are active for the NFκB-JAK/STAT.
ii. Evidence:It has been demonstrated previously that TLR4 is involved in LPS-mediated NFκB activa-
tion and subsequent JAK/STAT pathway [18,19]. Moreover, SOCS-1 has been presented as a negative
regulator of NFκB and JAK/STAT pathways in a number of studies [11-17].
iii. The values given to SMBioNet as input: 1 (fixed value).
iv. Implication: The value “1” was fixed based on the evidence, which implies that when TLR4 is in
an active state then NFκB and JAK/STAT pathway would preferably be in an active state even in the
presence of SOCS-1.
(c) Logical Parameter: KNFκB−JAK/STAT ({IFN−β}) = 1
i. Description of the logical parameter: IFN-β and SOCS-1 are active for the NFκB-JAK/STAT.
ii. Evidence: It has been demonstrated previously that along with MyD88 dependent pathway, MyD88
independent pathway through TRIF and TRAF6 (implicitly modelled in BRN through an activation
edge from IFN-β towards NFκB) can result in the activation of NFκB [20,21]. Moreover, IFN-β has
the ability to activate JAK/STAT pathway [22]. On the other hand, SOCS-1 has been presented as a
negative regulator of NFκB and JAK/STAT pathways in a number of studies [11-17].
iii. The values given to SMBioNet as input: 1 (fixed value).
iv. Value given as output by SMBioNet and its implication: The value “1” was fixed based on the
evidence, which implies that when IFN-β is in an active state then NFκB and JAK/STAT pathway
would preferably be in an active state even in the presence of SOCS-1.
(d) Logical Parameter: KNFκB−JAK/STAT ({PICyts}) = 1
i. Description of the logical parameter: PICyts and SOCS-1 are active for the NFκB-JAK/STAT.
ii. Evidence: It has been demonstrated previously that TNF-α , a PICyt, after expression through NFκB
can result back in its activation through TNF-α receptors [23]. Moreover, PICyts have the ability to
activate JAK/STAT pathway [22]. On the other hand, SOCS-1 has been presented as a negative regulator
of NFκB and JAK/STAT pathways in a number of studies [11-17].
iii. The values given to SMBioNet as input: 1 (fixed value).
iv. Value given as output by SMBioNet and its implication: The value “1” was fixed based on the
evidence, which implies that when PICyts is in active state, then NFκB and JAK/STAT pathway would
preferably also be in an active state even in the presence of SOCS-1.
(e) Logical Parameter: KNFκB−JAK/STAT ({T LR4, IFN−β}) = 1
i. Description of the logical parameter: TLR4, IFN-β and SOCS-1 are active for the NFκB-JAK/STAT.
ii. Evidence: As mentioned in point number 2.b and 2.c.
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “1” was returned as output, which
implies that when TLR4 or IFN-β would be activated then NFκB and JAK/STAT pathway would also
be in an active state even in the presence of SOCS-1.
(f) Logical Parameter: KNFκB−JAK/STAT ({T LR4,PICyts}) = 1
i. Description of the logical parameter: TLR4, PICyts and SOCS-1 are active for the NFκB-JAK/STAT.
ii. Evidence: As mentioned in point number 2.b and 2.d. Other references are [18,24,25].
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “1” was returned as output, which
implies that when TLR4 or PICyts would be in an active state then NFκB and JAK/STAT pathway
would also be in an active state even in the presence of SOCS-1.
(g) Logical Parameter: KNFκB−JAK/STAT ({IFN−β ,PICYts}) = 1
i. Description of the logical parameter: IFN-β , PICyts and SOCS-1 are active for the NFκB-JAK/STAT.
ii. Evidence: As mentioned in point number 2.c and 2.d [24-27].
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “1” was returned as output,
which implies that when both IFN-β and PICyts would be in an active state then NFκB and JAK/STAT
pathway would also be activated even in the presence of SOCS-1.
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(h) Logical Parameter: KNFκB−JAK/STAT ({T LR4, IFN−β ,PICyts}) = 1
i. Description of the logical parameter: TLR4, PICyts, IFN-β and SOCS-1 are active for the NFκB-
JAK/STAT.
ii. Evidence: As mentioned in point number 2.b-2.d. Other references to previous studies are [18,24-27] .
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “1” was returned as output, which
implies that when TLR4, IFN-β and PICyts would be in an active state then NFκB and JAK/STAT
pathway would also be in active state even in the presence of SOCS-1.
(i) Logical Parameter: KNFκB−JAK/STAT ({T LR4,SOCS−1}) = 1
i. Description of the logical parameter: TLR4 is active and SOCS-1 is inactive for the NFκB-JAK/STAT.
ii. Evidence: It has been demonstrated previously that TLR4 is involved in lipopolysaccharide-mediated
NFκB activation and subsequent JAK/STAT pathway [18,19].
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “1” was returned as output, which
implies that when TLR4 would activate then NFκB and JAK/STAT pathway would also activate.
(j) Logical Parameter: KNFκB−JAK/STAT ({IFN−β ,SOCS−1}) = 1
i. Description of the logical parameter: IFN-β is active and SOCS-1 is inactive for the NFκB-JAK/STAT.
ii. Evidence: It has been demonstrated previously that along with MyD88 dependent pathway, MyD88
independent pathway through TRIF and TRAF6 (implicitly modelled in BRN through an activation
edge from IFN-β towards NFκB) can result in the activation of NFκB [20,21]. Moreover, IFN-β has
the ability to activate JAK/STAT pathway [22].
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “1” was returned as output,
which implies that when IFN-β would be active then NFκB and JAK/STAT pathway would also be in
an active state.
(k) Logical Parameter: KNFκB−JAK/STAT ({PICyts,SOCS−1}) = 1
i. Description of the logical parameter: PICyts is active and SOCS-1 is inactive for the NFκB-JAK/STAT.
ii. Evidence: It has been analysed previously that TNF-α , a PICyt, after expression through NFκB can
result back in its activation through TNF-α receptors [23]. Moreover, PICyts have the ability to activate
JAK/STAT pathway [22]. Other references are [24,25,28].
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “1” was returned as output,
which implies that when PICyts would be active then NFκB and JAK/STAT pathway would also be in
an active state.
(l) Logical Parameter: KNFκB−JAK/STAT ({T LR4, IFN−β ,SOCS−1}) = 1
i. Description of the logical parameter: TLR4 and IFN-β are active, whereas SOCS-1 is inactive for
the NFκB-JAK/STAT.
ii. Evidence: As mentioned in points 2.i and 2.j.
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “1” was returned as output,
which implies that when TLR4 and IFN-β would be active then NFκB and JAK/STAT pathway would
also be in an active state.
(m) Logical Parameter: KNFκB−JAK/STAT ({T LR4,PICyts,SOCS−1}) = 1
i. Description of the logical parameter: TLR4 and PICyts are active, whereas SOCS-1 is inactive for
the NFκB-JAK/STAT.
ii. Evidence: As mentioned in point 2.i and 2.k.
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “1” was returned as output,
which implies that when TLR4 and PICyts would be active then NFκB and JAK/STAT pathway would
also be in an active state.
(n) Logical Parameter: KNFκB−JAK/STAT ({PICyts, IFN−β ,SOCS−1}) = 1
i. Description of the logical parameter: PICyts and IFN-β are active, whereas SOCS-1 is inactive for
the NFκB-JAK/STAT.
ii. Evidence: As mentioned in points 2.j and 2.k.
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “1” was returned as output,
which implies that when PICyts and IFN-β would be active then NFκB and JAK/STAT pathway would
also be in an active state.
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(o) Logical Parameter: KNFκB−JAK/STAT ({SOCS−1}) = 1
i. Description of the logical parameter: Activating factors and SOCS-1 are inactive for the NFκB-
JAK/STAT.
ii. Evidence: NFκB and JAK/STAT pathways remain inactivated in the absence of activating factors.
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “0” was returned as output,
which implies that in the absence of any activator, NFκB and JAK/STAT pathway would be inactive.
(p) Logical Parameter: KNFκB−JAK/STAT ({SOCS−1,T LR4, IFN−β ,PICyts}) = 1
i. Description of the logical parameter: TLR4, PICyts and IFN-β are active, whereas SOCS-1 is inac-
tive for the NFκB-JAK/STAT.
ii. Evidence: As mentioned in points 2.i-2.k.
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “1” was returned as output, which
implies that in the presence of 3 activators including TLR4, PICyts and IFN-β (MyD88 independent
pathway), NFκB and JAK/STAT pathway would be in an active state.
3. PICyts
(a) Logical Parameter: KPICyts({}) = 0
i. Description of the logical parameter: SOCS-1 and IFN-β are active for PICyts.
ii. Evidence: The suppressor of cytokine signalling-1 (SOCS1) is a potent negative regulator of various
cytokines and it has been implicated in the regulation of immune responses, reviewed in [17]. Moreover,
in a previous study it has been observed that IFN-β can shift Th1 immune response to Th2 pattern, thus
increasing the production of anti-inflammatory Th2 cytokines, including IL-4, IL-10, and reducing the
proinflammatory Th1 cytokines including IFN-γ [29]. Other supporting references to previous studies
[30-32].
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “0” was returned as output,
which implies that in the absence of any activator and presence of SOCS-1 and IFN-β , PICyts would
become inactive.
(b) Logical Parameter: KPICyts({NFκB}) = 0
i. Description of the logical parameter: NFκB, IFN-β and SOCS-1 are active for PICyts.
ii. Evidence: The SOCS-1 is a potent negative regulator of various cytokines and it has been implicated
in the regulation of immune responses, reviewed in [17]. Moreover, in a previous study it has been
observed that IFN-β can shift Th1 immune response to Th2 pattern, thus increasing the production
of anti-inflammatory Th2 cytokines, including IL-4, IL-10, and reducing the proinflammatory Th1
cytokines including IFN-γ [29]. Other supporting references to previous studies [30-32].
iii. The values given to SMBioNet as input: Range 0-2.
iv. Value given as output by SMBioNet and its implication: The value “0” was returned as output, which
implies that in the presence of inhibitors such as SOCS-1 and IFN-β , PICyts would become inactivated
even in the presence of active NFκB.
(c) Logical Parameter: KPICyts({IFN−β}) = 0
i. Description of the logical parameter: SOCS-1 is only active, whereas IFN-β is inactive for PICyts.
ii. Evidence: As mentioned in point 3.b.
iii. The values given to SMBioNet as input: Range 0-2.
iv. Value given as output by SMBioNet and its implication: The value “0” was returned as output, which
implies that in the absence of any activator and presence of SOCS-1, PICyts would be inactivated.
(d) Logical Parameter: KPICyts({SOCS−1}) = 0
i. Description of the logical parameter: IFN-β is only active, whereas SOCS-1 is inactive for PICyts.
ii. Evidence: As given in point 3.b.
iii. The values given to SMBioNet as input: Range 0-2.
iv. Value given as output by SMBioNet and its implication: The value “0” was returned as output, which
implies that in the absence of any activator and presence of SOCS-1, PICyts would be inactivated.
(e) Logical Parameter: KPICyts({NFκB, IFN−β}) = 0
i. Description of the logical parameter: NFκB and SOCS-1 are active, whereas IFN-β is inactive for
PICyts.
ii. Evidence: It has been demonstrated that SOCS-1 inhibits cytokine signalling preferably through JAK/-
STAT pathway [13,16,34].
iii. The values given to SMBioNet as input: 0 (fixed value).
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iv. Implication: The value “0” was fixed based on the evidence, which implies that the presence of SOCS-
1 can result in the inactivation of PICyts meditated signalling even the NFκB is actively involved in the
production of PICyts.
(f) Logical Parameter: KPICyts({NFκB,SOCS−1}) = 0
i. Description of the logical parameter: NFκB and IFN-β are active, whereas SOCS-1 is inactive for
PICyts.
ii. Evidence: It has been shown that IFN-β can shift the immune response from Th1 to Th2 pattern, and
decrease the production of proinflammatory Th1 cytokines such as IFN-γ [29] as mentioned in point
22.
iii. The values given to SMBioNet as input: 0 (fixed value).
iv. Implication: The value “0” was fixed based on the evidence, which implies that the presence of IFN-β
can result in the inactivation of PICyts signalling even the NFκB is actively involved in the production
of PICyts.
(g) Logical Parameter: KPICyts({IFN−β ,SOCS−1}) = 0
i. Description of the logical parameter: IFN-β and SOCS-1 are inactive for PICyts.
ii. Evidence: Presence of active NFκB is a necessary event for the production of PICyts [35].
iii. The values given to SMBioNet as input: Range 0-2.
iv. Value given as output by SMBioNet and its implication: The value “0” was returned as output,
which implies that in the absence of NFκB, PICyts would become inactive.
(h) Logical Parameter: KPICyts({NFκB, IFN−β ,SOCS−1}) = 2
i. Description of the logical parameter: NFκB is active, whereas IFN-β and SOCS-1 are inactive for
PICyts.
ii. Evidence: Presence of active NFκB is a necessary event for the production of PICyts [35].
iii. The values given to SMBioNet as input: 2 (fixed value)
iv. Implication: The value “2” was fixed, which implies that NFκB can produce PICyts with an activation
level “2”. The possible implication for activation level “2” is to reflect symbolically that PICyts can
reach to a greater concentration then any other entity in the system and in turn could activate NFκB
and JAK/STAT at threshold level 2 as mentioned in the Methods section.
4. SOCS-1
(a) Logical Parameter: KSOCS−1({}) = 0
i. Description of the logical parameter: No activating factors are present for the SOCS-1.
ii. Evidence: Absence of any activator of SOCS-1 would result in its inactivation [17].
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “0” was returned as output,
which implies that SOCS-1 would be inactive in the absence of its activators.
(b) Logical Parameter: KSOCS−1({PICyts}) = 1
i. Description of the logical parameter: PICyts are active for the SOCS-1.
ii. Evidence: SOCS-1 are induced by several PICyts [13,16,17,34].
iii. The values given to SMBioNet as input: 1 (fixed value).
iv. Implication: The value “1” was fixed based on the evidence, which implies that SOCS-1 would activate
in the presence of PICyts.
(c) Logical Parameter: KSOCS−1({IFN−β}) = 1
i. Description of the logical parameter: IFN-β is active for the SOCS-1.
ii. Evidence: It has been reported that in response to LPS, IFN-β can result in the induction of SOCS-1
[36,37].
iii. The values given to SMBioNet as input: 1 (fixed value).
iv. Implication: The value “1” was fixed, which implies that SOCS-1 would become active in the presence
of IFN-β .
(d) Logical Parameter: KSOCS−1({PICyts, IFN−β}) = 1
i. Description of the logical parameter: PICyts and IFN-β are active for the SOCS-1.
ii. Evidence: As mentioned in the point 30 and 31.
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “1” was fixed, which implies
that SOCS-1 would become active in the presence of IFN- β and PICyts.
5. IFN-β
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(a) Logical Parameter: KIFN−β ({}) = 0
i. Description of the logical parameter: NFκB and SOCS-1 are active where activating factor is inactive
for the IFN-β .
ii. Evidence: As TLR4 is involved in the production of IFN-β through TRIF dependent pathway [38], so
IFN-β cannot be activated in the absence of activated TLR4. Moreover, the inhibitors of IFN-β are
SOCS-1 [39] and SARM [40], implicitly modelled by an edge from NFκB to IFN-β , can inactivate its
production or signalling.
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “0” was returned as output,
which implies that IFN- β would be inactivated in the presence of active SOCS-1 and NFκB.
(b) Logical Parameter: KIFN−β ({T LR4}) = 0
i. Description of the logical parameter: TLR4, NFκB and SOCS-1 are active for the IFN-β .
ii. Evidence: It has been shown that TLR4 can induce IFN-β , which is MyD88- and PKR (double-
stranded RNA-dependent protein kinase)-independent, but TIRAP (Toll-interleukin 1 receptor domain-
containing adapter protein)-dependent [38] . Moreover, IFN-β is differentially involved in biological
responses through TLR4 [41]. Moreover, the inhibitors of IFN-β are SOCS-1 [39] and SARM [40],
implicitly modelled by an edge from NFκB to IFN-β , can inactivate its production or signalling.
iii. The values given to SMBioNet as input: 0 (fixed value).
iv. Implication: The value “0” was fixed, which implies that in the presence of SOCS-1 and NFκB along
with the activated TLR4 signalling, IFN- β would preferably be inactivated.
(c) Logical Parameter: KIFN−β ({SOCS−1}) = 0
i. Description of the logical parameter: TLR4 and SOCS-1 are inactive whereas NFκB is active for the
IFN-β .
ii. Evidence: Previous study has reported that SARM [40], implicitly modelled in the system by an edge
from NFκB to IFN-β , can inactivate production or signalling of TRIF mediated signalling.
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “0” was returned as output, which
implies that active NFκB would result in the inhibition of IFN-β through SARM, implicitly modelled
in the BRN.
(d) Logical Parameter: KIFN−β ({NFκB}) = 0
i. Description of the logical parameter: TLR4 and NFκB are inactive whereas SOCS-1 is active for the
IFN-β .
ii. Evidence: Previous study has shown that SOCS-1 [39] can inhibit IFN-β signalling.
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “0” was returned as output,
which implies that active SOCS-1 would result in the inhibition of IFN-β .
(e) Logical Parameter: KIFN−β ({T LR4,SOCS−1}) = 1
i. Description of the logical parameter: TLR4 and NFκB are active, whereas SOCS-1 is inactive for
the IFN-β .
ii. Evidence: It has been shown that TLR4 can induce IFN-β , which is MyD88- and PKR (double-
stranded RNA-dependent protein kinase)-independent, but TIRAP (Toll-interleukin 1 receptor domain-
containing adapter protein)-dependent [38]. Moreover, IFN-β is differentially involved in biological
responses through TLR4 [41]. A previous study has reported that SARM [40],implicitly modelled in
the system by an edge from NFκB to IFN-β , can inactivate its production or signalling.
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “1” was returned as output,
which implies that in the presence of active TLR4, IFN-β could not be inhibited.
(f) Logical Parameter: KIFN−β ({T LR4,NFκB}) = 1
i. Description of the logical parameter: TLR4 and SOCS-1 are active, whereas NFκB is inactive for
the IFN-β .
ii. Evidence: In a previous study, analysis of the early TLR4 signalling pathway demonstrated that SOCS1
had no regulatory effect on the activation or on the DNA binding capacity of NFκB. The late effects of
LPS are mediated in part through the MyD88-independent pathway activating IRF3 and initiating the
production of IFNβ [28].
iii. The values given to SMBioNet as input: 1 (fixed value).
iv. Implication: The value “1” was fixed in speculation that in the presence of active TLR4, the inhibitory
effect of SOCS-1 may weakly inhibit IFN-β .
(g) Logical Parameter: KIFN−β ({SOCS−1,NFκB}) = 0
i. Description of the logical parameter: TLR4, SOCS-1 and NFκB are inactive for the IFN-β .
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ii. Evidence: It has been shown that TLR4 can induce IFN-β , which is MyD88- and PKR (double-
stranded RNA-dependent protein kinase)-independent, but TIRAP (Toll-interleukin 1 receptor domain-
containing adapter protein)-dependent [38] . Moreover, IFN-β is differentially involved in biological
responses through TLR4 [41].
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “0” was returned as output,
which implies that in the absence of TLR4, IFN- β would become inactive.
(h) Logical Parameter: KIFN−β ({T LR4,SOCS−1,NFκB}) = 1
i. Description of the logical parameter: TLR4 is active, whereas SOCS-1 and NFκB are inactive for
the IFN-β .
ii. Evidence: It has been shown that TLR4 can induce IFN-β , which is MyD88- and PKR (double-
stranded RNA-dependent protein kinase)-independent, but TIRAP (Toll-interleukin 1 receptor domain-
containing adapter protein)-dependent [38] . Moreover, IFN-β is differentially involved in biological
responses through TLR4 [41].
iii. The values given to SMBioNet as input: 0 and 1.
iv. Value given as output by SMBioNet and its implication: The value “0” was returned as output,
which implies that active TLR4 would result in active IFN-β .
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Abstract
Sepsis is one of the major causes of human morbidity and results in a considerable number of deaths each year.
Lipopolysaccharide-induced sepsis has been associated with TLR4 signalling pathway which in collaboration with the JAK/
STAT signalling regulate endotoxemia and inflammation. However, during sepsis our immune system cannot maintain a
balance of cytokine levels and results in multiple organ damage and eventual death. Different opinions have been made in
previous studies about the expression patterns and the role of proinflammatory cytokines in sepsis that attracted our
attention towards qualitative properties of TLR4 and JAK/STAT signalling pathways using computer-aided studies. Rene´
Thomas’ formalism was used to model septic and non-septic dynamics of TLR4 and JAK/STAT signalling. Comparisons
among dynamics were made by intervening or removing the specific interactions among entities. Among our predictions,
recurrent induction of proinflammatory cytokines with subsequent downregulation was found as the basic characteristic of
septic model. This characteristic was found in agreement with previous experimental studies, which implicate that
inflammation is followed by immunomodulation in septic patients. Moreover, intervention in downregulation of
proinflammatory cytokines by SOCS-1 was found desirable to boost the immune responses. On the other hand,
interventions either in TLR4 or transcriptional elements such as NFkB and STAT were found effective in the downregulation
of immune responses. Whereas, IFN-b and SOCS-1 mediated downregulation at different levels of signalling were found to
be associated with variations in the levels of proinflammatory cytokines. However, these predictions need to be further
validated using wet laboratory experimental studies to further explore the roles of inhibitors such as SOCS-1 and IFN-b,
which may alter the levels of proinflammatory cytokines at different stages of sepsis.
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Introduction
Sepsis is a serious medical condition associated with complica-
tions of an exacerbated human immune response against
endotoxin/lipopolysaccharides (LPS) mediated severe infections
[1]. It can lead to endotoxin shock, organ damage, morbidity and
eventual death [2,3]. The incidence of sepsis is growing regardless
of advances in the therapeutic and supportive treatments [4,5]. In
1992, nearly 500,000 cases of sepsis were found in the United
States among which 35% of the patients led to mortality [6]. In
2001, around 750,000 cases of sepsis with 28.6% mortality rate per
annum was recorded [7]. In a trend analysis from 1993 to 2003, a
significant increase in the cases of severe sepsis and hospitalization
was reported [8], which is still rising [9].
Pro- and anti-inflammatory cytokines are groups of proteins,
which mediate endogenous inflammation and immunomodula-
tion, respectively. Proinflammatory cytokines (PICyts) including
tumour necrosis factor (TNF)-a, interferon (IFN)-c, interleukin
(IL)-la, IL-1b and IL-6 induce a series of immune responses to
overcome the pathogen load [10]. In contrast, anti-inflammatory
cytokines such as transforming growth factor (TGF)-b, IL-4, IL-10,
IL-13 and other cytokine inhibitors including soluble tumour
necrosis factor receptor (sTNFR)-I and II, IL-lra, or soluble IL-1
receptors (sIL-1r) modulate the immune responses and can induce
temporary immunosuppression in septic patients [11].
Our understandings about the contributory role of pro- and
anti-inflammatory immune responses in sepsis evolved with the
passage of time and highlighted disparities among the scientific
findings. Earlier animal studies suggested that proinflammatory
responses were the major cause of the systemic inflammatory
response syndrome (SIRS) and mortality, whereas anti-inflamma-
tory responses were associated with comparatively less severe
complications [12]. In contrast, recently submitted suggestions
disprove previous studies and indicated that the anti-inflammatory
responses and immunosuppression might in fact be responsible for
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compensatory anti-inflammatory response syndrome (CARS),
severe sepsis, organ damage and subsequent mortality [13–17].
Moreover, other studies implicated that pro- and anti-inflamma-
tory responses are correlated with each other and provide
opportunities for septic patients for the management of pathogens
and hyperinflammation at different levels of sepsis [18,19].
Toll like receptors (TLRs) are pattern recognition receptors and
play their important role in the induction of innate immunity
against endotoxins [20]. Previous studies have demonstrated that
the expression levels of TLR4 were elevated on human monocytes
in healthy volunteers challenged with LPS [21] as well as in septic
patients [22,23]. Activation of TLR4 leads to the production of
pro- and anti-inflammatory cytokines by inducing two different
signalling pathways [24]. TLR4 is unique among other TLRs due
to its ability to induce myeloid differentiation primary response
gene (MyD)88 and TIR-domain-containing-adapter-inducing
interferon-b (TRIF) dependent pathways [25]. These two path-
ways culminate in the generation of PICyts and Interferon-b (IFN-
b), respectively. Along with the production of IFN-b, TRIF
dependent signalling has also been implicated to induce the NFkB
activation through TRAF6 [26]. On the other hand, IFN-b has
been implicated in the modulation of late hyperinflammation in
sepsis [27]. Figure 1 is the simple representation of the TLR4 and
Janus kinase (JAK)/signal transducer and activator of transcription
(STAT) (JAK/STAT) signalling pathways adapted from previous
experimental studies and databases associated with biological
signalling [28–34].
MyD88 dependent pathway activates due to the formation of a
complex between MyD88, TLR4 and toll-interleukin 1 receptor
(TIR) domain containing adaptor protein (TIRAP also known as
MAL). This pathway culminates in the activation of NFkB with
subsequent production of PICyts [35]. In contrast, the TRIF
dependent pathway is activated by the formation of a complex
between TRIF, TRIF related adaptor molecule (TRAM or
TICAM2) and TLR4 [36]. This complex results in the activation
of transcriptional regulator interferon regulatory factor 3 (IRF3)
with subsequent transcription of IFN-b [37]. Moreover, the TRIF
dependent pathway has also been implicated for the delayed
activation of NFkB, through TRIF mediated TRAF6 activation,
however, MyD88 dependent pathway is reported for its explicit
contribution in the production of PICyts [38]. PICyts and IFN-b
mediated JAK/STAT signalling is essential for the induction of
pro- or anti-inflammatory immune responses, respectively [31,39].
PICyts and IFN-b stimulate JAKs with subsequent translocation of
STATs into the nucleus where it transcribes necessary genes
responsible to react appropriately against the pathogen or
inflammation [30,31].
TLR4 mediated immune responses are downregulated by
several negative feedback mechanisms [40]. Regulation of TLR4
mediated signalling maintain homeostasis between infectious
challenge and hyperinflammatory responses [41]. Negative
regulatory proteins such as suppressor of cytokine signalling-1
(SOCS-1), A20 zinc finger protein and sterile alpha-and armadillo-
motif-containing protein (SARM) are well reported for their
inhibitory roles in TLR4 signalling [42–44]. Recently, IFN-b is
found associated with the induction of TH1 to TH2 response shift
to reduce the levels of circulating PICyts [27,45–47]. Various
experiments on SOCS-1 knockout cells highlighted that SOCS-1
is necessary to protect against endotoxemia and hyperinflamma-
tion by inhibiting PICyts and IFN-b mediated JAK/STAT
signalling, respectively [48–50].
In this study, we devised qualitative (discrete) model of TLR4
and JAK/STAT signalling, which was constructed by using the
well-known mathematical formalism of Rene´ Thomas [51–53].
Construction of the models according to this formalism do not
require quantitative data (the expression of entities and kinetic rate
parameters of reactions), which is often difficult to obtain for the
biological regulatory networks (BRNs) [54]. Construction of the
qualitative model requires only the qualitative thresholds and
logical parameters, which can be easily adjusted (see Definitions in
Material and Methods section). The qualitative model encom-
passes all the possible qualitative states or levels of entities present
in a BRN. The dynamics of the BRN are captured by the state
graph (representing the states and trajectories) where important
behaviours can be seen as cyclic paths and paths diverging towards
stable states. These cycles and stable states represent the activation
profiles of the entities, respectively. The advantage of the state
graph is that it can represent a state space in any dimension as a
discrete abstraction, while in other approaches, like ordinary
differential equations, this may be very challenging. Comparison
of the qualitative model with its differential equation counterpart is
given by Rene´ Thomas et al. in [55] to prove that both approaches
are equivalent, however, the qualitative modelling is more suitable
for model checking based reasoning to infer unknown parameters
[56].
In our previous study, TLR4 mediated MyD88 dependent
pathway was studied, with a particular focus on the role of
Bruton’s tyrosine kinase and MAL in the production of
hyperinflammatory responses especially in the case of cerebral
malaria [57]. The current study presents the dynamics of the
TLR4 and JAK/STAT signalling pathway by updating our
previous study with new interactions and entities to gain an insight
into a different pathological condition of sepsis. Additionally, the
current study also provides an understanding about the impor-
tance of signalling downregulated by SOCS-1, IFN-b, A20 and
SARM. Moreover, modelling of interventions in signalling were
used to understand the roles of NFkB, PICyts, IFN-b, JAK/STAT
and SOCS-1 in immune responses [55].
The BRN of TLR4-JAK/STAT (Figure 2) in this study
implicates that TLR4, IFN-b, JAK/STAT and SOCS-1 mediated
signalling perform their roles in a recursive manner. Intervention
in the SOCS-1 mediated downregulation of PICyts is associated
with the production of overactive immune response, whereas,
interventions either in TLR4 or NFkB-JAK/STAT signalling is
connected with downregulation of overactive immune responses.
Additionally, IFN-b downregulates PICyts in the earlier phase of
signalling, whereas SOCS-1 regulates the levels of cytokines in late
phase. On this account, levels of PICyts fluctuate within different
qualitative levels during sepsis and may provide the basis for the
differences in scientific findings [18,19]. However, these predic-
tions were generated by the use of computer-aided models and
need to be further validated in wet laboratory experiments.
Materials and Methods
The formalism of Rene´ Thomas
Traditionally, biological systems are modelled using ordinary
differential equations, which require time derivatives of expression
levels, temperature, physical state and kinetic rates of entities, etc.
[58]. Due to the complexity of the biological systems, each variable
with all of its parameters are either system specific or rarely
known. For this reason, computer-aided qualitative modelling of
biological systems is generally preferred to understand the
dynamics of the BRN at a preliminary level, which can then be
validated using in vitro experiments.
In 1970, Rene´ Thomas introduced Boolean logic for the
qualitative modelling of BRNs, which was later generalized to
kinetic logic [59–66]. Using kinetic logic, possible dynamics of a
Modelling of TLR4 and JAK/STAT Signalling
PLOS ONE | www.plosone.org 2 September 2014 | Volume 9 | Issue 9 | e108466
Figure 1. TLR4 and JAK/STAT signalling pathway. Overview of TLR4 and JAK/STAT signalling pathway adopted from previous experimental
studies and databases associated with signalling pathways [20,28–33]. TLR4 activates two separate signalling pathways, including MyD88 and TRIF
dependent pathways [103]. TIRAP/Mal and TRAM are recruited by TLR4 as adaptor proteins to activate MyD88 and TRIF dependent pathways,
respectively [35,103]. Following MYD88 activation, IRAK4 is phosphorylated by MyD88-MAL complex, which ultimately results in the phosphorylation
of IRAK1 protein. Phosphorylated IRAK1 activates TRAF6 [104] which after forming a complex with TAK1-TAB1/2 activates Ikk complex [105]. Ikka and
Ikkb catalyse the phosphorylation of IkB, resulting in its dissociation from NFkB. Afterwards NFkB translocate into nucleus [106] and transcribes
PICyts which results in the subsequent induction of SOCS-1 [48,107]. Along with PICyts, SARM and A20 are also transcribed by NFkB which inhibit
TRIF and TRAF6, respectively [44,108]. Interaction of SOCS-1 with MAL results in its polyubiquitylation and degradation of MAL [42]. SOCS-1 also result
in the degradation of NFkB after binding with its p65 subunit [109]. Moreover, it is also responsible for inhibiting PICyts mediated JAK/STAT signalling
[110]. The alternate pathway for the MyD88 independent induction of NFkB is TRIF which associates with RIP-1 and induce TRAF6 [111]. Cytoplasmic
Modelling of TLR4 and JAK/STAT Signalling
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BRN can be determined in a scalable but rigorous manner.
Kinetic logic provided its effectiveness in preference to the
Boolean logic by the successful modelling of different BRNs
[67]. Effectiveness of the kinetic logic has been proved by
analysing lambda phage genetic switch, differentiation process in
helper T cells, control of organ differentiation in Arabidopsis
thaliana flowers and segmentation during embryogenesis in
Drosophila melanogaster [51–53]. The kinetic logic formalism is
an influential method for examining BRNs in which interactions
among entities are well reported. Use of logical parameters
consistent with threshold values eliminate the necessity of various
parameters of expression, temperature, physical state and kinetic
rates etc. Moreover, this approach has the ability to model the
system close to the approximations obtained by differential
equations [55].
Semantics of the Kinetic Logic Formalism
The semantics of the kinetic logic formalism [55] have been
discussed in our previous work [57], where we have explained the
following formal definitions by considering an example of a toy
BRN composed of three entities (shown as Figure 6 in the previous
study). The definitions and the terms necessary to understand the
semantics used in this study have been mentioned below, adapted
from our previous study [57].
Definition 1 (Directed Graph). ‘‘A directed graph is an
ordered pair D(V ,E), where:
N V is the set of all nodes and
N E(V|V is the set of ordered pairs called edges or arcs’’
An edge e.g. (a,b) is directed from an entity or node ‘‘a’’ to ‘‘b’’,
where ‘‘a’’ is the tail and ‘‘b’’ is the head of that respective edge. In
a directed graph, D{(x) and Dz(x) denote the set of predecessors
and successors of a specific node x[V , respectively’’.
domain of TLR4 associates with TRAM and TRIF, and interacts with a complex of TBK1 and Ikki to induce phosphorylation of IRF3 [103]. After
dimerization, phosphorylated IRF3 translocate into nucleus which results in the production of type I IFNs. IFN-b is responsible for the downregulation
of PICyts through a shift of TH1 to TH2 responses and induce immune regulation. Recently SOCS-1 mediated downregulation of IFN-b has been
observed [50].
doi:10.1371/journal.pone.0108466.g001
Figure 2. The BRN of TLR4 and JAK/STAT signalling pathway. The reduced BRN of TLR4 and JAK/STAT signalling pathway is derived from
Figure 1. Nodes represent entities, whereas interactions between them are shown as edges. Sign on the edges represent the type of interaction
between nodes i.e. positive for activation (solid arrows) and negative for inhibition (dotted arrows). Integers ‘‘1’’ and ‘‘2’’ on the edges represent the
threshold levels of entities (see Material and Methods section).
doi:10.1371/journal.pone.0108466.g002
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Definition 2 (Biological Regulatory Network). ‘‘A BRN is
a labelled directed graph D(V ,E), where V is a set of nodes which
represents biological entities and E(V|V is a set of all possible
edges, which represent the interaction between entities’’.
N Each edge can be labelled with a pair of variables (s,y), where
s represents the qualitative threshold levels and is a positive
integer and y is ‘‘+’’ or ‘‘–’’ representing the type of
interaction, which can either be ‘‘activation’’ or ‘‘inhibition’’,
respectively.
N Each node e.g. ‘‘a’’ has a limit (la), in its threshold level, which
is equal to its out-degree (the total number of outgoing edges
from ‘‘a’’). This relation can be presented by Vb[Dz(a) and
sab[f1,2,3,::::,rag where raƒla which means that the
threshold levels of entity ‘‘a’’ can be set within a range ‘‘1’’
to ‘‘total number of outgoing edges’’ and because it has only
one outgoing edge towards predecessor ‘‘b’’ so the threshold
level which can be set for it can be only be ‘‘1’’.
N Each entity, e.g. ‘‘a’’, has its abstract expression in the set
Za~f0,1,2,:::,rag.
Definition 3 (States). ‘‘The state of a BRN is a tuple s[M,
where M in terms of entity ‘‘a’’ is:
Figure 3. State graph of TLR4 and JAK/STAT signalling during non-septic and septic conditions. (A) Each node represents a particular
state observed during signalling associated with non-septic and septic conditions. Integers ‘‘0’’, ‘‘1’’ and ‘‘2’’ within the nodes represent qualitative
levels of proteins in the order of TLR4, IFN-b, NFkB, PICyts and SOCS-1. Inactive entities are represented by integer ‘‘0’’ whereas active and overactive
entities are represented by integers ‘‘1’’ and ‘‘2’’, respectively. Nodes and trajectories, which were specifically observed during signalling dynamics
associated with sepsis, are shown in red, whereas common nodes and trajectories found in both conditions are shown in black. Trajectories start from
state ‘‘10000’’, representing the activation of TLR4, and ultimately lead towards ‘‘00000’’, which is a stable state in non-septic condition. On the other
hand, a trajectory labelled with ‘‘g’’ from state ‘‘00000’’ to starting state ‘‘10000’’ results in a cyclic path during signalling dynamics associated with
sepsis. MyD88 and TRIF dependent signalling are shown as black lines and dashed arrows, respectively. Nodes, which represent crosstalk of both
signalling pathways i.e. IFN-b and NFkB with qualitative level ‘‘1’’ are presented in oval shapes. Arrows labelled with Greek small letters are used to
represent trajectories associated with different signalling events (see legend in the figure). The conditions necessary to produce a state graph shown
in the figure are given in Table 1. (B–D) specific states and trajectories which can possibly represent the complete state graph given in (A).
doi:10.1371/journal.pone.0108466.g003
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M~Pa[VZa
The qualitative states are represented by vector (Mv)Va[V ,
where v denotes the level of expression of an entity like ‘‘a’’.
According to this definition M is the Cartesian product of the sets
of abstract expressions of all entities. A qualitative state represents
a configuration of all the elements of a BRN at any instant of time.
The number of activators of a particular variable at a given level of
expression are represented by its set of resources (see the definition
of resources given below)’’.
Definition 4 (Resources). ‘‘The set of resources Rva of a
variable a[V at a level v is defined as Rva~fb[D{(a)j
vb§sba and yba~z) or (vbvsba and yba~{)g. The dynamic
behaviours of BRN depends on logical parameters. The set of
these logical parameters is defined as K(D)~fKa(Rva )[ZaVa[Vg.
The parameter Ka(Rva ) (at a level v of a) gives the information
about the evolution of a. There are three cases: 1) if vavKa(Rva )
then va increases by one unit 2) if vawKa(Rva ) then va decreases
Figure 4. State graph of CASE 1-N and 1-S. (A) Each node represents a particular state observed during signalling associated with CASE 1-N and
CASE 1-S. Integers ‘‘0’’, ‘‘1’’ and ‘‘2’’ within the nodes represent qualitative levels of proteins in the order of TLR4, IFN-b, NFkB, PICyts and SOCS-1.
Inactive entities are represented by integer ‘‘0’’ whereas active and overactive entities are represented by integers ‘‘1’’ and ‘‘2’’, respectively. States
and trajectories, which were specifically observed during signalling dynamics associated with CASE 1-S, are shown in red, whereas common states
and trajectories found in both CASES are shown in black. Trajectories start from state ‘‘10000’’, representing the activation of TLR4 and ultimately lead
towards ‘‘00000’’ and ‘‘00121’’, which are stable states in CASE 1-N. On the other hand, only one stable state ‘‘00121’’ was observed during signalling
dynamics associated with CASE 1-S and a trajectory labelled with ‘‘g’’ from state ‘‘00000’’ to starting state ‘‘10000’’ results in cyclic path. Trajectories
associated with loss of SOCS-1 mediated downregulation of PICyts in CASE 1-N and CASE 1-S are presented as bold arrows labelled with symbol ‘‘De’’.
Nodes are labelled with stars in which NFkB and PICyts were active simultaneously and have the probability to lead towards overactive immune
response. MyD88 and TRIF dependent signalling are shown as black lines and dashed arrows, respectively. Nodes, which represent crosstalk of both
signalling pathways i.e. IFN-b and NFkB with qualitative level ‘‘1’’ are presented in oval shapes. Arrows labelled with Greek small letters are used to
represent trajectories associated with different signalling events (see legend in the figure). The conditions necessary to produce a state graph are
shown in the figure are given in Table 3. (B–D) specific states and trajectories which can possibly represent the complete state graph given in (A).
doi:10.1371/journal.pone.0108466.g004
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by one unit and 3) if va~Ka(Rva ) then va cannot evolve from its
current level.
It is convenient to describe the evolution from one level to
another by an evolution operator ‘‘ ’’ [68], which is defined in
terms of entity ‘‘a’’ as follows:
va Ka(Rva )~
vaz1 if vavKa(Rva );
va{1 if vawKa(Rva );
va if va~Ka(Rva ):
8><
>:
:
Where va and Ka(Rva )[Z§0’’.
Figure 5. State graph of CASE 2-N and 2-S. (A) Each node represents a particular state observed during signalling associated with CASE 2-N and
CASE 2-S. Integers ‘‘0’’, ‘‘1’’ and ‘‘2’’ within the nodes represent qualitative levels of proteins in the order of TLR4, IFN-b, NFkB, PICyts and SOCS-1.
Inactive entities are represented by integer ‘‘0’’ whereas active and overactive entities are represented by integers ‘‘1’’ and ‘‘2’’, respectively. Nodes
and trajectories, which were specifically observed during signalling dynamics associated with CASE 2-S, are shown in red, whereas common nodes
and trajectories found in both CASES are shown in black. Trajectories start from state ‘‘10000’’, representing the activation of TLR4 and ultimately lead
towards ‘‘00000’’ and ‘‘00121’’, which are stable states in CASE 2-N. On the other hand, only one stable state ‘‘00121’’ was observed during signalling
dynamics associated with CASE 2-S and a trajectory labelled with ‘‘g’’ from state ‘‘00000’’ to starting state ‘‘10000’’ results in cyclic path. Trajectories
associated with loss of SOCS-1 mediated downregulation of PICyts in CASE 2-N and CASE 2-S are presented as bold arrows labelled with symbol ‘‘De’’
whereas loss of SOCS-1 mediated downregulation of IFN-b are labelled with symbol ‘‘Dd’’. MyD88 and TRIF dependent signalling are shown as black
lines and dashed arrows, respectively. Nodes, which represent crosstalk of both signalling pathways i.e. IFN-b and NFkB with qualitative level ‘‘1’’ are
presented in oval shapes. Arrows labelled with Greek small letters are used to represent trajectories associated with different signalling events (see
legend in the figure). The conditions necessary to produce a state graph shown in the figure are given in Table 3. (B–D) specific states and trajectories
which can possibly represent the complete state graph given in (A).
doi:10.1371/journal.pone.0108466.g005
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Definition 5 (State Graph). ‘‘Let D be the BRN and va
represents the expression level of an entity e.g. ‘‘a’’ in a state s[M.
Then the state graph of the BRN will be the directed graph
G~(S,T), where S is set of states and T(S|S represents a
relation between states, called the transition relation, such that
s?s’[T if and only if:
N A a unique a[V such that sva=sva ’ and sva ’~sva Ka(Rva ) and
N Vb[V \fagsvb ’~svb ’’
According to this definition states evolve asynchronously, thus,
in a successor state only one entity changes its level.
Reduction of the BRN
One of the limitations of the kinetic logic approach is that it has
been designed to analyse relatively small BRNs because of its
scalability limitations [55]. For example, the TLR4 and JAK/
STAT pathway as given in Figure 1 has 22 entities and on
simulation its state graph would be composed of 6291456 states as
compared to less than 50 states (Figures 3–8) generated by the
reduced BRN (Figure 2).
Figure 6. State graph of CASE 3-N and 3-S. (A) Each node represents a particular state observed during signalling associated with CASE 3-N and
CASE 3-S. Integers ‘‘0’’, ‘‘1’’ and ‘‘2’’ within the nodes represent qualitative levels of proteins in the order of TLR4, IFN-b, NFkB, PICyts and SOCS-1.
Inactive entities are represented by integer ‘‘0’’ whereas active and overactive entities are represented by integers ‘‘1’’ and ‘‘2’’, respectively. Nodes
and trajectories, which were specifically observed during signalling dynamics associated with CASE 3-S, are shown in red, whereas common nodes
and trajectories found in both CASES are shown in black. Trajectories start from state ‘‘10000’’, representing the activation of TLR4, ultimately, lead
towards ‘‘00000’’, which is the stable state in CASE 3-N. On the other hand, a trajectory labelled with ‘‘g’’ from state ‘‘00000’’ to starting state ‘‘10000’’
results in a cyclic path during signalling dynamics associated with CASE 3-S. Trajectories associated with loss of IFN-b mediated downregulation of
PICyts in CASE 3-N and CASE 3-S are presented as bold arrows labelled with symbol ‘‘Dc’’. MyD88 and TRIF dependent signalling are shown as black
lines and dashed arrows, respectively. Nodes, which represent crosstalk of both signalling pathways i.e. IFN-b and NFkB with qualitative level ‘‘1’’ are
presented in oval shapes. Arrows labelled with Greek small letters are used to represent trajectories associated with different signalling events (see
legend in the figure). The conditions necessary to produce a state graph shown in the figure are given in Table 3. (B–D) specific states and trajectories
which can possibly represent the complete state graph given in (A).
doi:10.1371/journal.pone.0108466.g006
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The complexity of TLR4 and JAK/STAT pathways was
reduced to make the BRN (shown in Figure 2) and resultant state
graphs (Shown in Figures 3–8) tractable. Starting with the
complete signalling pathways of TLR4 and JAK/STAT, adopted
from previous experimental studies and databases associated with
biological signalling [28–33], the BRN was reduced iteratively by
following the strategies of Naldi et. al. [69] and Assieh et. al. [70].
Briefly, one such example is if an entity X1 activates another entity
X2, which in turn activates X3 such that X3 inhibits X1, then we
can omit X2 and represent this relation as a simple feedback loop
where X1 activates X3 and X3 inhibits X1. In the process of
reduction, the behaviour of the removed entity X2 was preserved
implicitly in the activation of X3 by X1 to account for the related
interactions and their effects on the target nodes. Another example
is given in the Figure 3.3 of the study by Assieh et al. [70], where a
network of 13 proteins (Figure 3.3a) is reduced to 3 proteins
(Figure 3.3b) using the reduction rules. Similarly in the study of
Naldi et.al. [69], Figure 2 is presenting another example of the
BRN reduction.
Figure 7. State graph of CASE 4-N and 4-S. Each node represents a particular state observed during signalling associated with CASE 4-N and
CASE 4-S. Values ‘‘0’’ and ‘‘1’’ within the nodes represent qualitative levels of proteins in the order of TLR4, IFN-b, NFkB, PICyts and SOCS-1. Inactive
entities are represented by integer ‘‘0’’ whereas active entities are represented by integer ‘‘1’’. Trajectories, which were specifically observed during
signalling dynamics associated with CASE 4-S, are shown in red, whereas common states and trajectories found in both CASES are shown in black.
Trajectories start from state ‘‘10000’’, representing the activation of TLR4, ultimately, lead towards ‘‘00000’’, which is a stable state in CASE 4-N. On the
other hand, a trajectory labelled with ‘‘g’’ from state ‘‘00000’’ to starting state ‘‘10000’’ results in a cyclic path during signalling dynamics associated
with CASE 4-S. State ‘‘00121’’ which represents the immune response was absent in state graph and not shown in this figure. MyD88 and TRIF
dependent signalling are shown as black lines and dashed arrows, respectively. Nodes, which represent crosstalk of both signalling pathways i.e. IFN-
b and NFkB with qualitative level ‘‘1’’ are presented in oval shapes. Arrows labelled with Greek small letters are used to represent trajectories
associated with different signalling events (see legend in the figure). The conditions necessary to produce a state graph shown in the figure are given
in Table 3.
doi:10.1371/journal.pone.0108466.g007
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Discrete Modelling of the BRN
GENOTECH (provided at http://code.google.com/p/
genotech/downloads/list. Steps necessary to model a BRN in
GENOTECH have been described in [57]) and GINSIM
(documentation and software for modelling BRNs in GINSIM
are available at www.ginsim.org) [71] facilitated the construction
of qualitative model of BRN (Figure 2) according to Thomas’
formalism. Modelling of the BRN was performed by inserting the
required entities as nodes and drawing the corresponding
interactions as edges. Threshold levels and logical parameters for
each entity were adjusted as discussed below. Using asynchronous
strategy, the results were produced in the form of state graphs
composed of states and trajectories consisting of cycling paths and
paths diverging towards stable states. These state graphs were used
to study the dynamics of the BRN. GENOTECH files and
equivalents in GINSIM format have been provided as Files S1–
S24, for each condition discussed in results.
Threshold values of each entity in the BRN
According to the Definition 2, the threshold level 00s00 is a
positive integer, which represents the minimum qualitative level of
an entity necessary to activate or inhibit its target entities. In
contrast to the Boolean logic, kinetic logic (multivalued) permits
the use of threshold level§1 [61,72]. The threshold values, which
can be used, depend upon the outgoing edges from any entity.
These values range from ‘‘1’’ to the number of outgoing edges
from an entity. The reason for multivalued formalism is that a
particular entity can activate or inhibit its target entities at
different activation levels and thus require more than one
threshold level to perform its role as an activator or inhibitor.
Figure 8. State graph of CASE 5-N and 5-S. (A) Each node represents a particular state observed during signalling associated with CASE 5-N and
CASE 5-S. Integers ‘‘0’’ and ‘‘1’’ within the nodes represent qualitative levels of proteins in the order of TLR4, IFN-b, NFkB, PICyts and SOCS-1. Inactive
entities are represented by integer ‘‘0’’ whereas active entities are represented by integer ‘‘1’’. Nodes and trajectories, which were specifically
observed during signalling dynamics associated with CASE 5-S, are shown in red, whereas common nodes and trajectories found in both CASES are
shown in black. Trajectories start from state ‘‘10000’’, representing the activation of TLR4, ultimately, lead towards ‘‘00000’’, which is a stable state in
CASE 5-N. On the other hand, a trajectory labelled with ‘‘g’’ from state ‘‘00000’’ to starting state ‘‘10000’’ results in a cyclic path during signalling
dynamics associated with CASE 5-S. MyD88 and TRIF dependent signalling are shown as black lines and dashed arrows, respectively. Nodes, which
represent crosstalk of both signalling pathways i.e. IFN-b and NFkB with qualitative level ‘‘1’’ are presented in oval shapes. Arrows labelled with Greek
small letters are used to represent trajectories associated with different signalling events (see legend in the figure). The conditions necessary to
produce a state graph shown in the figure are given in Table 3. (B–D) specific states and trajectories which can possibly represent the complete state
graph given in (A).
doi:10.1371/journal.pone.0108466.g008
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For example SOCS-1 has been implicated for its inhibitory role in
TLR4, NFkB, IFN-b and PICyts mediated signalling [48] but the
specific expression levels of SOCS-1 which are necessary to inhibit
all of these four entities in the presence of other resources
(activators or inhibitors) are not reported. Therefore, according to
Thomas’ formalism, the threshold levels of SOCS-1 for its
interaction with these four entities can be within the range
f1{4g. In order to keep the model simple, the threshold levels of
SOCS-1 were set at level ‘‘1’’. Similarly, for other entities,
including TLR4, IFN-b and NFkB, the threshold levels were set at
‘‘1’’. Only PICyts mediated activation of NFkB-JAK/STAT was
set at ‘‘2’’. Therefore, PICyts was supposed to activate SOCS-1 at
the activation level ‘‘1’’ and NFkB-JAK/STAT at activation level
‘‘2’’. Threshold level ‘‘2’’ was used in speculation that PICyts
Table 1. Logical parameters used for each entity in modelling of non-septic TLR4 and JAK/STAT signalling using the BRN shown in
Figure 2.
S.No. Logical Parameters
1 KTLR4({}) = 0
2 KTLR4({NFkB}) = 0
3 KTLR4({SOCS-1}) = 0
4 KTLR4({SOCS-1, NFkB}) = 0
5 KNFkB-JAK/STAT({}) = 0
6 KNFkB-JAK/STAT({TLR4}) = 1
7 KNFkB-JAK/STAT({IFN-b}) = 1
8 KNFkB-JAK/STAT({PICyts}) = 1
9 KNFkB-JAK/STAT({TLR4, IFN-b}) = 1
10 KNFkB-JAK/STAT({TLR4, PICyts}) = 1
11 KNFkB-JAK/STAT({IFN-b, PICyts}) = 1
12 KNFkB-JAK/STAT({TLR4, PICyts, IFN-b}) = 1
13 KNFkB-JAK/STAT({TLR4, SOCS-1}) = 1
14 KNFkB-JAK/STAT({IFN-b, SOCS-1}) = 1
15 KNFkB-JAK/STAT({PICyts, SOCS-1}) = 1
16 KNFkB-JAK/STAT({TLR4, IFN-b, SOCS-1}) = 1
17 KNFkB-JAK/STAT({TLR4, PICyts, SOCS-1}) = 1
18 KNFkB-JAK/STAT({PICyts, IFN-b, SOCS-1}) = 1
19 KNFkB-JAK/STAT({SOCS-1}) = 0
20 KNFkB-JAK/STAT({SOCS-1, TLR4, IFN-b, PICyts}) = 1
21 KPICyts({}) = 0
22 KPICyts({NFkB}) = 0
23 KPICyts({IFN-b}) = 0
24 KPICyts({SOCS-1}) = 0
25 KPICyts({NFkB, IFN-b}) = 0
26 KPICyts({NFkB, SOCS-1}) = 0
27 KPICyts({IFN-b, SOCS-1}) = 0
28 KPICyts({NFkB, IFN-b, SOCS-1}) = 2
29 KSOCS-1({}) = 0
30 KSOCS-1({PICyts}) = 1
31 KSOCS-1({IFN-b}) = 1
32 KSOCS-1({PICyts, IFN-b}) = 1
33 KIFN-b({}) = 0
34 KIFN-b({TLR4}) = 0
35 KIFN-b({SOCS-1}) = 0
36 KIFN-b({NFkB}) = 0
37 KIFN-b({TLR4, SOCS-1}) = 1
38 KIFN-b({TLR4, NFkB}) = 1
39 KIFN-b({SOCS-1, NFkB}) = 0
40 KIFN-b({TLR4, SOCS-1, NFkB}) = 1
Each logical parameter has been discussed in detail in File S26.
doi:10.1371/journal.pone.0108466.t001
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activate the products of NFkB-JAK/STAT signalling pathway
after reaching a certain qualitative threshold level, which may
differ from its other actions such as activation of SOCS-1 [73–75].
Types of interaction
The entities in a BRN may represent proteins or genes, which
can interact with each other. Depending upon the threshold levels,
entities can either activate or inhibit other entities termed as
evolving or target entities (see Definition 2 where y~z for
activators and y~{ for inhibitors). As shown in the BRN
(Figure 2), TLR4, IFN-b, NFkB and PICyts are the entities, which
can either activate each other or SOCS-1 depending upon their
threshold levels. According to formalism, whenever the activation
of these entities will reach to their threshold levels, generally taken
as ‘‘1’’, then successors of these entities will also be activated. This
relationship can be depicted by sigmoidal graph presented as
Figure 5A in our previous study [57]. It can be seen that an
activator below a threshold level (s) slightly affects the activation
level of its target entity. However, as soon as the activator achieves
its threshold level, then the target entity also reaches to active state
where it can perform its further interactions. In other words,
whenever entity has threshold level ,s then it cannot activate its
target entities but when threshold level of an entity $s then it can
activate its target entities. In this scenario, the entities are termed
as positive regulators or activators when they activate other entities
during the dynamics of the BRN shown as state graphs.
On the other hand, IFN-b, NFkB and SOCS-1 can inhibit
either each other or TLR4 and PICyts. These entities are termed
as negative regulators or inhibitors and process is termed as
downregulation or inactivation. Entities which can inhibit evolving
entities also depend upon their threshold levels. The effect of
inactivation is also of sigmoidal nature and is shown as Figure 5B
in our previous study [57].
Logical parameters of each entity in the BRN
Logical parameters have been described by using the relation
Ktarget entity(fresourcesg)~n where n[f0,1,2,:::g. Where resourc-
es are those entities of BRN, which are connected with evolving or
target entity. These resources can be either activators or inhibitors
depending upon their presence or absence, respectively, during a
particular state. Activators were taken as resources when they were
present in a particular state. On the other hand, inhibitors were
taken as resources only when they were absent during a particular
state.
According to the formalism, the possible number of logical
parameters, which we have to define for each evolving entity
depends upon the number of resources. If the number of resource
is one, then the possible number of logical parameters, which we
have to define, will be two. This relation can be shown as a power
set of the set of regulators (set of activators and inhibitors) of an
entity. Therefore, each logical parameter corresponds to one
element of the power set. In accordance with the Rene´ Thomas’
formalism, the total number of logical parameters for TLR4, IFN-
b, NFkB, PICyts and SOCS-1 are 4, 8, 16, 8 and 4, respectively
(Table 1).
The value n for each logical parameter was unknown a priori,
and was computed using the Selection of Models of Biological
Networks (SMBioNet) tool [76–78]. Briefly, this tool is based on
the kinetic logic formalism of Rene´ Thomas that takes a BRN with
unspecified parameters and Computational Tree Logic (CTL) [79]
formulae of the form W~W1? A=Ef g G=F=Xf gW2 representing a
specific biological behaviour (observation). In the formula W, the
path quantifier A or E governs if a specific property should hold in
all trajectories (A) originating from a current state or in at least one
trajectory (E). Whereas, the state quantifiers G, F and X govern if
a property should hold in all states (G), in a future state (F ), or in
the immediate successor state (X ) in a trajectory (path); and finally
W1 and W2 represent the Boolean logic formulae representing the
initial expression levels and the observed expression levels of the
entities, respectively. In the formula W, the symbol ‘‘?’’ represents
the Boolean implication operator. For example, the formula
W~((TLR4 = 1 AND IFN-b= 0 AND NFkB = 0 AND PICyts = 0
AND SOCS-1 = 0) ? EF(NFkB = 1)) is a CTL formula where
W1~ (TLR4 = 1 AND IFN-b= 0 AND NFkB = 0 AND PI-
Cyts = 0 AND SOCS-1 = 0) representing the initial expression
levels of entities (TLR4 is currently active and others are inactive),
and EF(W2) with W2~(NFkB = 1) represents the observation that
NFkB eventually activates. In this example, AND is the Boolean
conjunction operator. The CTL encoded observed biological
behaviours from the literature pertaining to the TLR4 and JAK/
STAT pathway are given in Table 2. The input and output of the
SMBioNet are provided in File S25.
Value ‘‘0’’ represents that evolving entity deactivates in the
presence of its resources, whereas a value ‘‘1’’ represents activation
of an entity. However, the logical parameter
KPICyts fNFkB, IFN{b, SOCS{1gð Þ was with a value ‘‘2’’
depending upon the threshold level of PICyts for the induction of
JAK-STAT pathway as discussed earlier. The values of these
computed logical parameters were validated by previous literature.
An informal description of the logical parameters with relevant
evidences has been provided as File S26 that form the basis for
using a specific value for each logical parameter given in Table 1.
These logical parameters were further validated by the proved
conjectures [a positive feedback circuit (respectively negative
feedback circuit) is a necessary condition for multistationarity
Table 2. Biological observations and concerned references from previous literature which were used to generate the CTL formula
as given as input to SMBioNet.
S# Biological observations CTL formula in SMBioNet
1 Once TLR4 gets activated, it will then
activate the downstream signaling
in response to infection, which eventually
leads to the induction of NFkB and IFN-b
[103,112–116].
((TLR4 = 1&IFNb= 0&NFkB = 1&PICyts = 0&SOCS1= 0)-.EF(TLR4 = 1&IFNb = 1&NFkB = 1))
2 After a successful immune
response or clearance of infection,
all the entities will be
downregulated [20,25,117].
((TLR4 = 1&IFNb= 0&NFkB = 0&PICyts = 0&SOCS1= 0)-.
EF(AG(TLR4 = 0&IFNb = 0&NFkB = 0&PICyts = 0&SOCS1= 0)))
doi:10.1371/journal.pone.0108466.t002
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(respectively homeostasis). In a BRN a positive feedback circuit
(respectively negative feedback circuit) is the one which contains
even (respectively odd) number of negative interactions] of Rene´
Thomas [55] and biologically observed stable states. Logical
parameters given in Table 1 were finally used to study the
dynamics of the BRN (Figure 2) in the form of state graphs. These
parameters have also been shown as tendency graphs in Figures
S9–S13 using sigmoidal graphs among evolving entities and their
resources.
Modelling of interventions
Models with interventions were derived by removing one or
more of the interactions of IFN-b, SOCS-1, NFkB and PICyts
present in the BRN (Figure 2). Associated logical parameters were
also changed or removed to maintain the integrity of each model
(Table 3). These interventions (discussed as CASES) were used to
observe their impact on the signalling events (effects on the cyclic
paths and stable states during signalling modelled for septic and
non-septic) and for comparison with non-intervened or intact
models. All the models which are discussed in this study have been
provided as files in GENTOCH (Files S1–S12) and GINSIM (Files
S13–S24) formats.
Results
Different perspectives of the TLR4 and JAK/STAT signalling
were studied by simulating septic and non-septic conditions, both
in the presence and absence of specific interactions among entities.
The devised logical parameters for all entities (Table 1) were used
to model non-septic dynamics of TLR4 and JAK/STAT signalling
shown as BRN in Figure 2. Changes in specific logical parameters
by removing respective edges or interactions between the entities
as given in Figure 2 were used to model septic and intervened
signalling (Table 3). State graphs shown in Figures 3–8 represent
signalling events or dynamics of different perspectives of BRN
discussed in detail below. Qualitative levels (0, 1 or 2) of TLR4,
IFN-b, NFkB, PICyts and SOCS-1 represent qualitative states,
which are shown as nodes, whereas trajectories represent possible
progress or evolution paths of entities depending upon the logical
parameters and qualitative threshold levels (Figures 3–8). In each
state graph, state ‘‘10000’’ represents the starting state (activation
of TLR4 as first signal) whereas states of ‘‘00000’’ and ‘‘00121’’
represents the downregulated and overactive immune responses,
respectively.
Signalling in non-septic case
All the logical parameters used in modelling the non-septic
signalling are defined in Table 1 and shown as dummy tendency
graphs in Figures S9–S13. Model related to non-septic condition
has been provided as File S1. Logical parameters devised for each
entity were based on the experimental findings, but the
incorporation of several experimental findings as a single rule for
evolving entity were devised as discussed in the methods. Logical
parameters were devised in such a way that after the production of
overactive immune response (state ‘‘00121’’), the dynamics of the
BRN should reach to a stable state ‘‘00000’’ representing the
downregulation of immune response. Simulation of non-septic
model led to the generation of a state graph shown in Figure 3.
Complete TLR4 mediated induction of TRIF and MyD88
adaptor proteins are represented by the induction of IFN-b
(10000?11000) and NFkB (10000?10100o), respectively. Ac-
cording to the previous experimental studies, MyD88 dependent
pathway is induced in preference to the TRIF dependent pathway
[80,81]. In the state graph, it can be noticed that the induction of
PICyt was achieved only in those trajectories in which NFkB
mediated signalling was activated in preference to IFN-b. On the
other hand, chances for the induction of PICyt were found
comparatively lower in the presence of earlier induced IFN-b.
Probably, this may create a platform for immediately required
immune response against the pathogen. States, which represent a
crosstalk mechanism of MyD88 and TRIF dependent signalling,
are shown within the oval shapes. Downstream to these states, the
presence of SOCS-1 and/or IFN-b compelled the system towards
immunocompromised states (states with level ‘‘0’’ or ‘‘1’’ of
PICyts). Most of the crosstalk states were observed during the
activated TLR4. However, in the absence of TLR4, TRIF
induced activation of NFkB (shown as 01001?01101) can be
specifically observed in trajectories labelled with ‘‘b’’ in Figure 3.
Correlated with previous experimental study, this transition was
produced nearly at the end of dynamics and triggered the late
phase induction of NFkB mediated proinflammatory immune
responses [36].
During dynamics of the BRN, trajectories (labelled with ‘‘a’’ in
Figure 3) were found most important for the over activation of
PICyts which include (10110?10120) and (00110?00120). Both
of these trajectories were associated with the absence of SOCS-1
and IFN-b along with elevated levels of PICyts (shown by level
‘‘2’’). Moreover, both of these trajectories may represent the
importance of TLR4 and JAK/STAT mediated induction of
inflammatory responses.
The presence of IFN-b and/or SOCS-1 at different levels in the
state graph were found necessary to downregulate the levels of
PICyts. After the expression of PICyts, recursive action of IFN-b
and then SOCS-1 maintained the homeostasis of the immune
system by downregulating the levels of PICyts. After achieving the
hyperinflammatory state ‘‘00121’’, dynamics of the BRN were led
towards stable state ‘‘00000’’, which represents the downregula-
tion of the immune system. Trajectories labelled with ‘‘c’’ in
Figure 3 highlights the role of IFN-b mediated downregulation of
PICyts. The presence of IFN-b reduced the chances for induction
of PICyts (trajectories downstream of state ‘‘11100’’) and delayed
effective immune response. However, in the absence of IFN-b, fate
of system was shifted towards NFkB mediated induction of PICyts.
Trajectories labelled with ‘‘d’’ and ‘‘e’’ in Figure 3 represent
SOCS-1 mediated downregulation of IFN-b and PICyts, respec-
tively. Generally, the behaviour of SOCS-1 was found to
downregulate the levels of IFN-b in preference to PICyts.
Indirectly, SOCS-1 allowed PICyts to higher expression levels in
the system and then regulated the same. Some of the trajectories
(labelled with ‘‘f’’ in Figure 3) in the state graph infer the
combination of SOCS-1 and IFN-b mediated downregulation of
PICyts and observed mostly during crosstalk of MyD88 and TRIF
dependent pathways, which led the dynamics towards downreg-
ulated immune response. In this setting, it can be assumed that
SOCS-1 may allow extra time for the induction of PICyts so that
the immune system can cope up with the pathogens. However,
subsequent SOCS-1 mediated inhibition of PICyts may implicate
the decrease in damage to the host by its exacerbating immune
response.
The presence of cyclic paths, termed as strongly connected
components (SCC)-1 and SCC-2, in the state graph can be seen in
Figure S1 and S2, respectively. SCC-1 highlights the importance
of states ‘‘10100’’ and ‘‘10101’’ (Figure S1). The cyclic path
between these two states represent the recurrent activation of
PICyts in non-septic TLR4 signalling with subsequent downreg-
ulation. Due to the presence of IFN-b and SOCS-1, system cycled
through trajectory ‘‘10100?11100?11101?10101’’ and pro-
duced sustained immunosuppression. On the other hand, SCC-2
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Table 3. Intervened signalling.
CASE
Evolving
Entity
Target
entity/ies
Removed
parameters
Changed
parameters
Removed
edge/s in Figure 2.
Produced
Stable states
1-N SOCS-1 PICyts KPICyts({SOCS-1}) = 0,
KPICyts({NFkB, SOCS-1}) = 0,
KPICyts({NFkB, IFN-b, SOCS-1}) = 0
KPICyts({NFkB, IFN-b}) = 2 SOCS-1 mediated
downregulation of PICyts
00000 & 00121
1-S SOCS-1 PICyts KPICyts({SOCS-1}) = 0,
KPICyts({NFkB, SOCS-1}) = 0,
KPICyts({NFkB, IFN-b, SOCS-1}) = 0
KPICyts({NFkB, IFN-b}) = 2,
KTLR4({SOCS-1, NFkB}) = 1
SOCS-1 mediated
downregulation of PICyts
during recurrent TLR4 signalling
00121
2-N SOCS-1 PICyts &
IFN-b
KPICyts({SOCS-1}) = 0,
KPICyts({NFkB, SOCS-1}) = 0,
KPICyts({NFkB, IFN-b,
SOCS-1}) = 0,
KIFN-b({SOCS-1}) = 0,
KIFN-b({TLR4, SOCS-1}) = 1,
KIFN-b({SOCS-1, NFkB}) = 0,
KIFN-b({TLR4, SOCS-1, NFkB}) = 1
KPICyts({NFkB, IFN-b}) = 2 SOCS-1 mediated
downregulation of
IFN-b and PICyts
00000 & 00121
2-S SOCS-1 PICyts &
IFN-b
KPICyts({SOCS-1}) = 0,
KPICyts({NFkB, SOCS-1}) = 0,
KPICyts({NFkB, IFN-b, SOCS-1}) = 0,
KIFN-b({SOCS-1}) = 0,
KIFN-b({TLR4, SOCS-1}) = 1,
KIFN-b({SOCS-1, NFkB}) = 0,
KIFN-b({TLR4, SOCS-1, NFkB}) = 1
KPICyts({NFkB, IFN-b}) = 2,
KTLR4({SOCS-1, NFkB}) = 1
SOCS-1 mediated
downregulation of IFN-b
and PICyts during recurrent
TLR4 signalling
00121
3-N IFN-b PICyts KPICyts({IFN-b}) = 0,
KPICyts({IFN-b, NFkB}) = 0,
KPICyts({IFN-b, SOCS-1}) = 0,
KPICyts({NFkB, IFN-b, SOCS-1}) = 2
KPICyts({NFkB, SOCS-1}) = 2 IFN-b mediated
downregulation of PICyts
00000
3-S IFN-b PICyts &
SOCS-1
KPICyts({IFN-b}) = 0,
KPICyts({IFN-b, NFkB}) = 0,
KPICyts({IFN-b, SOCS-1}) = 0,
KPICyts({NFkB, IFN-b, SOCS-1}) = 2
KPICyts({NFkB, SOCS-1}) = 2,
KTLR4({SOCS-1, NFkB}) = 1
IFN-b mediated
downregulation PICyts during
recurrent TLR4 signalling
00000
4-N NFkB PICyts KPICyts({NFkB}) = 0,
KPICyts({NFkB, IFN-b}) = 0,
KPICyts({NFkB, SOCS-1}) = 0,
KPICyts({NFkB, IFN-b, SOCS-1}) = 2
- NFkB mediated
induction of PICyts
00000
4-S NFkB PICyts KPICyts({NFkB}) = 0,
KPICyts({NFkB, IFN-b}) = 0,
KPICyts({NFkB, SOCS-1}) = 0,
KPICyts({NFkB, IFN-b, SOCS-1}) = 2
KTLR4({SOCS-1, NFkB}) = 1 NFkB mediated induction
of PICyts during recurrent
TLR4 signalling
00000
5-N PICyts NFkB-JAK/STAT KNFkB-JAK/STAT({PICyts}) = 1,
KNFkB-JAK/STAT({TLR4, PICyts}) = 1,
KNFkB-JAK/STAT({IFN-b, PICyts}) = 1,
KNFkB-JAK/STAT({TLR4, PICyts, IFN-b}) = 1,
KNFkB-JAK/STAT({PICyts, SOCS-1}) = 1,
KNFkB-JAK/STAT({TLR4, PICyts,
SOCS-1}) = 1,
KNFkB-JAK/STAT({PICyts, IFN-b,
SOCS-1}) = 1,
KNFkB-JAK/STAT({SOCS-1, TLR4, IFN-b,
PICyts}) = 1
- PICyts mediated induction
of JAK/STAT signalling
00000
5-S PICyts NFkB-JAK/STAT KNFkB-JAK/STAT({PICyts}) = 1,
KNFkB-JAK/STAT({TLR4, PICyts}) = 1,
KNFkB-JAK/STAT({IFN-b, PICyts}) = 1,
KNFkB-JAK/STAT({TLR4, PICyts, IFN-b}) = 1,
KNFkB-JAK/STAT({PICyts, SOCS-1}) = 1,
KNFkB-JAK/STAT({TLR4, PICyts,
SOCS-1}) = 1,
KNFkB-JAK/STAT({PICyts, IFN-b,
SOCS-1}) = 1,
KNFkB-JAK/STAT({SOCS-1,
TLR4, IFN-b, PICyts}) = 1
KTLR4({SOCS-1, NFkB}) = 1 Loss of PICyts mediated
induction of JAK/STAT
signalling during
recurrent TLR4 induction.
00000
Different CASES have been presented with respective changes in parameters. Changes presented here in each CASE accompanied other logical parameters described in
Table 1 to model each CASE.
doi:10.1371/journal.pone.0108466.t003
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is a representation of the cycle among states produced after the
induction of JAK/STAT pathway (Figure S2). During this cycle,
only SOCS-1 mediated downregulation of PICyts can be seen in
absence of IFN-b.
Signalling in sepsis
The continuous presence of pathogens or recurrent infections can
ignite rigorous immune responses in the host’s body [82]. Previous
experimental studies suggested the role of recurrent induction of
TLRs in persistent infections and sepsis [83,84]. In this study,
continuous induction of TLR4 was the only difference between the
set of logical parameters used for model septic and non-septic
signalling. Therefore, recurrent induction of TLR4, represented by
logical parameter (KTLR4 fSOCS{1, NFkBgð Þ~1), was used
with other logical parameters of entities given in Table 1 to model
the sepsis related signalling. Model related to sepsis has been
provided as File S2. Dynamics of the BRN were studied in the form
of a state graph, which was merged in Figure 3 for the purpose of
comparison. In Figure 3, red highlighted states in squares and
dotted trajectories represent the additional states and trajectories
produced during septic signalling whereas common states and
trajectories both in non-septic and septic systems are shown in black.
Unlike non-septic TLR4 and JAK/STAT signalling, new events
of recurrent TLR4 induction (trajectories 00000?10000, labelled
with ‘‘g’’ and 00010?10010, labelled with ‘‘h’’) and the absence
of stable state ‘‘00000’’ were observed as characteristics of sepsis.
Overall, two phases of signalling were observed in the state graph
shown in Figure 3. The first phase of signalling was comparable to
non-septic signalling whereas the second phase of signalling
represented a late phase of signalling dynamics produced due to
repetitive TLR4 induction. In this phase, TLR4 was re-induced
during pre-existing levels of PICyts (trajectory 00010?10010
labelled with ‘‘h’’). Later to which, influence of IFN-b or SOCS-1
tolerated the levels of PICyts with subsequent degradation of
PICyts. Comparatively, most of the states in the late phase of
dynamics represented immunosuppression due to the presence of
both IFN-b and SOCS-1.
Induction of NFkB as in the trajectory (10010?10110 labelled
with ‘‘k’’ in Figure 3) was the only trajectory, which strengthened
the levels of PICyts and led the system to overactive immune
response (state ‘‘00121’’) in the late phase of signalling. However,
all the trajectories ultimately led the system towards downregu-
lated immune response (state ‘‘00000’’). Subsequent activation of
the new round of TLR4 mediated signalling after the state
‘‘00000’’ represented the recurrent induction of TLR4 (transition
labelled with ‘‘g’’) in absence of any other downstream proteins.
In summary, the phenomenon of oscillation was present repre-
senting activation and inactivation of PICyts during complete
dynamics related to the condition of sepsis along with the
suppressed expression levels of PICyts in late phase of signalling
dynamics of the BRN.
Interventions in signalling
Mutations and/or therapeutic interventions can change the role
of resources with subsequent changes in the dynamics of the BRN
(see Definition 4 in methods section). Interventions were modelled
by removing one or more interactions associated with any entity
present in the BRN (Figure 2) to reproduce mutations or
therapeutic interventions. The effects of interventions in IFN-b,
SOCS-1, NFkB and PICyts mediated signalling were compared
both in septic and non-septic signalling to elaborate their
importance in the dynamics of the BRN. These interventions
are discussed as ‘‘CASES’’ and changes in logical parameters are
mentioned in Table 3. Other possible interventions, given in
Table S1, were also analysed to observe their overall effects on the
system in terms of stable states produced by each type of
intervention.
CASE 1 (Intervention in SOCS-1 mediated downregulation
of PICyts). Intervention in SOCS-1 mediated downregulation of
PICyts during non-septic signalling is discussed as CASE 1-N
whereas in case of sepsis, it is discussed as CASE 1-S. Modelling of
CASE 1-N was performed using the logical parameters given in
Table 1 except with some changes as given in Table 3. The model
is provided as File S3. Figure 4 represents the state graph produced
due to the simulation of CASE 1-N. In this case, two stable states
were observed including downregulated or normal (state ‘‘00000’’)
and overactive PICyt levels (state ‘‘00121’’). The overall dynamics of
the system were found comparable to the non-septic signalling (as
shown in Figure 3) but some trajectories involving SOCS-1
mediated inhibition of PICyts were different (trajectories labelled
with ‘‘De’’ in Figure 4). In those trajectories, SOCS-1 mediated
inhibition of PICyts was suppressed and permitted continuous
activation of PICyts with subsequent induction of JAK/STAT
pathway (stable state ‘‘00121’’). These trajectories were also found
opposite in directions from those observed in non-septic signalling
(trajectories labelled with ‘‘e’’ in Figure 3); where SOCS-1 mediated
downregulation of PICyts led the system towards stable state
‘‘00000’’. IFN-b mediated downregulation of PICyts in CASE 1-N
was found ineffective to reduce the levels of PICyts because IFN-b
performed its inhibitory role in the earlier part of the dynamics
(trajectories labelled with ‘‘c’’ in Figure 4). Moreover, PICyts was
capable enough to induce SOCS-1 mediated inhibition of IFN-b
which results in its continuous inactivated state during later stages of
the signalling. Thus higher levels of PICyts led the system to
overactive immune response (trajectories labelled with ‘‘d’’ in
Figure 4).
It was observed that the system evolved mostly towards stable
state ‘‘00000’’ in absence of activated TLR4. This condition was
true except for those states in which NFkB and PICyts were
present simultaneously in the system (downstream signalling
dynamics after states 10111,00110,00111 and 10120 labelled with
stars in Figure 4). All of these states had a higher probability to
produce overactive immune state (stable state ‘‘00121’’) in the
system. The presence of homeostasis in the state graph was found
comparable to SCC-1 (Figure S1) whereas SOCS-1 mediated
downregulation and homeostasis in PICyts levels was absent.
States and trajectories related to CASE 1-S were incorporated
in Figure 4. Model of CASE 1-S is provided as File S4. Overall,
dynamics of the BRN in CASE 1-S were found similar to the
CASE 1-N but some of the trajectories involving re-activation of
TLR4 were found different (trajectory labelled with ‘‘g’’ in
Figure 4). Instead of two stable states as seen in CASE 1-N, only
one stable state ‘‘00121’’ was found in CASE 1-S. New events of
recurrent TLR4 induction (trajectories 00000?10000, labelled
with ‘‘g’’ and 00010?10010, labelled with ‘‘h’’) were comparable
to signalling in sepsis without any intervention as shown in
Figure 3. Unlike signalling in sepsis without any interventions,
SOCS-1 did not play its part in late phase signalling dynamics.
Induction of IFN-b in the late phase of septic signalling was also
found ineffective to attenuate the overactive immune responses in
the absence of SOCS-1.
CASE 2 (Intervention in SOCS-1 mediated downregulation
of IFN-b and PICyts). One of the important effects on the
dynamics of the BRN would be the complete loss of SOCS-1
mediated inhibition of IFN-b and PICyts so that their levels could
be elevated. To evaluate this, intervention in SOCS-1 mediated
inhibition of IFN-b and PICyts was executed. Intervention in non-
septic state is discussed as CASE 2-N, whereas this intervention in
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case of sepsis is discussed as CASE 2-S. Dynamics of the BRN in
these CASES are shown as a state graph in Figure 5. Modelling was
performed using the logical parameters given in Table 1 along with
certain modifications (Table 3). Moreover, respective edges, which
represent SOCS-1 mediated inhibition of IFN-b and PICyts in
Figure 2, were also removed.
Model of CASE 2-N is provided as File S5. The dynamics of the
BRN produced in CASE 2-N were found comparable to non-
septic case (Figure 3) except those trajectories which reflected
SOCS-1 mediated inhibition of IFN-b and PICyts (trajectories
labelled with ‘‘Dd’’ and ‘‘De’’, respectively in Figure 5). Trajec-
tories labelled with ‘‘Dd’’ and ‘‘De’’ were found opposite in the
direction as compared to their counterparts in non-septic
signalling (Figure 3). Stable states ‘‘00000’’ and ‘‘00121’’ were
comparable to those found in CASE 1-N. Similar to other state
graphs discussed above, the simultaneous presence of NFkB-JAK/
STAT and PICyts led the trajectories mostly towards elevated
levels of PICyts even in the absence of SOCS-1 mediated
inhibition of IFN-b. Homeostatic downregulation was seen
comparable to SCC-1 (Figure S1), whereas another homeostasis
produced during non-intervened signalling (SCC-2) was abolished.
Signalling in CASE 2-S was incorporated into the Figure 5 and
its model is provided as File S6. In this CASE, most of the states
and trajectories associated with sepsis were found comparable to
those in CASE 2-N. Only one stable state ‘‘00121’’ was found in
CASE 2-S, whereas another stable state ‘‘00000’’ led the dynamics
of the BRN towards recurrent induction of TLR4 like other sepsis
related dynamics in this study. New events of recurrent TLR4
induction (trajectories 00000?10000, labelled with ‘‘g’’ and
00010?10010, labelled with ‘‘h’’) were similar to the sepsis related
non-intervened dynamics of the BRN (Figure 3). However, in this
CASE, SOCS-1 could not play its inhibitory role in late phase
signalling dynamics. Moreover, interventions in SOCS-1 mediated
inhibition of IFN-b produced similar results as seen in CASE 1-S
due to the activated levels of TLR4.
CASE 3 (Intervention in IFN-b mediated downregulation
of PICyts). Intervention in IFN-b mediated inhibition of PICyts
during non-septic and septic conditions are discussed as CASE 3-
N and CASE 3-S, respectively. These CASES were used to
evaluate the dynamics of the BRN and consequential immune
responses in the absence of IFN-b mediated inhibition of PICyts.
Intervention was derived by removing the inhibitory edge from
IFN-b to PICyts as given in Figure 2. Modelling was performed
using the logical parameters given in Table 1 with some
exceptions given in Table 3 for CASE 3-N and CASE 3-S.
Models of CASE 3-N and CASE 3-S are also provided as File S7
and File S8, respectively). A state graph of CASE 3-N is shown in
Figure 6.
Only one stable state ‘‘00000’’ was observed during the
dynamics of the BRN associated with CASE 3-N. It was observed
that IFN-b mediated inhibition of PICyts during earlier phase of
signalling was abolished from the system (trajectories labelled with
‘‘Dc’’ in Figure 6). This interaction was speculated to resist the
elevated levels of PICyts as seen above in Figures 3–5. However,
the elevated levels of PICyts were downregulated by SOCS-1
when IFN-b was unable to inhibit PICyts.
Homeostatic signalling in CASE 3-N (SCC-3) was similar to
that produced during the dynamics of non-septic model (SCC-1),
however, trajectories were slightly shifted towards elevated levels of
PICyts (Figure S3). Homeostasis during overactive PICyts (state
‘‘00121’’) was observed in the presence of SOCS-1 (SCC-4 and
SCC-5 shown in Figure S4 and Figure S5, respectively), which
represents that even in the absence of IFN-b, SOCS-1 cater the
inhibition of PICyts.
Signalling in CASE 3-S was integrated in the state graph
produced by CASE 3-N (Figure 6). Most of the trajectories and
nodes were found common except those which involved re-
activation of TLR4, as discussed above. Late phase IFN-b
mediated downregulation of PICyts during septic signalling was
not found.
CASE 4 (intervention in NFkB mediated induction of
PICyts). NFkB mediated induction of PICyts has been targeted
in various experimental studies [85,86]. This targeting was
performed either by degrading the complex of NFkB or by
compromising the resultant gene transcription pathway. The
model was evaluated for this intervention by removing the NFkB
mediated induction of PICyts as given in Figure 2. To model this
intervention, logical parameters given in Table 1 were used with
some exceptions given in Table 3. This intervention in non-septic
and septic signalling are discussed as CASE 4-N and CASE 4-S,
respectively. The models of CASE 4-N and CASE 4-S have been
provided as File S9 and File S10, respectively. Simulation of CASE
4-N resulted in a single normal stable state (00000) with the
absence of PICyts throughout the system (Figure 7). Homeostasis
(SCC-6) was seen only between IFN-b and SOCS-1 (Figure S6).
Dynamics of the BRN produced in CASE 4-N and CASE 4-S
were comparable except the recurrent induction of TLR4, as
discussed above. The results implicate that an immune response
could neglect the elevated endotoxemia and allow the pathogen to
infect within the immunocompromised host due to the complete
absence of PICyts.
CASE 5 (intervention in PICyts mediated induction of
NFkB and JAK/STAT pathway). Intervention in PICyts
mediated induction of NFkB and JAK/STAT pathway during
non-septic signalling is discussed as CASE 5-N whereas in case of
sepsis, it is discussed as CASE 5-S. Modelling of CASE 5-N and
CASE 5-S were performed using the logical parameters given in
Table 1 with exceptions given in Table 3. Moreover, the edge
from PICyts towards NFkB-JAK/STAT, as shown in Figure 2,
was also removed. The models of CASE 5-N and CASE 5-S have
been provided as File S11 and File S12, respectively. The
dynamics of both CASES are shown in Figure 8. Events during
the simulation of CASE 5-N were slightly different from non-septic
signalling (shown in Figure 3), in terms of loss of PICyts mediated
induction of JAK/STAT pathway. Moreover, the higher levels of
PICyts were not observed throughout the state graph, however,
normal levels of PICyts were present. Stable state ‘‘00000’’ was
present in CASE 5-N, however, in CASE 5-S, this state led
towards recurrent induction of TLR4 (trajectories 00000?10000,
labelled with ‘‘g’’). Homeostasis due to the cyclic paths SCC-7 and
SCC-8 in CASE 5-N were found comparable to SCC-1 and SCC-
2 (Figures S7 and Figure S8) except that elevated levels of PICyts
were not observed within any cycle.
Discussion
Methods of high throughput gene expression profiling facilitate
the description of complex cellular regulatory networks and
present pictures of valuable information about the signalling
networks [87,88]. Regardless of the enormous amount of data
associated with molecular and cellular processes produced in
various settings, the dynamicity of biological networks in the
presence of several interconnected factors still need to be further
explored [89]. ‘‘Computational systems biology’’ is a discipline,
which is concerned with modelling of experimentally determined
values to improve our understanding about BRNs [90]. Compu-
tational modelling of BRNs provide useful information about
dynamics of various signalling pathways, including control of
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differentiation process in helper T cells, control of organ
differentiation in Arabidopsis thaliana flowers, segmentation
during embryogenesis in Drosophila melanogaster and TLRs
mediated signalling [51–53].
Sepsis is a complex pathological state of the body, which
involves heterogeneous immune responses of exacerbated inflam-
mation and immunosuppression [82]. Pathophysiology of the
sepsis has been associated with pro- or anti-inflammatory
responses in different scientific studies, which led to the
inconsistency of the overall findings, and failure in its treatment
[4]. Some studies associated the deaths in the early phase of sepsis
with unrestricted and irrational SIRS in the host [91] and impelled
anti-inflammatory treatments [92,93]. On the other hand, it has
also been hypothesized that SIRS is followed by CARS [4,94,95].
Moreover, concomitant production of pro- and anti-inflammatory
responses have also been demonstrated in polymicrobial infectious
challenges, which support the continuous, highly mixed anti-
inflammatory response (MARS) and implicated that both pro- and
anti- inflammatory cytokines are integral parts of sepsis [96,97].
TLR4 is a central mediator of LPS induced TH1 or
proinflammatory responses, whereas induction of inhibitory
mediators can lead the system towards downregulated levels of
PICyts [98]. Moreover, binding of cytokines to JAK/STAT
receptors induce changes in gene expression levels of various other
co-factors necessary for the downregulation of immune response
[30]. In order to study the mechanism of sepsis at cellular level, we
evaluated the qualitative roles of TLR4 and JAK/STAT signalling
with their negative and positive feedback loops necessary to
produce effective immune response.
TLR4 and JAK/STAT mediated signalling was designed in the
current study by incorporating previous experimental studies
associated with interaction of entities and their overall effect in
case of sepsis (Figure 1). Reduction of the model was performed to
reduce the possible states and trajectories produced during
qualitative modelling (Figure 2). In this process, roles of resources
in logical parameters were carefully devised so that useful
information about the role of any entity present in the model
should not be lost. The model was further used with different sets
of logical parameters to produce non-septic, septic and intervened
signalling to produce dynamics in the form of state graphs. The
results of non-septic signalling (Figure 3) were used to compare
any interpretations present in this study.
State graphs produced in non-septic signalling were found
different from signalling during sepsis in terms of recurring
signalling and activation of IFN-b and SOCS-1 in the late phase,
which may reflect the immunosuppressive state of the septic
patient in the later stages of sepsis. In non-septic signalling,
induction of TLR4 and subsequent JAK/STAT signalling mount
a successful immune response, which ultimately culminates in
downregulated immune response. However, during sepsis, absence
of stable state ‘‘00000’’ and recursive signalling through state
‘‘00121’’ can be correlated with the phenomenon of SIRS.
Induction of TLR4 mediated MyD88 and TRIF dependent
signalling produced different responses. MyD88 dependent
signalling was associated with early induction of PICyts whereas
TRIF dependent signalling was associated with late induction of
PICyts through Myd88 independent mechanism. This type of
early PICyts and delayed IFN-b inductions have been suggested in
previous experimental studies associating the time of their onsets in
response to pathogen induced immune reaction [99]. Delayed
activation from previous experimental studies suggested that IFN-
b was produced 24 hours later to Listeria monocytogenes infection
[100]. Moreover, IFN-b has been observed to attenuate the late
hyperinflammatory responses in septic peritonitis [27]. Our study
implicates that induction of IFN-b may be present in two stages of
septic signalling. In the first stage, IFN-b regulates the levels of
PICyts before the induction of SOCS-1, whereas in second stage
IFN-b can be induced and downregulate PICyts in late phases of
sepsis. Chances for the induction of IFN-b and SOCS-1 were
found equal in the late phase of the dynamics of the BRN
associated with sepsis and due to this in late phase dynamics of
sepsis, there are fewer chances for activation of PICyts to higher
levels.
Sequential production and then downregulation of PICyts was
observed as one of the interesting phenomenon. The swing in the
expression levels of PICyts has already been reported which
revealed the pro-inflammation with subsequent immunosuppres-
sion [13]. In our study, proinflammatory state can be correlated
with those states which had higher activation levels of PICyts
(qualitative level ‘‘2’’) whereas immunosuppression can be
correlated with lower levels of PICyts (qualitative level ‘‘0 or 1’’).
SOCS-1 mediated inhibition of PICyts through inactivation of
JAK/STAT signalling was found intriguing in the management of
immunosuppression. While, inactivation of TLR4 and NFkB
mediated induction of PICyts was associated with management of
hyperinflammatory responses. This may suggest that therapeutic
strategies during the course of sepsis should be devised according
to the immune responses and expression levels of SOCS-1 and
IFN-b as discussed in other studies for their role in sepsis
[31,47,82].
In vitro studies suggested that recurrent induction of TLR4
through LPS challenge result in the decreased immune response
known as LPS tolerance [101]. Our study suggests, that late phase
induction of both SOCS-1 and IFN-b may play their roles in LPS
tolerance and can produce immunosuppression. Moreover,
tolerance may be related with complete absence of PICyts levels
even in the continuous signalling through TLR4.
Intervened signalling presented some of the interesting assump-
tions produced during this study. Mutations or therapeutic
intervention of SOCS-1 mediated inhibition of JAK/STAT
signalling may result in the non-reversible hyperinflammatory
process compared to any other intervention studied here.
Moreover, the presence of SOCS-1 can balance the levels of
PICyts even during incapable IFN-b mediated inhibition. On the
other hand, if non-reversible immunosuppression is required, then
intervention of NFkB mediated PICyts expression would produce
competitive results.
The overall dynamics of the BRN have been given in Figure 9-
A to show the pattern of activation and inactivation of entities. It
can be seen that starting from the activation of TLR4, the
dynamics actually proceed greatly towards the activation of IFN-b
and then SOCS-1 during normal signalling. However, in the case
of recurrent signalling, the activation of IFN-b and SOCS-1 at the
same time inhibit the activation of PICyts. Based on these
predictions, we hypothesize that in normal infections, which do
not often lead to sepsis, the phases of regulatory signalling are
somewhat different from those seen in case of sepsis as shown in
Figure 9 (B–C). This is supported by previous experimental studies
in which the continuous presence of pathogens repeatedly induce
immune responses and produce oscillatory levels of PICyts [102].
Recurrent infections, which can lead to sepsis, have the capability
to induce innate immune responses repeatedly. During this state,
PICyts are inhibited to a greater extent which can lead the
immune system of the host towards the temporary immunocom-
promised state. Inhibition may be due to the prior presence of
negative regulatory factors such as SOCS-1 and IFN-b in the
system, which may be induced in some earlier phase of infection or
because of a co-infection. Due to this reason, innate immune
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response may not efficiently generate an effective PICyts burst to
manage the pathogen load. Moreover, the expression pattern of
negative regulators such as SOCS-1 and IFN-b can be detrimental
in case of sepsis. In normal infections, the pattern of IFN-b and
SOCS-1 is sequential, whereas in case of sepsis, this sequential
pattern of IFN-b and SOCS-1 may be changed and system
becomes more vulnerable towards higher levels of pathogen load
due to compromised levels of PICyts.
Conclusion
In summary, logical modelling of TLR4 and JAK/STAT
dependent signalling pathways indicated specifically designed
crosstalk mechanism which can induce a successful pathogenic
response along with management of hyperinflammation. If entities
present in these pathways lose a specific pattern of activation and/
or inactivation, then signalling can lead towards diverse outcomes.
Using computer-aided qualitative approach, we have tried to
highlight these patterns of entities necessary to maintain a balance
in a successful immune response. Qualitative results implicated
that TLR4 and JAK/STAT pathways induced elevated levels of
PICyts with subsequent downregulation. This pattern of activation
and then inactivation of PICyts produced homeostasis in the
system while changes in the inhibitory role of SOCS-1 created
overactive immune responses. The inhibitory role of IFN-b was
observed during the initial stages of dynamics, but it is tempting to
speculate that SOCS-1 possibly inhibit the role of IFN-b during
sepsis but has the ability to manage the hyperinflammatory
condition. Overall, this study suggests that intervention in SOCS-1
mediated PICyts inhibition may produce useful results in case of
immunocompromised septic patients. On the other hand,
intervening the TLR4 or PICyts mediated induction of NFkB-
JAK/STAT pathways may be used for the management of
hyperinflammatory immune responses. This computational study
highlighted many questions with provision of possible answers,
which need further experimental investigations. In the future, we
will perform in vitro experiments to further investigate our
predictions and produce explicit insights into the diagnosis and
treatment of sepsis by involving IFN-b and SOCS-1.
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a  b  s  t  r  a  c  t
A  number  of  diseases  including  sepsis,  rheumatoid  arthritis,  diabetes,  cardiovascular  diseases  and
hyperinﬂammatory  immune  disorders  have  been  associated  with  Toll  like  receptor  (TLR)  2  and  TLR4.
Endogenous  adaptor  protein  known  as  MyD88  adapter-like  protein  (MAL)  bind  exclusively  to  the cyto-
solic  portions  of TLR2  and  TLR4  to  initiate  downstream  signalling.  Brutons  tyrosine  kinase  (BTK)  and
protein  kinase  C  delta  (PKCı)  have been  implicated  to phosphorylate  MAL and activate  it to  initiate
downstream  signalling.  BTK  has been  associated  with  phosphorylation  at positions  Tyr86  and  Tyr106,
necessary  for  the  activation  of MAL  but  deﬁnite  residual  target  of PKCı  in MAL  is  still to  be explored.
To produce  a better  understanding  of the  functional  domains  involved  in  the  formation  of  MAL–kinase
complexes,  computer-aided  studies  were  used  to  characterize  the  protein–protein  interactions  (PPIs)  of
phosphorylated  BTK and  PKCı  with  MAL.  Docking  and  physicochemical  studies  indicated  that  BTK was
involved  in  close  contact  with  Tyr86  and  Tyr106  of  MAL  whereas  PKCı  may  phosphorylate  Tyr106  only.
Moreover,  the  electrostatics  charge  distribution  of  binding  interfaces  of  BTK  and  PKCı were  distinct  but
compatible  with  respective  regions  of MAL.  Our results  implicate  that  position  of  Tyr86  is  speciﬁcally
phosphorylated  by  BTK  whereas  Tyr106  can be  phosphorylated  by competitive  action  of both  BTK  and
PKCı.  Additionally,  the residues  of  MAL  which  are  necessary  for interaction  with  TLR2, TLR4,  MyD88
and  SOCS-1  also  play  their  roles  in  maintaining  interaction  with  kinases  and  can be  targeted  in  future  to
reduce  TLR2  and TLR4  induced  pathological  responses.
© 2014  Elsevier  Ltd.  All  rights  reserved.
1. Introduction
There are about 10 different types of TLRs which belong to a
family of transmembrane proteins and super-family of interleukin-
1 receptor/Toll-like receptors (Trinchieri and Sher, 2007; Takeda
and Akira, 2005). Pathogen associated molecular patterns (PAMPS)
attach with the extracellular portion of TLRs and initiate innate
immune responses (Bianchi, 2007). In case of TLR2 and TLR4, PAMPS
bind with the extracellular portion of TLRs and induce oligomeri-
zation of their juxtamembrane parts followed by dimerization of
∗ Corresponding author. Tel.: +92 3339191903.
∗∗ Corresponding author.
E-mail addresses: amjad uni@yahoo.com (A. Ali),
jamil.ahmad@rcms.nust.edu.pk (J. Ahmad).
their cytosolic portions known as Toll/interleukin-1 receptor (TIR)
domains (Trinchieri and Sher, 2007). TLR2 makes heterodimer with
TLR1 or TLR6 whereas homo-dimerization takes place between
two TLR4s to initiate downstream signalling (Farhat et al., 2008;
Lu et al., 2008; Nez Miguel et al., 2007). TIR domains have been
reported for their importance to induce downstream signalling by
recruiting other TIR domain containing adaptor proteins such as TIR
domain-containing adapter inducing Interferon (IFN)-ˇ, known as
TLR adaptor molecule 1 (TICAM-1 or TRIF), TRIF-related adaptor
molecule, known as TLR adaptor molecule 2 (TICAM-2 or TRAM),
myeloid differentiation factor 88 (MyD88) and MyD88-adaptor-
like protein (TIRAP or MAL)(Fitzgerald et al., 2003; Yamamoto and
Akira, 2005; Kawai et al., 1999; Gray et al., 2006).
TIR domains mostly consists of ﬁve parallel ˇ-sheets, desig-
nated as ˇA–ˇE surrounded by 5 ˛-helices, termed as ˛A–˛E
(Xu et al., 2000). Both of these secondary structures are linked
http://dx.doi.org/10.1016/j.compbiolchem.2014.04.001
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by loops of variable lengths, which provide speciﬁcity to TIR–TIR
domain interactions with different TLRs and their adaptor pro-
teins. Different TLRs recruit individual adaptor proteins. Among
others, TLR2 and TLR4 have the ability to recruit MAL  protein. For-
mation of MAL–MyD88 complex with either TLR2 or TLR4 dimers
have been implicated for the induction of nuclear factor  B (NFB)
and mitogen-activated protein kinase (MAPK) dependent induction
of pro-inﬂammatory cytokines such as interferon (IFN)  , tumour
necrosis factor (TNF) ˛, interleukin (IL) la, IL1  ˇ and IL6 (Dinarello,
2000). MAL  has been also found in association with other mul-
tiple regulatory events after interacting with plasma membrane,
interleukin-1 receptor-associated kinase (IRAK)-1, IRAK-2, IRAK-
4, TNF-receptor-associated factor (TRAF) 6, suppressor of cytokine
signalling protein (SOCS)-1, BTK and PKCı (Kagan and Medzhitov,
2006; Verstak et al., 2009; Dunne et al., 2010; Muzio et al., 1997;
Mansell et al., 2006).
Phosphorylation of tyrosine (Tyr) residues in MAL  have been
suggested as an important event for the activation of MAL  and for
TLR2 and TLR4 downstream signalling (Piao et al., 2008). BTK, a Tec
family tyrosine kinases, has been observed to induce phosphory-
lation at positions Tyr86 and Tyr106 of MAL  (Gray et al., 2006). It
has been associated with pathological conditions in case of autoim-
munity and TLR mediated hyperinﬂammatory responses (Ahmad
et al., 2012; Barral, 2013). Study of Kubo-Murai et al. suggested the
involvement of PKCı in TLR4 signalling through phosphorylation
of TIR domain of MAL  (Loegering and Lennartz, 2011; Kubo-Murai
et al., 2007). However, site of phosphorylation is yet to be deter-
mined. Phosphorylation at sites Tyr159 and Tyr187 have also been
associated with activation of MAL, but the available data is con-
troversial (Gray et al., 2006; Piao et al., 2008). Mutagenic studies
of MAL  at positions 96, 100, 108,115, 117, 121, 132, 143, 165, 180,
184, 190 and 197 are suggested for their possible roles in loss of the
function of MAL  (Nagpal et al., 2009; Khor et al., 2007; Fitzgerald
et al., 2001). This phenomenon suggests that with modulating the
structure of MAL, immune disorders related with TLR2 and TLR4
can be controlled.
Previous study of our group was about the characterization of
PPI of MAL  with MyD88 and SOCS-1 (Niazi et al., 2011). In extension,
current study is presented for characterization of the possible inter-
action sites of MAL  with BTK and PKCı. The ﬁndings of the studies
suggest that BTK may  speciﬁcally be involved in the phosphoryla-
tion of Tyr86 whereas, BTK and PKCı can play their competitive
roles in the phosphorylation of Tyr106. Moreover, several sites
reported for the loss of function are also discussed for their pres-
ence in binding interfaces and support the interaction of BTK and
PKCı with MAL, which can affect not only the interaction of MAL
with TLR2, TLR4, MyD88 or SOCS-1 but can also affect the phos-
phorylation of MAL  and may  result into partial or complete loss of
its activation.
2. Materials and methods
2.1. Loop modelling of MAL
The AB loop in crystal structure of human TIR domain
(residues 80–221) of MAL  (PDB ID: 3UB2-crystal structure of
TIR domain of MAL/TIRAP) deposited in protein data bank (PDB)
(www.rcsb.org/pdb) was not resolved due to its ﬂexible nature (Lin
et al., 2012). So the AB loop was modelled using MODELLER (Eswar
et al., 2006) and 100 loop models were generated. Loop conﬁr-
mations were reﬁned using 500 steps in variable target function
method (VTFM) with conjugate gradients (CG), and then use slow
reﬁnement in molecular dynamics (MD) with simulated anneal-
ing (SA) reﬁnement stage as implemented in MODELLER (Sali and
Blundell, 1994). Optimizations were repeated three times for the
generation of loop models. Models were clustered into groups
based on root mean square distance (RMSD) between correspond-
ing residues of each structure using NMRCLUST (Kelley et al., 1996).
Clustered models were evaluated for the selection of representative
model. ERRAT score (Colovos and Yeates, 1993), Verify3D (Bowie
et al., 1991), potential energy of complete structure and of AB loop,
Ramachandran plot (Ramachandran et al., 1963), and energy score
calculated by MODELLER were used as criteria for evaluation of
models.
2.2. Modelling of phosphorylated PKC delta
The sequence of catalytic domain of PKCı (Phe349-Lys669)
was obtained from Uniprot (www.uniprot.org) (ID No. Q05655).
Sequence was  submitted to NCBI provided protein speciﬁc iteration
(PSI)-BLAST facility to obtain the homologous sequences of three
dimensional (3D) structures present in PDB. Two structures includ-
ing PDB IDs: 1XJD (crystal structure of kinase domain of human PKC
theta (PKC) complexed with Staurosporine resolved at 2 A˚) (Xu
et al., 2004) and 2JED (crystal structure of kinase domain of human
PKC in complex with Nvp-Xaa228 resolved at 2.32 A˚) have maxi-
mum  sequence identity and smallest distance on the phylogenetic
tree from kinase domain of human PKCı. These 3D structures were
used as templates for the homology modelling of PKCı. 3D-Coffee
was used for the structural alignment among the sequences of PKCı
and its templates (Poirot et al., 2004). MODELLER was  used for the
homology modelling of PKCı. One hundred models were produced,
which were clustered into groups according to RMSD between
corresponding residues in their structures using NMRCLUST. Rep-
resentative models were selected from each cluster based on scores
provided by ERRAT, Qmean, PROSA (Wiederstein and Sippl, 2007),
PROCHECK (Laskowski et al., 1993), Ramachandran plot, MOD-
ELLER and their potential energies. Glycine rich phosphate-binding
loop (GPL) was  reﬁned using loop modelling module as imple-
mented in MODELLER. Tyrosines at position 374 and 567, serines
at positions 503,645, 654, 658 and 664 and threonine at position
507 were mutated to their phosphate group derivatives by using
Chemistry at HARvard Molecular Mechanics (CHARMM) provided
TP2, SP2 and THP2 patches, respectively, by MODELLER (Patel et al.,
2004).
2.3. Structure of phosphorylated BTK (pBTK)
Crystal structure of kinase domain of BTK was  obtained from
PDB deposited under ID: 1K2P (crystal structure of Bruton’s tyro-
sine kinase domain resolved at 2.1 A˚) (Mao  et al., 2001). Structure
was phosphorylated at sites Tyr551, Tyr617, Ser623 by using the
same procedure as adopted in case of phosphorylating the residues
in model of pPKCı. Structure was protonated in Molecular Oper-
ating Environment (MOE) software (Chemical computing group’s
MOE  software, version 2013) using default parameters and utilized
for further analysis (Inc., 2013).
2.4. Preparation of structures
Visual molecular dynamics (VMD) and Not Another Molecular
Dynamics program (NAMD) were used to prepare the structures
before and after performing PPIs (Phillips et al., 2005; Humphrey
et al., 1996). CHARM22 force ﬁeld was  used to perform mini-
mization, equilibration and heating steps (MacKerell et al., 1998).
Parameters and force ﬁelds for modiﬁed amino acids were used as
provided by CHARMM. In each case of preparation of a structure,
box of TIP3P water molecules was  used as solvent. System was neu-
tralized by adding the physiological concentration of Na+ and Cl−
ions. Each system was subjected to minimization in stepwise man-
ner. First a 3000 steps of minimization were performed only for
water molecules and hydrogens atoms, ﬁxing the rest of the system,
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so that water molecules could easily enter the grooves of structures.
After the minimization of water and hydrogens of the system, 1000
steps of minimization were performed to the side chains of residues
to reduce local strains. Seven thousand steps were used to minimize
the backbone restraints followed by 10,000 steps of minimization
on the overall system. In minimization stage, the number of steps
were pre-calibrated for a point where the potential energy of each
system became constant. After minimization stage each structure
was heated from 0 K to 310 K (≈ body temperature) followed by
equilibration at 310 K for 300 ps.
2.5. Protein–protein interactions
PPIs of pBTK and pPKCı with MAL  were studied using GURU level
interface provided at High Ambiguity Driven biomolecular DOCK-
ing (HADDOCK) web-server (haddock.science.uu.nl) (De Vries et al.,
2010). HADDOCK web-server is driven on the approach of HAD-
DOCK that makes use of biochemical and/or biophysical interaction
data (Dominguez et al., 2003). It also offers protein–protein ab ini-
tio dockings based on random patch deﬁnition and centre of mass
restraints. The docking protocol support the solvated docking, auto-
matic deﬁnition of semi-ﬂexible regions and modiﬁed amino acids.
Scoring is based on the desolvation energy term and other statistics
including common contacts among cluster of complexes and RMSD
values of interfaces of each structure in a complex etc.
Possible residues of interfaces in each structure were predicted
using the CPORT (Consensus Prediction Of interface Residues in
Transient complexes) facility (de Vries and Bonvin, 2011). CPORT
combine six interface prediction algorithms including PINUP (Liang
et al., 2006), PIER (Kufareva et al., 2007), WHISCY (de Vries et al.,
2006), ProMate (Neuvirth et al., 2004), cons-PPISP (Chen and Zhou,
2005) and SPPIDER (Porollo and Meller, 2007) collectively into one
framework. It has been implicated that CPORT provides reliable
predictions for the residues which can be integrated into the HAD-
DOCK program.
Two regions of MAL  were used in the study of PPIs with kinases,
which were recursively docked in those regions. Among them one
region presents the CPORT predicted interface residues around
the Tyr86 of MAL  whereas another region presents the interface
residues around Tyr106 of MAL. Conﬁning the PPI of MAL with
kinases was supported by already known phosphorylation sites,
which can be used as interfaces for interaction with kinases.
2.6. Modelling of ATP in protein complexes
The modelling of ATP in complexes of pBTK and pPKCı with MAL
were performed to outline the distance of phosphorylatable atoms
in Tyr86 and Tyr106 from -phosphate of ATP. Present version of
HADDOCK webserver lack the capacity to calculate the PPIs in pres-
ence of any ligand or other biological small molecules. So modelling
of ATP in the structures of pBTK and pPKCı was performed after
PPIs.
Complexes of pBTK and pPKCı with MAL  were aligned to
structures of Abl tyrosine Kinase complexed with Adenosine
diphosphate (ADP), (PDB ID: 2G2I; a Src-like inactive conformation
in the abl tyrosine kinase domain) (Levinson et al., 2006) and struc-
ture of atypical PKC, i.e. PKC iota (PKC) complexed with ATP, (PDB
ID: 3A8W; Crystal structure of PKC iota kinase domain) (Takimura
et al., 2010), respectively, via automatic structural alignment in
MOE. The molecule of ADP in Abl tyrosine kinase was updated
to ATP by introducing a group of phosphate at ˇ-phosphate fol-
lowed by the energy minimization with Merck Molecular Force
Field (MMFF94) force ﬁeld (Halgren, 1996) implemented in MOE
before modelling of ATP in pBTK-MAL. Crystal structures of Abl
tyrosine kinase and PKC used for modelling of ATP in pBTK and
pPKCı were homologous to respective kinases.
At ﬁrst step, GPL of kinases and the surrounding residues
within an area of 9 A˚ of ATP in each complex were energy min-
imized to decrease the steric clashes and harmonic restraints.
In this case, the remainder structure and ATP were kept ﬁxed.
Finally, the molecule of ATP was energy minimized by keep-
ing the remainder structure ﬁxed. The energy minimizations
of protein structures and its parts were carried out using
CHARMM22 force ﬁeld whereas minimization of ATP was  per-
formed using MMFF94. Other programs including Jalview (Clamp
et al., 2004), Pymol (Schrödinger, 2010), PDBSUM (Laskowski,
2001), Swiss-PDB Viewer (Kaplan and Littlejohn, 2001), UCSF
Chimera (Pettersen et al., 2004), PISA server (www.ebi.ac.uk/msd-
srv/prot int/pistart.html) (Krissinel and Henrick, 2007) were used
for sequence and structural analysis. Delphi (Li et al., 2012) was
used for calculating the electrostatic charges on the surfaces of pro-
teins. Residual interactions were determined using default set of
parameters available in MOE.
3. Results
3.1. Loop models of MAL
The secondary structure of MAL  has been shown in Fig. 1. 3D
structure of TIR domain of MAL  (PDB ID: 3UB2) is composed of
ﬁve parallel ˇ-sheets including ˇA-ˇE and four ˛-helices (˛A and
˛C–˛E) (naming conventions of helices and sheets are used as in
ref (Lin et al., 2012)). Phosphorylatable residues, Tyr86 and Tyr106
are part of the strand ˇA and helix ˛A, respectively. Both of these
Fig. 1. TIR domain of MAL. (A) Sequence and secondary structure of the recently crystallized TIR domain of MAL  (PDB ID: 3UB2). Variants and phosphorylatable residues are
marked. (B) Topology diagram of the MAL  showing the ﬁve parallel ˇ-sheets and four ˛-helices. The secondary structure notation is based on the crystallized structure of
human MAL  protein as presented in (Lin et al., 2012).
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Fig. 2. Energy scores of loop models of MAL. (A) The molpdf energies are plotted against DOPE scores provided by the MODELLER for 100 loop models of MAL. (B) Potential
energies of complete models of MAL  against their AB loops are plotted against each other for 100 models generated through MODELLER. (C) Potential energies of template
structure (PDB ID: 3UB2) along with selected loop models of MAL  obtained after protonation and energy minimizations.
secondary structures are interconnected with a long loop known
as AB loop. In recently submitted crystal structure of MAL  (PDB ID:
3UB2), AB loop was absent possibly due to the inherent elasticity
(Lin et al., 2012). We  performed the comparative modelling of AB
loop using crystal structure of MAL  (PDB ID: 3UB2) as template
for the characterization of different domains and residues of MAL
involved in PPIs with pBTK and pPKCı.
One hundred loop models of the MAL  were generated using
MODELLER. Modelling of AB loop was performed in such a way
that carbon skeleton, orientation of side chains and disulphide link-
ages (Cys89-Cys134 and Cys142-Cys174) of models should remain
intact in original position as seen in the crystal structure of MAL
(PDB ID: 3UB2) except for AB loop. Graph of MODELLER reported
discrete optimized protein energy (DOPE) against molecular PDF
(molpdf) energies is shown in Fig. 2A, whereas graph of potential
energies of the complete structure against those of AB loop has been
shown in Fig. 2B. RMSD based clustering of the models resulted in
12 clusters among which 10 models had optimum RMSD values and
MODELLER reported energy scores. ERRAT quality factors for all of
the 10 models were in a range of ≈70–90 in comparison to the qual-
ity factor of 94 for template structure (PDB ID: 3UB2). After energy
minimization, models with ERRAT score >80 were assessed for the
potential energies of complete structure and of AB loop. Potential
energies of selected models in comparison to the template structure
(PDB ID: 3UB2) has been shown in Fig. 2C.
The MD  reﬁnement as implemented in MODELLER produced
two major conformational spaces for the intra-molecular interac-
tion of AB loop with remainder structure. Superimposed structures
of models can be seen in Fig. 3. In one of the conformational
mode (Fig. 3A: models 1 and 2), the AB loop was slanted towards
˛E helix and participated in the residual interaction with helix
˛E (Figure S1). Hydrogen and hydrophobic interactions stabilized
the orientation of AB loop with ˛E helix and thus the Tyr86 and
Tyr106 were solvent accessible and took part in interaction with
Fig. 3. Loop models of MAL. (A) Cartoon of superposed models 1 and 2 reﬂect the conformations of AB loop towards ˛E helix. Tyr86 and Tyr106 are solvent exposed as ridges
in  these models. Figures on the upper right side reﬂects the two  dimensions of superposed models 1 and 2 with mesh surfaces. (B) Cartoon of superposed models 3–10 which
reﬂects the conformations of AB loop sequestered away from ˛E helix. Buried areas of Tyr86 and Tyr106 can be seen in lower right side mesh surface diagrams of models
3–10.
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Fig. 4. Energy scores of homology models of pPKCı. (A) The molpdf energies are plotted against DOPE scores provided by the MODELLER for 100 homology models of pPKCı.
(B)  Potential energies of 10 selected models of pPKCı having lowest energies. Model 1 was selected for further analysis.
kinases (discussed below). Moreover, electrostatic surface analy-
sis revealed that Tyr86 and Tyr106 were exposed as ridges and
projected as putative sites for interaction with ATP (explained
below). Whereas in another conformational mode (Fig. 3B: mod-
els 3–10), AB loop was oriented in opposite direction to the 1st
mode of its conformation and sequestered away from ˛E helix.
Intra-molecular interactions of AB loop with other residues were
comparatively fewer in number in models 3–10, which might
resulted in the increased ﬂexibility of AB loop. Moreover, analysis
of solvent exposed surfaces of these models presented that Tyr86
was buried under the AB loop and caused non-functional complexes
with kinases during pre-experimental exercises.
Supplementary Fig. S1 can be found, in the online version, at
http://dx.doi.org/10.1016/j.compbiolchem.2014.04.001.
Analysis of models with respect to energies revealed that lowest
energies models were model 1 and 2 which belong to 1st conforma-
tional mode and could be compared to crystal structure of MAL, in
terms of energies and ERRAT score. As our concern was  with the PPI
of MAL  by involving Tyr86 and Tyr106 with kinases, so we  proposed
to use the model 1 with solvent exposed Tyr86 and Tyr106.
3.2. Modelling of pPKC delta
Comparative modelling of catalytic domain of PKCı (residues
349–603) in phosphorylated form (pPKCı) was performed to eval-
uate its interaction with MAL. Crystal structures of PKC (PDB IDs:
1XJD and 2JED) were used as templates to create models. The
template structures were submitted in catalytically active form
but in the presence of ATP-competitive inhibitors (Staurosporine
and Nvp-Xaa228). These inhibitors induced changes especially in
the region of GPL. So the selected models of pPKCı were further
subjected to GPL reﬁnement for the adjustment of ATP in com-
plexes (See methods). In this section, we  present insights into
the selection of pPKCı model and its comparison with template
structures.
Using MODELLER, 100 models of catalytic domain of PKCı were
generated. MODELLER reported energies for all of the models have
been shown in Fig. 4A. These models were clustered into groups
using NMRCLUST and models were selected from each cluster.
Based on the scores provided by ERRAT, Qmean and MODELLER, 10
models were selected for further analysis. ERRAT scores for all of
the 10 models were in a range of ≈70–80 whereas the Qmean score
was in a range of ≈0.5–0.6, so the best models in terms of lower
energy values and higher ERRAT score were selected for prepara-
tion. After preparation, models were re-evaluated for the scores of
ERRAT, Qmean and their potential energies. Final selection of the
model was based on the highest ERRAT score which was increased
up to 95, Qmean score which was  increased up to 0.738 (Figure S2)
and potential energy which was  comparatively lower than those of
other models (Fig. 4B).
Supplementary Fig. S2 can be found, in the online version, at
http://dx.doi.org/10.1016/j.compbiolchem.2014.04.001.
Multiple sequence alignment (Fig. 5A) and superposition of
comparative structures of pPKCı with its template shown compa-
rable secondary structures of N (residues 349–431) and C-terminal
(residues 435–603) domains (Fig. 5B). N-terminal of pPKCı was
Fig. 5. Comparison of homology models of pPKCı with its template structure. (A) Multiple sequence alignment of pPKCı and PKC (template structure). Secondary structures
are  represented by arrows and cylinders which indicate the  ˇ strands and  ˛ helices, respectively. Residues of pPKCı which are dissimilar from the residues at same position
in  PKC are highlighted with light colour while similar residues (positive BLOSUM62 pairwise score) are highlighted with dark colour. Stars represent the phosphorylatable
sites  in pPKCı. (B) Superposed cartoon of pPKCı (light) with its template PKC (dark). Atoms of modelled ATP in the cavity of kinases are presented as balls.
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Fig. 6. HADDOCK provided scores for clusters 1–9 of pBTK–Tyr86:MAL. (A) Graph of scores provided by HADDOCK for top 9 clusters of pBTK–Tyr86:MAL. (B) Superposed
cartoon of top four conformations from each complex 1–9 of pBTK–Tyr86:MAL. pBTK is presented in light shaded cartoon while loop model of MAL is in dark shades.
composed of 2 ˛-helices (˛B and ˛C) and 5 ˇ-sheets (ˇ1–ˇ5)
whereas comparatively larger C-terminal lobe comprised of 8 ˛-
helices (˛D–˛K) and 3 strands of ˇ-sheets (ˇ6–ˇ8). Both of the
terminals were connected with residues of hinge linker (432–435).
Some of the important domains including GPL, helix-˛C, activa-
tion loop (residues 522–544), hydrophobic groove at N-terminal,
turn motif (residues 662–685), hydrophobic motif (HM) FXXFS at
C-terminal were analysed for the comparison among pPKCı and its
template.
Most of the intra-molecular residual interactions in pPKCı were
comparable to the corresponding interactions in its templates
except those of GPL. The GPL connects ˇ1 and ˇ2 strands of the
protein (residues 356–361) and make a ridge above ATP bind-
ing cavity. In crystal structures of PKC, GPL was slanted towards
its ligands and was stabilized by the interaction of Phe360 with
Lys378 (residues are numbered according to pPKCı). This interac-
tion produced clashes with the -phosphate moiety of ATP during
modelling of ATP in kinases (see Section 2). So loop reﬁnement
of GPL in pPKCı was performed to eliminate the interaction of
Phe360 with Lys378. Loop modelling implicated that GPL could
adopt extensive collection of orientations ranging from open to
closed conformations with respect to the ATP binding cavity. For
correct positioning of ATP inside the complexes, different confor-
mations of GPL were used and veriﬁed with modelling of ATP in
the cavity. The selected loop model for further analysis was used in
which no steric hindrances were seen among residues of GPL and
ATP.
Catalytic key residues including Lys378, Asp473, and Asp491
preserved the same molecular interactions as seen in its template
structures. The central helix-˛C and the activation loop share crit-
ical roles in catalytic activity of kinases. Proper alignment of helix
˛C and extended conformation of activation loop bearing the essen-
tial phosphorylated Thr507 (pThr507) validated the model as active
enzyme. Oxygen of the pThr507 made conserved interactions with
neighbouring residues except with Ala505. Moreover, the cationic
cluster formation by pThr507, with Arg472 and Lys496 was  intact
in the model of pPKCı and projected the correct orientation of
catalytic base Asp473, as seen in its templates. Inter-domain resid-
ual interaction among Glu497 of activation loop with Arg399 and
Glu392 of helix-˛C formed a similar double salt bridges as seen
in the template structures. The C-terminal hydrophobic motif con-
tains pSer664 on the same position as in the template, which might
performed comparable functions during the docking of pPKCı.
The orientation of HM preserved as seen in template. Turn motif
(631–654) in pPKCı was  observed extending across the ATP bind-
ing site and found comparable to its conformation as in template
structures.
3.3. Protein–protein interaction of pBTK with MAL  within an area
of Tyr86
Protonated structure of pBTK was docked with selected loop
model of MAL  using default settings at GURU interface of HADDOCK
web-server. CPORT predictions for active and passive residues of
pBTK and MAL  within a region of Tyr86 are shown in Figures S3 and
S4A, respectively. HADDOCK resulted into 166 water-reﬁned com-
plexes, clustered into 9 groups. Statistics provided by HADDOCK
for the top 9 clusters have been shown in Figure S5. HADDOCK
score for the best possible complex of pBTK within a region of
Tyr86 of MAL  (termed as pBTK–Tyr86:MAL) was  −13.4 ± 2.7, which
represented the highest probable complex among other predic-
tions. Cluster size, RMSD from the overall lowest-energy structure,
Van der Waals energy, electrostatic energy, desolvation energy,
restraints violation energy, buried surface area and Z-score of top
9 clusters are shown in Fig. 6. The top cluster was reﬁned for ori-
entation of molecules against each other to improve the HADDOCK
score. Statistics for the complexes formed after reﬁnement has been
shown in Figure S6. Cartoon of reﬁned complex of pBTK–Tyr86:MAL
has been shown in Fig. 7A which was  used for further analysis. Anal-
ysis of deformation of structures in terms of bond lengths, angles,
dihedrals, atomic clashes and contact energies of pBTK and MAL
implicated that structures maintained their reliability and quality
after PPIs through HADDOCK.
Supplementary Figs. S3-S6 can be found, in the online version,
at http://dx.doi.org/10.1016/j.compbiolchem.2014.04.001.
Analysis of intermolecular interactions among pBTK and MAL
in selected complex of pBTK–Tyr86:MAL presented that complex
was a result of 21 non-covalent bonding interactions. Among which
9 hydrogen bond, 5 ionic and 7 hydrophobic interactions were
observed among different residues of pBTK and MAL.
The selected complex of pBTK–MAL represented notable con-
formations of pBTK against MAL  in which -phosphate of ATP
modelled in pBTK (ATP:pBTK) (see Section 2) was  observed within
a distance of 3.1 A˚ from the phosphorylatable atom of Tyr86:MAL
(Fig. 7B). Moreover, the atoms of GPL were involved in making con-
tacts with strand-ˇB:MAL in vicinity of Tyr86 of MAL  (Tyr86:MAL).
Interaction of Gln412:GPL of pBTK with the Tyr86:MAL might
stabilized its position and helped in the ﬂexible transition of -
phosphate of ATP:pBTK towards its phosphorylatable atom. AB loop
of MAL  was  stabilized by the interaction of strand-ˇ3:pBTK involv-
ing Lys433 with Gly126:MAL. Helix-˛A of MAL was stabilized with
pBTK by involving salt bridges between Glu94:MAL with Arg487
and Lys595 of pBTK along with Leu97:MAL with Leu483:pBTK. Loop
among ˇB and ˇC strands in MAL  performed further interactions
with pBTK to stabilize the complex. In this interaction, Gln135
28 R.Z. Paracha et al. / Computational Biology and Chemistry 51 (2014) 22–35
Fig. 7. Complex of pBTK–Tyr86:MAL. (A) Cartoon of pBTK–Tyr86:MAL. Tyr86:MAL and ATP:pBTK are coloured black and labelled. pBTK is presented in light while loop model
of  MAL  is in dark shades. (B) Focused image of ATP binding site of pBTK which represents the closeness of -phosphate of ATP:pBTK situated within a region of 3.1 A˚ around
Tyr86:MAL. Both are presented in dots and sticks.
and Glu132 of MAL  made a salt bridge with the catalytic residue
Arg525:pBTK. Another salt bridge was observed between Ser138
and Ser139 of MAL  with Lys558:pBTK. Moreover, Leu133, Ala136
and Leu137 of MAL  invovled in interaction with Leu483, Asn603
and Trp563 of pBTK, respectively, to stabilize the complex. Helix-˛C
of MAL  was also found involved in the interaction with pBTK at the
loop between helix ˛E and ˛F. In this region, Asp154:MAL was  mak-
ing salt bridges with Lys595:pBTK. Additionally, the interaction of
Pro155:MAL with Arg600:pBTK and Trp156:MAL with Met596:BTK
stabilized the helix-˛C of MAL  with loop between helix ˛E and ˛F
of pBTK.
3.4. Protein–protein interaction of pBTK with MAL  within an area
of Tyr106
In this approach, the CPORT predicted interface residues of MAL
within a region of Tyr106 (Figure S4B) and for pBTK (Figure S3),
were used for analysing the PPI of pBTK with MAL. HADDOCK pro-
duced 191 complexes clustered into 4 groups. Statistics for the top
4 clusters have been shown in Figure S7. HADDOCK score for the
best possible complex of pBTK within a region of Tyr106 of MAL
(termed as pBTK–Tyr106:MAL) was −65.2 ± 5.8. Buried surface
area, Z-score, cluster size, RMSD from the overall lowest-energy
structure, Van der Waals, electrostatic, desolvation and restraints
violation energies for all clusters are shown in Fig. 8. The top clus-
ter was reﬁned for orientation of molecules against each other to
improve the overall scores of selected complex (Figure S8). Car-
toon of reﬁned complex of pBTK–Tyr106:MAL has been shown
in Fig. 9A which was used for further analysis. Analysis of defor-
mation of structures in terms of bond lengths, angles, dihedrals,
atomic clashes and contact energies of pBTK and MAL  implicated
that structures maintained their reliability and quality after PPIs
through HADDOCK.
Supplementary Figs. S7 and S8 can be found, in the online ver-
sion, at http://dx.doi.org/10.1016/j.compbiolchem.2014.04.001.
Intermolecular interactions in selected complex of
pBTK–Tyr106:MAL presented 29 non-covalent bonding interac-
tions. Among which 21 hydrogen bond, 4 ionic and 4 hydrophobic
interactions were observed among different residues of pBTK and
MAL.
The selected complex of pBTK–Tyr106:MAL presented promi-
nent conformations of pBTK against MAL  in which -phosphate
of ATP modelled in pBTK (ATP:pBTK) was  observed within a dis-
tance of 3.5 A˚ from the phosphorylatable hydroxyl of Tyr106:MAL
(Fig. 9B). Lys558 of pBTK was  making interactions with Tyr106,
Leu107, Gly109 and Ser110 of MAL  to stabilize the Tyr106 in
place. In contrast Tyr86 was making interaction with the ˇ2 strand
of pBTK. The major domains of MAL  including ˛A, ˇB and ˛E
helices was interacting with GPL, portion between ˇ3  and ˛A, loop
between ˛E and ˛F and activation loop of pBTK. Within the region of
˛A helix:MAL, Val98 and Ala99 was  observed in making interaction
with activation loop of pBTK, which might restricted the activa-
tion loop in place. Gln101 was interacting with Gln412, Arg520
and Arg544 of pBTK. Moreover, Asp102 of MAL  made salt bridges
with Arg520:pBTK to further stabilize the ˛A helix:MAL against
pBTK. Region of ˇB helix of MAL  mostly interacted with Lys433 of
Fig. 8. HADDOCK provided scores for clusters 1–4 of pBTK–Tyr106:MAL. (A) Graph of scores provided by HADDOCK for top 4 clusters of pBTK–Tyr106:MAL. (B) Superposed
cartoons of top four conformations from each complex 1–4 of pBTK–Tyr106:MAL.pBTK is presented in light while loop model of MAL  is in dark shades.
R.Z. Paracha et al. / Computational Biology and Chemistry 51 (2014) 22–35 29
Fig. 9. Complex of pBTK–Tyr106:MAL. (A) Cartoon of ATP modelled in pBTK situated within a region of 3.5 A˚ around Tyr106:MAL. Tyr106:MAL and ATP:pBTK are coloured
black. pBTK is presented in light while loop model of MAL  is in dark shades. (B) Focused image of ATP binding site of pBTK which represents the closeness of -phosphate of
ATP:pBTK with Tyr106:MAL. Both are presented in dots and sticks.
Fig. 10. HADDOCK provided cores for clusters 1–10 of pPKCı–Tyr86:MAL. (A) Graph of scores provided by HADDOCK for top 10 clusters of pPKCı–Tyr86:MAL. (B) Superposed
cartoons of top four conformations from each cluster 1–10 of pPKCı–Tyr86:MAL. pPKCı is presented in light while loop model of MAL  is in dark shades.
pBTK. Region of ˛E helix:MAL involving Asp203 and Arg207 was
found in interaction with Glu599-Asn603 of pBTK, which form a
loop between ˛E and ˛F.
3.5. Protein–protein interaction of pPKC delta with MAL within
an area of Tyr86
Docking of pPKCı within the region of Tyr86 of MAL  (termed
as pPKCı–Tyr86:MAL) were performed using the default settings
at GURU level interface of HADDOCK web-server. CPORT predicted
active and passive residues of pPKCı is shown in Figure S9 which
were used in PPI against the region of Tyr86 of MAL  (Figure S4A).
HADDOCK resulted 176 water-reﬁned complexes, clustered into
10 groups. HADDOCK statistics for the top 10 clusters are shown
in Figure S10. HADDOCK score for complex of pPKCı and MAL  was
−96.4 ± 3.0 representing the highest probable complex in all of the
probabilities. Cluster size, RMSD from the overall lowest-energy
structure, Van der Waals energy, electrostatic energy, desolvation
energy, restraints violation energy, buried surface area and Z-score
of the complex has been shown in Fig. 10. The cluster with rela-
tively low HADDOCK score was selected for further reﬁnement to
improve the statistics of energy scores Figure S11. Reﬁned complex
of pPKCı with MAL  has been shown in Fig. 11 which was  used for
further analysis. Analysis of deformation of structures in terms of
bond lengths, angles, dihedrals, atomic clashes and contact ener-
gies of pBTK and MAL  implicated that structures maintained their
reliability and quality after PPIs through HADDOCK.
Supplementary Figs. S9-S11 can be found, in the online version,
at http://dx.doi.org/10.1016/j.compbiolchem.2014.04.001.
Analysis of selected complex of pPKCı–Tyr86:MAL implicated
that although 21 non-covalent interactions were present in the
selected complex of pPKCı–Tyr86:MAL but the -phosphate of
ATP:pPKCı was at a distance of 25.6 A˚ around phosphorylatable
atom of Tyr86:MAL. Major interactions of ˛C-ˇD region of MAL
were found with the GPL and activation loop of pPKCı.
Fig. 11. Complex of pPKCı–Tyr86:MAL. Cartoon of ATP modelled in pPKCı situated
within a region of 25.6 A˚ around Tyr86:MAL. Tyr86:MAL and ATP:pBTK are coloured
black. pPKCı is presented in light while loop model of MAL  is in dark shades.
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Fig. 12. HADDOCK provided scores for clusters 1–8 of pPKCı–Tyr106:MAL. (A) Graph of scores provided by HADDOCK for top 8 clusters of pPKCı–Tyr106:MAL. (B) Superposed
cartoons of top four conformations from each cluster 1–8 of pPKCı–Tyr106:MAL. pPKCı is presented in light while loop model of MAL  is in dark shades.
3.6. PPI of pPKC delta with MAL  within an area of Tyr106
Default settings at GURU level of docking interface at HAD-
DOCK web-server were used for the docking of protonated
structure of pPKCı within the region of Tyr106 of MAL  (termed
as pPKCı–Tyr106:MAL). CPORT predictions for active and passive
residues of pPKCı are shown in Figure S9, which were used in
PPI against the region of Tyr106 of MAL  (Figure S4B). HADDOCK
resulted into 185 water-reﬁned complexes, clustered into 8 groups.
Statistics provided by HADDOCK for the top 4 clusters are shown
in Figure S12. HADDOCK score of complex of pPKCı–Tyr106:MAL
was −72.4 ± 4.0 representing the highest probable complex among
other probabilities. Cluster size, RMSD from the overall lowest-
energy structure, Van der Waals energy, electrostatic energy,
desolvation energy, restraints violation energy, buried surface area
and Z-score of the complex has been shown in Fig. 12. The top clus-
ter had relatively low HADDOCK score and was selected for further
analysis. Reﬁnement of the top cluster was performed to improve
the energy and HADDOCK scores. Statistics for the complexes
formed after reﬁnement have been shown in Figure S13. Reﬁned
complex of pPKCı with MAL  has been shown in Fig. 13A, which was
used for further analysis. Analysis of deformation of structures in
terms of bond lengths, angles, dihedrals, atomic clashes and contact
energies of pBTK and MAL  implicated that structures maintained
their reliability and quality after PPIs through HADDOCK.
Supplementary Figs. S12 and S13 can be found, in the online ver-
sion, at http://dx.doi.org/10.1016/j.compbiolchem.2014.04.001.
Analysis of intra-molecular interactions have shown that out of
33 non-covalent interactions, 20 hydrogen bonds, 10 ionic and 3
hydrophobic interactions were existed. The complex had signiﬁ-
cant conformation of pPKCı against MAL  in which -phosphate of
ATP:pPKCı  was observed within a region of 3.9 A˚ around phospho-
rylatable atom of Tyr106:MAL (Fig. 13B). Most of the interactions
among MAL  and pPKCı involved helix-˛A and ˛E of MAL  with
pPKCı. Within helix-˛A of MAL, Val98 was making interactions
with Val384, Asp648 and Leu651 of pPKCı. Additionally, Leu97 and
Val98 of MAL  interacted with Asp648:Turn motif of pPKCı, which
might restricted the ﬂexibility of turn motif:pPKCı and reduced
the chances of its collapse into the interfaces of two proteins.
Asp102:MAL involved in making salt bridges with Lys357 and 362
of pPKCı, which might tethered the GPL:pPKCı  in place. In region
of AB loop:MAL, Arg115 interacted with Asp635 and Glu637 of
pPKCı whereas Ser180, Gly181:region of loop after strand-ˇD and
Arg200:helix E of MAL  interacted with Asp388 of pPKCı to fas-
ten the complex of pPKCı–MAL from two opposite sides of each
protein. Helix-˛E was  protrude into the groove between N and C
domains of pPKCı below the ATP binding site and projected the
Tyr106 near -phosphate of ATP. Helix-˛E was stabilized in con-
formation by forming 5 salt bridges with pPKCı involving Asp203,
Arg207, Gln208 and Arg215 of MAL  with Lys475, Asp477:Thr511:
Asp513, Glu553 and Asp551 of pPKCı.
3.7. Physicochemical characteristics of binding interfaces
Different approaches were used to predict and validate the PPIs,
but it was observed that charge distribution and hydrophobic char-
acteristics of protein interfaces proved better in explaining PPIs
of MAL  with pBTK and pPKCı. In this section, we  elaborate the
physicochemical characteristics of the surfaces of MAL, pBTK and
pPKCı with special emphasis on their binding regions. The pur-
pose of presenting this section is to elaborate the differences in
interaction sites, which may  compel the MAL  to bind in the speciﬁc
Fig. 13. Complex of pPKCı–Tyr106:MAL. (A) Cartoon of ATP modelled in pPKCı situated within a region of 3.9 A˚ around Tyr106:MAL. Tyr106:MAL and ATP:pPKCı are coloured
black. pPKCı is presented in light while loop model of MAL  is in dark shades. (B) Focused image of ATP binding site of pPKCı which represents the closeness of -phosphate
of  ATP:pPKCı with Tyr106:MAL. Both are presented in dots and sticks.
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Fig. 14. Charge distributions at the binding interfaces of complexes. (A) The Delphi calculated surface electrostatic potential map  of MAL  complexed with pBTK and pPKCı
at  regions of Tyr86 and Tyr106. (B) The electrostatic potential map of binding interface of MAL  within a region of Tyr86 shows negative charge. (C) The electrostatic potential
map  of binding interface of MAL  within a region of Tyr106 shows comparatively positive charge. (D) The electrostatic potential map of binding interface of pBTK within a
region  of ATP binding site shows positive charge. (E) The electrostatic potential map of binding interface of pPKCı within a region of ATP binding site shows strong negative
charge. (F) Complex of pBTK:Tyr86:MAL. (G) Complex of pPKCı:Tyr86:MAL. (H) Complex of pBTK:Tyr106:MAL. (I) Complex of pPKCı:Tyr106:MAL. Ribbons represent pBTK
and  pPKCı while black sticks represents ATP in respective complexes. MAL  has been shown with electrostatic surfaces in F–I.
regions with pBTK and pPKCı for its phosphorylation. Electrostatic
charge distribution was calculated on the surfaces of MAL, pBTK and
pPKCı by solving the Poisson-Boltzmann equation using Delphi (Li
et al., 2012) whereas hydrophobicity of surfaces were studied using
Kyte–Doolittle algorithm (Kyte and Doolittle, 1982).
Analysis of charge complementarity at binding interfaces were
found interesting which support PPI of MAL  with pBTK at the site of
Tyr86:MAL. Binding interfaces of MAL  and pBTK had strong charge
complementarity, in which MAL  was found with strong negative
charge around the area of Tyr86 and pBTK with strong positive
charge at its binding interface (Fig. 14F). AB Loop of MAL  was  found
interacting with the N-terminal region of GPL in pBTK because of
strong electrostatic forces among Arg115:MAL and Glu 407:BTK.
Region of GPL in pBTK was found positive which interacts with
the negatively charged residues of strand ˇA and ˇB of MAL  and
resulted in the correct orientation of Tyr86:MAL against ATP:pBTK.
Moreover, the region of helix-˛A:MAL was mostly composed of
negatively charged residues and its interaction with positively
charged residues including Leu483, Arg487 and Lys595 of pBTK sta-
bilized the complex. Glu132 and Gln135:MAL were found in making
salt bridges with catalytic residue Arg525 of pBTK. This interaction
was also accompanied by charge complementarity in this region.
Additionally, helix-˛C:MAL was involved in interaction within the
region of helices ˛E and ˛F:pBTK, which also supported the elec-
trostatic complementation in this region to further stabilize the
complex. Interaction of pPKCı around the region of Tyr86:MAL was
non-functional most probably due to the strong adhesive charge
similarities on binding interfaces (Fig. 14G). This might be the rea-
son due to which functional complex of pPKCı–Tyr86:MAL could
not be formed.
Region of Tyr106 presented an interesting case of charge het-
erogeneity for MAL  against pBTK and pPKCı. pBTK interacted with
the negative region around Tyr106 in such a conformation that
-phosphate could be in position to phosphorylate the hydroxyl
group of Tyr106:MAL (Fig. 14H). N-lobe of pBTK was  involved in
interaction with the negative charged surface of MAL  whereas C-
lobe of pBTK was found in the vicinity of positively charged region of
Tyr106, however Asp203:MAL stabilized the C-lobe in this region.
Moreover, the activation loop of pBTK was also found in the vicinity
of negatively charged region of MAL. In contrast, the binding inter-
face of MAL  with pPKCı in complex pPKCı–Tyr106:MAL reﬂected
changes from those observed in case of pBTK–Tyr106:MAL. In
complex of pPKCı–Tyr106:MAL, the binding interface of MAL  was
positively charged whereas pPKCı had negative charges on its bind-
ing interface (Fig. 14I). N-lobe of pPKCı was found in the vicinity
of negatively charged region of MAL  whereas C-lobe interacted
with the positively charged region. But all of the non-covalent
interactions in pPKCı–Tyr106:MAL were supported by the charge
complementarity. For example, Asp102 in helix ˛A of MAL  shown
interaction with the Lys357 and Lys362, which were charge com-
patible regions. Moreover, the positively charged residues of MAL
in a region of helix ˛E including Arg207, Gln208 and Arg215 were
also involved in electrostatic interaction with compatible charged
residues of pPKCı for stabilizing the complex.
Hydrophobicity of protein interfaces has been shown in
Fig. 15 for complexes of pBTK–Tyr86:MAL, pPKCı–Tyr86:MAL,
pBTK–Tyr106:MAL and pPKCı–Tyr106:MAL. Complex of
pBTK–Tyr86:MAL share more hydrophobic contacts including
Phe117:MAL with Phe404:pBTK, Val104, Leu107:MAL with
Val415: pBTK, Leu97,Leu133:MAL with Leu483:pBTK, Val98:MAL
with Met489:pBTK and Trp156:MAL with Met596:pBTK. In con-
trast, only three hydrophobic interactions were found in complex
of pPKCı–Tyr86:MAL including Trp156:MAL with Val384 of pBTK
and Leu137:MAL with Ile387 and Leu651 of pPKCı. Whereas other
hydrophobic regions in both of the complexes were observed at
the distance of greater than 7 A˚.
In  case of pBTK–Tyr106:MAL, three hydrophobic interactions
were found including Leu133:MAL with Phe413:pBTK, Val130:MAL
with Val415:pBTK and Val98:MAL with Val555:pBTK. Similarly
in complex of pPKCı–Tyr106:MAL, Val98 of MAL  interacted with
Val384 and Leu651 of pPKCı and Leu114:MAL interacted with
Met436 of pPKCı. Whereas other hydrophobic regions in both com-
plexes were observed at the distance of greater than 7 A˚.  Results
implicated that the interaction of pBTK with MAL  from side of
Tyr86 involves non-polar residues mediated hydrophobic interac-
tions whereas interaction of pBTK and pPKCı with MAL from the
side of Tyr106 might involved mostly the polar residues.
4. Discussion
The TIR domain of MAL, recruits MyD88 and other proteins
to induce TLR2 and TLR4 dependent differential innate immune
responses (Gray et al., 2006; Yamamoto et al., 2002; Horng et al.,
2002). Previous studies have reported the possible roles of MAL
in the induction of NFB and MAPK signalling pathways result-
ing in hyperinﬂammatory responses. Mutation at positions Tyr86
and Tyr106 residues within the TIR domain of MAL  are associated
with loss of its function and believed to be a good target to treat
hyperinﬂammatory disorders. Previous study of our group was an
attempt to discuss the role of phosphorylation at positions Tyr86
and Tyr106 in retaining interactions with SOCS-1 and MyD88 (Niazi
et al., 2011). This study characterized the PPIs of MAL  with pBTK and
pPKCı to identify the structural characteristics necessary to induce
32 R.Z. Paracha et al. / Computational Biology and Chemistry 51 (2014) 22–35
Fig. 15. Hydrophobicity at binding interfaces of complexes. (A) Hydrophobicity calculated by Kyte-Doolittle for binding interface of MAL  around the regions of Tyr86
and  Tyr106. (B) Hydrophobicity calculated by Kyte–Doolittle for binding interfaces of pBTK (left) and pPKCı (right). (C) Complex of pBTK:Tyr86:MAL. (D) Complex of
pPKCı:Tyr86:MAL. (E) Complex of pBTK:Tyr106:MAL. (F) Complex of pPKCı:Tyr106:MAL. Residues which take part in hydrophilic interactions are labelled on their respective
sites  on the binding interfaces of MAL, pBTK and pPKCı. Cartoons represent pBTK and pPKCı while black and white sticks represents ATP in respective complexes. MAL  has
been  shown with hydrophobic surfaces in C–F.
phosphorylation at Tyr86 and Tyr106. In the current study, molecu-
lar modelling and in-silico PPI techniques were used in conjunction
with previous experimental ﬁndings, to give an insight into the
speciﬁcity of pBTK and pPKCı for phosphorylation of Tyr86 and
Tyr106 of MAL.
Loops present in TIR domains of TLRs and TIR adaptor pro-
teins provide speciﬁcity in TLR mediated signalling and immune
outcomes (Gangloff et al., 2005). Conformation of loops are spe-
ciﬁc, and conserved within, each protein subfamily (Snyder et al.,
2013). Homology modelling of AB loop in the crystal structure of
TIR domain of MAL  have provided implications for its known ﬂexi-
bility nature and corresponding effect on the binding pattern with
kinases. Two major conformational spaces of AB loop reﬂected the
speciﬁc instance of its nature during interaction with the kinases.
The activation of MAL  seem to proceed, only when AB loop interacts
with ˛E helix in MAL, which represents one extreme for ﬂexible AB
loop, whereas its interaction with the area of Tyr86 can be consid-
ered as another. Interaction of AB loop with phosphorylated Tyr86
is proved to be important for downstream signalling after interac-
tion with MyD88 and is also necessary for its degradation through
SOCS-1 (Niazi et al., 2011). Both of these type of conformations are
also seen in BB loops of other TIR domains. For example, in case of
monomeric TLR2, homologous BB loop sequestered away from the
rest of the domain whereas the closure of loop against TIR domain
of TLR2 is observed necessary for dimerization of TLR2 (Tao et al.,
2002).
Accuracy of homology protein model is associated with the
percentage sequence identity of query and template sequences
(Daga et al., 2010). Homology models with high accuracy have
about 1 A˚ root mean square (RMS) error for the backbone atoms
and can be correlated with a structure resolved with medium
resolution nuclear magnetic resonance (NMR). Such an accuracy
in homology models can be achieved if the sequence of model
is 50% identical to its template (Baker and Sali, 2001). Homology
modelling of biological molecules is proved to be faster, reliable
and progressively accurate as comparable to other experimental
approaches (Kryshtafovych et al., 2014). Sequence of pPKCı is 76%
identical with 87% positives without any gaps to crystal structures
of PKC (PDB IDs: 1XJD and 2JED) which presents that homology
model of pPKCı used in the analysis of PPI with MAL  produced sig-
niﬁcant and intuitive results. To support the quality and reliability
of ﬁnal selection of homology model of pPKCı, several parameters
including ERRAT, Ramachandran, Qmean, PROSA and PROCHECK
were used to verify the models geometry during each round of
pre-experimental exercises for correction of backbone, side chains
orientation, rotamers of residues and to reduce the clashes among
atoms. Final selected homology model of pPKCı had bond angles,
lengths, dihedrals and interaction energies within allowed lim-
its in absence of any atomic clashes. Moreover 95% ERRAT score,
0.738 Qmean score with −0.43 Z-score and relative lower potential
energy were some of the other properties which support our conﬁ-
dence to use the ﬁnal selected homology model of pPKCı in further
analysis of PPI with MAL.
At molecular level, PPIs have essential roles to maintain activ-
ities of cell and life. Important information such as structure
ﬂexibility, binding area and residual interactions are crucial for
our understanding about the back end mechanisms involved in
diseases and designing new therapeutics for them. Complexity in
experimental techniques often produce limitations in the deter-
mination of structures of protein–protein complexes. However,
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computational modelling techniques of PPIs can be used to ﬁll those
gaps. Current study is an attempt to predict the binding inter-
faces involved in PPI of MAL  with pBTK and pPKCı. Presence of
crystal structures of MAL  and BTK along with the generation of
reliable model of pPKCı permit the analysis of numerous obser-
vations regarding the interaction regions, shape complementarity,
non-covalent interactions and physicochemical analysis. More-
over, knowledge of the phosphoryl transfer mechanisms within
kinases to phosphorylate the Tyr86 or Tyr106 in MAL  facilitated
us to reduce the size of conformational spaces of MAL against
pBTK and pPKCı (Kenyon et al., 2012). This approach is proved
to be helpful as demonstrated conclusively by assessments of
blind protein–protein interaction prediction experiments in differ-
ent rounds of critical assessment of predicted interactions (CAPRI)
(Janin et al., 2003).
Interaction of pBTK and MAL  for the phosphorylation of Tyr86
demonstrated the speciﬁcity in conformations of each molecule
against each other. This conformational adjustment results in the
closer proximity of -phosphate of ATP to Tyr86 of MAL. The
hydrophobic character which was involved in PPIs between pBTK
and MAL  was found about one-third of the interfaces. Hydrophobic
interactions were found surrounded by polar interactions. Analy-
sis of surface of MAL  through PISA suggested that interface surface
have promising hydrophobicity character and can be interaction-
speciﬁc with pBTK. All other possible complexes obtained through
HADDOCK produced a difference of 9-35 A˚  of difference between -
phosphate of ATP and phosphorylatable atoms (hydroxyl group) in
Tyr86:MAL which seem to be impossible for the phosphoryl trans-
fer (Kenyon et al., 2012). The interfaces of pBTK and MAL  in selected
complex have many interactions between them along with their
electrostatic charge complementarity. Previous studies identiﬁed
Pro125His, Tyr86Ala, Tyr106Ala, and Tyr159Ala of MAL  as puta-
tive mutations which failed to induce downstream signalling (Piao
et al., 2008). In contrast, mutagenesis of Tyr187, Tyr195, and Tyr196
were implicated with little or no effect. Our study support all of the
above implications, however Pro125:MAL has not been observed
as a putative site involved in the interaction with pBTK or pPKCı
which implicates that this site may  be actively involved in the inter-
action with other TIR domains necessary to induce a downstream
signal.
Interaction studies of pPKCı with MAL  implicates that pPKCı
might be competitively involved in the phosphorylation of Tyr106.
Selected complex had a closer proximity of -phosphate of ATP to
Tyr106 of MAL  in a distance of 3.9 A˚. From a 3D structural view-
point it appears to be in a good position to bind to pPKCı for
phosphorylation, however this case was not seen for Tyr86 which
was also exposed and solvent accessible on the surface of MAL. The
hydrophobic character which was involved in pPKCı-Tyr106:MAL
was found about one-eighth of the interfaces and comparatively
less than that seen in case of pBTK-Tyr86:MAL. However, the con-
formational adjustment of pPKCı against MAL  at region of Tyr106
had been found transient.This is because PISA reﬂected that the
interface of MAL  had less hydrophobic character and therefore
it was likely to be an artefact of crystal packing. Similarly the
complex of pBTK-Tyr106:MAL shown the comparative results for
interfaces. The crystal packing actually appear upon crystalliza-
tion of proteins and forces of interaction involved between these
complexes are considered too weak to form a stable complex at
cellular concentrations (Carugo and Argos, 1997). From our point
of view, the crystal packing values for MAL  were actually show-
ing the transient PPI with pPKCı and pBTK at region of Tyr106,
which might be necessary for the phosphorylation of MAL  in a man-
ner of transition reaction (Nooren and Thornton, 2003). Moreover,
the binding surface area (BSA) of complexes pPKCı and pBTK with
MAL  at region of Tyr106 support the possibility of such complexes
as proposed by the data of Chakrabarti and Janin (Chakrabarti
and Janin, 2002) calculated on a subset of the complexes of
Conte et al. (1999).
Horton and Lewis (1992) constituted a linear relationship
between the BSA and binding free energies of a set of complexes,
comprised mostly enzyme–inhibitor complexes. They predicted
very large binding free energies for all of the complexes with BSA
>2000 A˚2. All of the complexes studied here have comparative BSA
and can be related with them. However, it is still demanding that
what is the relation between BSA and binding free energies in case
of kinase and its substrate for phosphoryl transfer.
An important element for the predictions and evaluations of PPI
binding interfaces is the analysis of electrostatic properties of sur-
faces (Maleki et al., 2013; Aziz et al., 2011). Electrostatics are one of
the non-covalent interactions which compel to attract compatible
charged residues. The charge distribution at the binding surfaces of
pBTK (positively charged) and pPKCı (negatively charged) varied
from each other. Area surrounding the Tyr86 in MAL  (negatively
charged) implicated a major reason for which pBTK is supposed
to be a key kinase which can phosphorylate Tyr86 after attaching
this region. However, the region of Tyr106:MAL have charge het-
erogeneity and present the charge complementarity both for pBTK
and pPKCı. However, the region selection by both kinases reﬂects
their ability to phosphorylate Tyr106.
Several variants of MAL  have been documented which affected
the population in terms of their response to pathogens, diseases
and inﬂammation including Asp96Asn, Ala100Thr, Glu108Ala,
Arg115Ala, Phe117Ala, Arg121Ala, Glu132Lys, Arg143Gln,
Arg143Trp, Leu165Ala, Ser180Leu, Arg184Thr, Glu190Asp and
Val197Ile (Nagpal et al., 2009; An et al., 2011; George et al.,
2010; Dissanayeke et al., 2009; Valkov et al., 2011). Among these,
Asp96Asn, Glu132Lys, Arg143Gln and Glu190Asp have been
reported to cause a loss of function in MAL where Glu108Ala and
Phe117Ala are associated with moderately decreased binding of
MAL–TIR to MyD88–TIR. These studies mostly target the interac-
tion of TIR domain of MAL  with other TIR domains including those
of MyD88 and TLR4. To the best of our knowledge, our study has
proposed the role of these residues in binding with kinases for the
ﬁrst time. Among these Asp96, Ala100, Glu108 belong to a region
of ˛A helix of TIR domain of MAL  and observed in kinase–MAL
complexes. Several residues from this domain had been observed
which could made contacts with pBTK and pPKCı including, Glu94,
Leu97and Val98 and Asp102 of MAL. Moreover, Arg115, Phe117A,
Arg121 belong to AB loop of MAL  among which Arg115 and Phe117
were observed for their interaction with pBTK and pPKCı. Glu132
belongs to ˇB strand of MAL  and involved in forming salt bridges
with pBTK but not with pPKCı. In contrast, Ser180 was  found
involved in making contacts with pPKCı, but not with pBTK. So
these residues might be cooperatively involved in interaction
with TIR domains of TLR4 and MyD88 and pBTK and/or pPKCı.
Mutations or therapeutic targeting of these positions can attenuate
the phosphorylation of Tyr86 and Tyr106 which potentiate the loss
of activation with subsequent loss of attachment with TLR4 and
MyD88. As far as other mutations are concerned including Arg143,
Arg143, Leu165, Arg184, Glu190 and Val197, no possible role was
found in affecting the interaction of MAL  with pBTK and/or pPKCı
in this study.
5. Conclusion
As summary, the current study proposes structural and func-
tional studies of phosphorylation of MAL  by pBTK and pPKCı,
which are explicitly involved in the post translational modiﬁ-
cation of Tyr86 and Tyr106, respectively. Additional analysis of
structural complexes of pBTK and pPKCı with MAL  can provide
exclusive evidences about the categorical association of MAL  with
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interacting kinases. However, the data presented here deliver basic
informations about residual interaction among MAL  and kinases
for understanding the phosphorylation of TIR domain of MAL  and
is a part of important step towards the discovery of new strate-
gies, which can affect the TLR2 and TLR4 mediated pathological
signalling. In future, we would like to study point mutations of
interface residues of MAL, pBTK and pPKCı to improve our under-
standings, experimentally.
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APPENDIX D
Truth Table for Boolean Logic
Table D.1. Truth table of proposition logic
P Q ¬P ¬Q P∧Q P∨Q P⇒ Q P⇔ Q
0 0 1 1 0 0 1 1
0 1 1 0 0 1 1 0
1 0 0 1 0 1 0 0
1 1 0 0 1 1 1 1
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